PROGRAM GUIDE

TABLE OF CONTENTS

1 SUPPORTERS

7 FRIDAY, APRIL 17

11 SATURDAY, APRIL 18
16 Award Lecture | Team Science
22 Plenary Session

23 SUNDAY, APRIL 19
23 Opening Ceremony
23 Plenary Session
23 Award Lecture | Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research
28 Clinical Trials Plenary Session
28 Poster Sessions
30 Award Lecture | AACR Award for Lifetime Achievement in Cancer Research
30 Award Lecture | AACR-Irving Weinstein Foundation Distinguished Lectureship
31 Award Lecture | AACR James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research
37 Clinical Trials Plenary Session
38 Award Lecture | AACR-Princess Takamatsu Memorial Lectureship
38 Award Lecture |AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research
39 Presidential Address
40 AACR Annual Reception

41 MONDAY, APRIL 20
41 Plenary Session
41 Poster Sessions
47 Clinical Trials Plenary Session
52 Poster Sessions
60 Award Lecture | AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship
61 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
61 Award Lecture | AACR Award for Outstanding Achievement in Basic Cancer Research
62 Award Lecture | AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research
62 Award Lecture | AACR-St. Baldrick's Foundation Award for Outstanding Achievement in Pediatric Cancer Research
64 Award Lecture | AACR Award for Outstanding Achievement in Chemistry in Cancer Research
64 Award Lecture | AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research

65 TUESDAY, APRIL 21
65 Plenary Session
65 Poster Sessions
71 Clinical Trials Plenary Session
71 Award Lecture | AACR Gertrude B. Elion Cancer Research Award Lecture
75 Poster Sessions
82 Award Lecture | AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
83 Award Lecture | AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research
84 Award Lecture | AACR Award for Outstanding Achievement in Blood Cancer Research
85 Award Lecture | AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention

86 WEDNESDAY, APRIL 22
86 Plenary Session
86 Poster Sessions
90 Plenary Session

SUPPORTERS

Cure, Progress, Promise

Cure Level

AstraZeneca
GSK

Progress Level

Daiichi Sankyo, Inc.
Lilly, A Medicine Company
Victoria's Secret Global Fund for Women's Cancers, in Partnership with Pelotonia and AACR

Promise Level

AbbVie
American Brain Tumor Association
American Cancer Society
Amgen
Bayer
Breast Cancer Research Foundation
Canadian Institutes of Health Research
Cancer Research Institute
Chris "CJ" Johnson Foundation
Chromophobe and Oncocytic Tumor Alliance
Debbie's Dream Foundation
Doreen J. Putrah Cancer Research Foundation
Exelixis, Inc.
Fondazione Pezcoller
Genmab
Gilead and Kite Oncology
Irving Weinstein Foundation
Joey's Wings
Judy Nicholson Kidney Cancer Foundation
Kidney Cancer Action Network (KidneyCAN)
Kidney Cancer Association
Merck & Co., Inc.
Novartis
Parse Biosciences
Pfizer, Inc.
Prostate Cancer Foundation
Regeneron
Revolution Medicines
Sanofi
Sidney Kimmel Cancer Center at Jefferson
Silken Twine Charity
St. Baldrick's Foundation
Triple Negative Breast Cancer Foundation
VHL Alliance

The Scientific Program

Dharma Master Jiantai Advances in Lung Cancer Research Session: Neuroendocrine and Small Cell Lung Cancers

Dharma Master Jiantai Symposium in Biomarkers: Next-Gen Tools for ADCs—Defining Biomarkers of Response through Technological Innovation

Dharma Master Jiantai Symposium in Targeted Therapy: Immunotherapy and DNA Repair

AACR Awards and Lectureships

AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention
American Cancer Society

AACR Award for Outstanding Achievement in Blood Cancer Research
AbbVie

AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
Cancer Research Institute

AACR Gertrude B. Elion Cancer Research Award
GSK

AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research
Lilly, A Medicine Company

AACR-Irving Weinstein Foundation Distinguished Lectureship
Irving Weinstein Foundation

AACR-St. Baldrick's Foundation Award for Outstanding Achievement in Pediatric Cancer Research
St. Baldrick's Foundation

AACR Team Science Award
Lilly, A Medicine Company

Pezcoller Foundation-AACR International Award forExtraordinary Achievement in Cancer Research
Fondazione Pezcoller

AACR Outstanding Investigator Award for Breast Cancer Research
Breast Cancer Research Foundation

AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship
Gilead and Kite Oncology

AACR-Women in Cancer Research Charlotte Friend Lectureship
Gilead and Kite Oncology

AACR-Distinguished Lectureship In Breast Cancer Research
Aflac

AACR-Princess Takamatsu Memorial Lectureship
Princess Takamatsu Cancer Research Fund

AACR-Wuan Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research
Waun Ki Hong Endowment Fund

AACR Runners for Research 5K Run/Walk 2026

Presenting Sponsor ($100,000)
AstraZeneca

Visionary Sponsor ($50,000)
Revolution Medicines

Innovator Sponsor ($10,000)
Jefferson Health - Sidney Kimmel Comprehensive Cancer Center

Enthusiast Sponsor ($5,000)
Parse Biosciences
Inocras

AACR Travel Grants and Scholar Awards

AACR Women in Cancer Research Scholar Awards
Victoria's Secret Global Fund for Women's Cancers, in Partnership with Pelotonia and AACR

AACR Global Scholar-in-Training Awards
Amgen
Victoria's Secret Global Fund for Women's Cancers, in Partnership with Pelotonia and AACR

AACR Scholar-in-Training Awards

Agilent Technologies
Alfred & Cathy Fraser
American Association for Cancer Research
American Brain Tumor Association
Breast Cancer Research Foundation
Canadian Institutes of Health Research
Carol Henry
Chris "CJ" Johnson Foundation
Chromophobe and Oncocytic Tumor Alliance
The Davidson-Kensler Family Foundation
Debbie's Dream Foundation
Doreen J. Putrah Cancer Research Foundation
Draper Holdings
Dr. Tony and Mrs. Carrie Cheung
Family of Dan Y. Zhang
Fondazione Pezcoller
Glenn Skyes
James Creighton Scholarship
James V. Buzzitta, MD Family Fund
Jim and Mitzie Wittliff
Joey's Wings
Judy Nicholson Kidney Cancer Foundation
The Estate of June L. Biedler
Kidney Cancer Action Network
Kidney Cancer Association
Lorraine and Joseph Tumolo
The Margaret Foti Foundation
Merck & Co., Inc.
Novartis
Pfizer, Inc.
Prostate Cancer Foundation
Rachel Ringer
Sanofi
Silken Twine Charity
Stan Divorski and Nancy Staisey
Tony and Maurice Hallett
Triple Negative Breast Cancer Foundation
VHL Alliance

AACR Annual Meeting 2025 Supporters

AACR Advocacy Partners' Pavilion

Pfizer, Inc.

AACR Early-Career Scholar in the Field of Cancer Research Award

Merck & Co., Inc.

AACR Patient Advocacy Roundtable Discussions

Pfizer, Inc.

AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research Reception

Lilly, A Medicine Company

Mobile Charging Stations

Daiichi Sankyo, Inc.

Patient Advocacy Poster Session

Pfizer, Inc.

Regulatory and Science Track

Gilead and Kite Oncology

Mission Support

Regeneron
Exelixis, Inc.

Independent Education Grants

AstraZeneca Pharmaceuticals
Merck & Co., Inc.
Novartis Pharmaceuticals Corporation

AACR Scientist↔Survivor Program®

AbbVie
AstraZeneca
Bayer
CIHR
Exelixis, Inc.
Genmab
GSK
Lilly, A Medicine Company
Merck & Co., Inc.

Women in Cancer Research Constituency Group (WICR)

Novartis

SUPPORTERS

Research Grants and Fellowships

ALK Positive, Inc.
AstraZeneca
Bosarge Family Foundation
Breast Cancer Research Foundation
Bristol Myers Squibb
Conquer Cancer, the ASCO Foundation
Daiichi Sankyo, Inc.
Debbie's Dream Foundation
EMD Serono
Exelixis, Inc.
Fanconi Cancer Foundation
Friends of the AACR Foundation, Party with a Purpose
Genentech, A Member of the Roche Group
GSK
Hope Scarves
Incyte Corporation
The John and Elizabeth Leonard Family Foundation
Johnson & Johnson
KidneyCAN
Lobular Breast Cancer Alliance
Lustgarten Foundation
The Mark Foundation for Cancer Research
Merck & Co., Inc.
MPM BioImpact
Novocure
Ocular Melanoma Foundation
Pfizer, Inc.
QuadW
The Sontag Foundation
St. Baldrick's Foundation
Swim Across America
Takeda
Think Forward Foundation
Torrey Coast Foundation
Triple Negative Breast Cancer Foundation
Victoria's Secret Global Fund for Women's Cancers, in Partnership with Pelotonia and AACR

Special Conference Supporters for 2025-2026

Astellas
AstraZeneca
Bloomberg
Boehringer Ingelheim
Bristol Myers Squibb
Byondis
BrYet
City of Hope
Decheng Capital
Exelixis, Inc.
Genentech, A Member of the Roche Group
Gilead and Kite Oncology
GSK
IBA Proton Therapy
Johnson & Johnson
Leerink Partners
Let's Win Pancreatic Cancer
Lilly, A Medicine Company
Lobular Breast Cancer Alliance
Lustgarten Foundation
Merck & Co., Inc.
MPM BioImpact Capital
Novartis
Novocure
Ovarian Cancer Research Alliance
Pfizer
Revolution Medicines
Royalty Pharma
Sontag Foundation
The Mark Foundation for Cancer Research
Verastem Oncology
Zymeworks

SUPPORTERS

Sustaining Members

Leadership Sustaining Members

AbbVie
Amgen, Inc.
Astellas
AstraZeneca
Bayer
Boehringer Ingelheim International GmbH
Bristol Myers Squibb
Genentech, A Member of the Roche Group
Gilead and Kite Oncology
Lilly, A Medicine Company
Merck & Co., Inc.
Pfizer, Inc.

Strategic Sustaining Members

Eisai Inc.
Incyte Corporation
Novartis

Major Sustaining Members

BeOne Medicines
Daiichi Sankyo, Inc.
Exact Sciences is now Abbott
Exelixis, Inc.
Fondazione Pezcoller
Genmab
GSK
Ipsen Biopharmaceuticals, Inc.
Johnson & Johnson
Novocure
Regeneron
Revolution Medicines
Sanofi
Syndax Pharmaceuticals, Inc.
Takeda

Associate Sustaining Members

Byondis
GRAIL, Inc.
Guardant Health
Nurix Therapeutics
Nuvalent
PMV Pharmaceuticals
Verastem Oncology
Zai Lab

FRIDAY, APRIL 17

Professional Development Session
1:00 p.m.–4:00 p.m.

Grand Hall A - Manchester Grand Hyatt San Diego

Grant Writing Workshop: Tips for Success from Experienced Scientists
NOT ELIGIBLE FOR CME CREDIT

Cochairs: Valerie Odero-Marah, Baltimore, MD; Sandra W. Ryeom, New York, NY; Rui Li, Los Angeles, CA; Luz Maria Rodriguez, Rockville, MD

1:00 p.m. **Welcome from AACR Science Education and Career Advancement Committee Chair.** Brian M. Rivers, Atlanta, GA

1:05 p.m. **The Importance of Grant Writing: Perspectives from the NCI Director.** Anthony Letai, Bethesda, MD

1:25 p.m. **Part 1: Types of Grants and How to Identify Them and Work with Funding Organizations**

American Association for Cancer Research® (AACR). Christina D. Kline, Philadelphia, PA

National Institutes of Health (NIH). Tiffany A. Wallace, Rockville, MD

UK and European funding opportunities. Lorenzo De La Rica, London, United Kingdom

1:55 p.m. **Elements of Grant Writing**

Compelling specific aims page. Sandra W. Ryeom, New York, NY

Preliminary data and research strategy. Aimee Marie Crago, New York, NY

Preliminary data and research strategy. Katherine Y. Tossas, Richmond, VA

2:35 p.m. **Understanding peer review applications: How is your grant reviewed.** Luz Maria Rodriguez, Rockville, MD

2:55 p.m. **Mock Grant Review and Moderated Panel Discussion**

Moderator: Rui Li, Los Angeles, CA

SRO and Chair. Valerie Odero-Marah, Baltimore, MD

Primary reviewer. Sandra W. Ryeom, New York, NY

Tertiary reviewer. Katherine Y. Tossas, Richmond, VA; Tiffany A. Wallace, Rockville, MD

3:40 p.m. **Why write a grant and how to keep going when you feel like you can't?** William G. Nelson, Baltimore, MD

3:55 p.m. **Closing remarks and evaluation.** Valerie Odero-Marah, Baltimore, MD

Educational Sessions
3:00 p.m.–4:30 p.m.

Room 30 | Upper Level | Convention Center

Decoding Tumor Evolution through the Human Tumor Atlas Network: An Ecological and Evolutionary Perspective

Chair: Alan Hunter Shain, San Francisco, CA

3:00 p.m. **Introduction.** Indu Kohaar, Bethesda, MD

3:10 p.m. **Evolution of cutaneous squamous cell carcinoma.** Alan Hunter Shain, San Francisco, CA

3:36 p.m. **From precancer to metastasis: Evolution and microenvironment of breast and prostate tumors.** Li Ding, St. Louis, MO

4:03 p.m. **Risk stratification of precursor myeloma using single cell sequencing.** Irene M. Ghobrial, Boston, MA

Ballroom 20 CD - Upper Level - Convention Center

Next Generation Extracellular Vesicles and Particles as Biomarkers, Targets, and Deliverables

Chair: David C. Lyden, New York, NY

3:00 p.m. **Chair Introduction.** David C. Lyden, New York, NY

3:01 p.m. **Extracellular vesicles and particles: Biogenesis and function.** Crislyn D'Souza-Schorey, Notre Dame, IN

3:31 p.m. **Cancer extracellular vesicles: From biology to translation.** Dolores Di Vizio, Los Angeles, CA

4:01 p.m. **Next generation deliverables: T cell-derived EVPs.** David C. Lyden, New York, NY

Room 17 - Mezzanine Level - Convention Center

NK Cell-Based Cancer Immunotherapy: From Biology to the Clinic
NOT ELIGIBLE FOR CME CREDIT

Chair: Eric Vivier, Marseille, France

3:00 p.m. **Chair Introduction.** Eric Vivier, Marseille, France

3:01 p.m. **Harnessing NK cells in cancer therapies.** Eric Vivier, Marseille, France

3:30 p.m. **Novel NK cell approaches to cancer immunotherapy.** Rizwan Romee, Boston, MA

4:00 p.m. **Smart logic-gated cells for effective and selective cancer therapies.** Timothy K. Lu, South San Francisco, CA

Room 33 - Upper Level - Convention Center

Pathobiology of Sarcomas and Emerging Technologies

Chair: Miguel N. Rivera, Boston, MA

3:00 p.m. **Chair Introduction.** Miguel N. Rivera, Boston, MA

3:01 p.m. **Targeting pathobiology in sarcomas: From bench to bedside in EHE.** Brian P. Rubin, Cleveland, OH

3:30 p.m. **Understanding chromatin regulation in fusion driven sarcomas.** Miguel N. Rivera, Boston, MA

4:00 p.m. **GIST as a paradigm for personalized medicine in sarcoma.** Margaret von Mehren, Philadelphia, PA

Room 28 - Upper Level - Convention Center

The Dark Side of Cancer Therapies: Therapy-Induced Comorbidities Across the Lifespan

Chair: Sheila A. Stewart, St. Louis, MO

3:00 p.m. **Chair Introduction.** Sheila A. Stewart, St. Louis, MO

3:01 p.m. **Therapy-induced senescence drives chemotherapy-induced neuropathy.** Sheila A. Stewart, St. Louis, MO

3:30 p.m. **Comorbidities associated with cranial radiotherapy of brain malignancies.** Charles Limoli, Irvine, CA

4:00 p.m. **Prevalence and factors underpinning multimorbidity after childhood cancer.** Melissa Maria Hudson, Memphis, TN

ABIM CME MOC ACCREDITED

Methods Workshops
3:00 p.m.–4:30 p.m.

Room 29 - Upper Level - Convention Center

AI in Cancer Care: Practical Applications Transforming Oncology

Chair: Caroline Chung, Houston, TX

3:00 p.m. **Chair Introduction.** Caroline Chung, Houston, TX

3:01 p.m. **Embracing cancer complexity with data and AI in context.** Caroline Chung, Houston, TX

3:30 p.m. **AI-driven mapping of tumors in 3D and at single-cell resolution.** Denis Wirtz, Baltimore, MD

4:00 p.m. **From sequencing to treatment: The role of AI in precision oncology.** Michael F. Berger, New York, NY

Room 31 - Upper Level - Convention Center

Clinical Trial Design Workshop: Real World Evidence in Clinical Trial Design

Chair: Peter J. O'Dwyer, Philadelphia, PA

3:00 p.m. **Chair Introduction.** Peter J. O›Dwyer, Philadelphia, PA

3:01 p.m. **Integrating EHR-derived real-world data into therapeutic trials: Design and analysis strategies for hybrid control designs.** Rebecca Hubbard, Providence, RI

3:30 p.m. **The EHR as a source of real world data to ensure access, representativeness and efficiency in clinical trials.** Neal J. Meropol, New York, NY

4:00 p.m. **Design of a prospective RWD study of osimertinib +/- chemotherapy in patients with non-small cell lung cancer harboring an EGFR mutation.** Peter J. O'Dwyer, Philadelphia, PA

Room 16 - Mezzanine Level - Convention Center

Using Multiplex Assays of Variant Effects (MAVEs) in Clinical Oncology Practice

Chair: Fergus J. Couch, Rochester, MN

3:00 p.m. **Chair Introduction.** Fergus J. Couch, Rochester, MN

3:01 p.m. **Combining MAVE datasets for variant classification.** Fergus J. Couch, Rochester, MN

3:30 p.m. **Diverse functional readouts for clinical variant** interpretation. Jacob Kitzman, Ann Arbor, MI

4:00 p.m. **Discussion**

FRIDAY, APRIL 17

Educational Sessions
4:45 p.m.–6:15 p.m.

Ballroom 20 CD - Upper Level - Convention Center
Extracellular Matrix Remodeling in the Tumor Microenvironment and Distant Niches

Chair: Mario Paolo Colombo, Milan, Italy

4:45 p.m. **Chair Introduction.** Mario Paolo Colombo, Milan, Italy

4:46 p.m. **The contribution of the ECM microenvironment to metastatic dormancy.** Jose Javier Bravo-Cordero, New York, NY

5:16 p.m. **From matrix to immunity: The multifaceted role of SPARC in tumor progression.** Mario Paolo Colombo, Milan, Italy

5:45 p.m. **Neutrophil Elastase promotes myoepithelial layer disruption and breast cancer progression.** William J. Muller, Montréal, QC, Canada

Room 29 - Upper Level - Convention Center
Foundation Models and Multimodal AI for Cancer Research

Chair: Charlotte Bunne, Lausanne, Switzerland

4:45 p.m. **Chair Introduction.** Charlotte Bunne, Lausanne, Switzerland

4:46 p.m. **Toward virtual patients with multimodal foundation models and agents.** Charlotte Bunne, Lausanne, Switzerland

5:15 p.m. **Multimodal foundation models for modeling disease dynamics and reasoning over scientific knowledge.** Serena Yeung-Levy, Stanford,

5:45 p.m. **Towards reliable medical AI: Agents that plan, evaluate, and verify.** Michael Moor, Zurich, Switzerland

Room 28 - Upper Level - Convention Center
Implementation Science Approaches to Advancing Equitable Cancer Prevention and Control

Chair: Jennifer Tsui, Los Angeles, CA

4:45 p.m. **Chair Introduction.** Jennifer Tsui, Los Angeles, CA

4:46 p.m. **An introduction to implementation science using lung cancer screening in HIV care.** Jessica Yasmine Islam, Tampa, FL

5:15 p.m. **Using participatory, engaged approaches to tailor and select implementation strategies for safety-net contexts.** Denalee M. O'Malley, New Brunswick, NJ

5:45 p.m. **What happens after uptake? Implementation science approaches for sustaining and scaling adolescent HPV vaccination approaches in safety-net settings.** Jennifer Tsui, Los Angeles, CA

Room 30 - Upper Level - Convention Center
Intratumoral Drug Responses

Chair: Oliver Jonas, Boston, MA

4:45 p.m. **Chair Introduction.** Oliver Jonas, Boston, MA

4:46 p.m. **Spatially resolved metabolomics reveals pathway-specific responses to implantable microdevice-delivered compounds.** Shawn Davidson, Chicago, IL

5:31 p.m. **Cutting edge technologies for measuring drug responses and biomarkers in the tumor microenvironment.** Oliver Jonas, Boston, MA

Ballroom 20 AB - Upper Level - Convention Center
Mechanisms of Resistance to Targeted and IO Therapies and Strategies for Overcoming Resistance
NOT ELIGIBLE FOR CME CREDIT

Chair: Kevan M. Shokat, San Francisco, CA

4:45 p.m. **Chair Introduction.** Kevan M. Shokat, San Francisco, CA

4:46 p.m. **Mechanisms of resistance to direct Ras inhibitors and approaches for overcoming resistance.** Kevan M. Shokat, San Francisco, CA

5:15 p.m. **Preclinical models to validate rational combination therapies to target RAS.** Chiara Ambrogio, Torino, Italy

5:45 p.m. **Exploiting hippo-YAP/TEAD inhibition to overcome resistance to targeted and immune therapies.** J. Silvio Gutkind, La Jolla, CA

Room 33 - Upper Level - Convention Center

Taste and Smell in Cancer: Undervalued Drivers of Nutrition and Patient Impact

Chair: Valentina Parma, Philadelphia, PA

4:45 p.m. **Chair Introduction.** Valentina Parma, Philadelphia, PA

5:05 p.m. **Chemosensory dysfunction in cancer: Epidemiology, impact, and the case for integrated assessment.** Valentina Parma, Philadelphia, PA

5:15 p.m. **Using mouse and taste organoid models to understand mechanisms of dysgeusia in patients.** Linda Barlow, Aurora, CO

5:45 p.m. **From here to the future: Translating chemosensory research into excellent clinical care.** Anna Boltong, Parkville, Victoria, Australia

Room 31 - Upper Level - Convention Center

When Tumors Act Like Viruses: Mechanisms and Therapeutic Frontiers

Chair: Israel Cañadas, Philadelphia, PA

4:45 p.m. **Chair Introduction.** Israel Cañadas, Philadelphia, PA

4:46 p.m. **Turning "cold" tumors "hot": Viral mimicry as a therapeutic strategy in cancer.** Israel Cañadas, Philadelphia, PA

5:15 p.m. **Epigenetic regulation of the viral mimicry response in cancer.** Katherine B. Chiappinelli, Washington, DC

5:45 p.m. **Immune responses to viral mimicry in the TME.** Nicolas Vabret, New York, NY

Professional Development Session
5:00 p.m.–7:00 p.m.

Grand Hall A - Manchester Grand Hyatt San Diego

How to Design a Successful Career Path in Cancer Research: The Do's and Don'ts for Early-Stage Investigators

NOT ELIGIBLE FOR CME CREDIT

Cochairs: Jose G. Trevino, Richmond, VA; Greisha L. Ortiz Hernandez, Duarte, CA; Charnita Zeigler-Johnson, Philadelphia, PA; Mariana C. Stern, Los Angeles, CA

Panelists: Jose G. Trevino, Richmond, VA; Janeen R. Azare, New York, NY; John D. Carpten, Duarte, CA; Folakemi T. Odedina, Jacksonville, FL

Moderator: Mariana C. Stern, Los Angeles, CA

5:00 p.m. **Welcome.** Charnita M. Zeigler-Johnson, Philadelphia, PA

6:50 p.m. **Closing remarks and evaluation.** Greisha L. Ortiz Hernandez, Duarte, CA

SATURDAY, APRIL 18

Educational Session
8:00 a.m.–9:30 a.m.

Room 11 - Upper Level - Convention Center

Academic Entrepreneurship: Getting Your Discovery to Patients, Part 1— Liftoff

NOT ELIGIBLE FOR CME CREDIT

Chair: Michael A. Caligiuri, Duarte, CA

Chair Introduction. Michael A. Caligiuri, Duarte, CA

Panelists: Vanessa Almendro, Duarte, CA; Omer Butt, Twinsburg, OH; Tom Cirrito, Walnut, CA

Ballroom 20 AB - Upper Level - Convention Center

Advances in Pre-Metastatic Niche Biology: From Pre-Clinical Insights to Clinical Opportunities

Chair: Ilaria Malanchi, London, United Kingdom

8:00 a.m. **Chair Introduction.** Ilaria Malanchi, London, United Kingdom

8:01 a.m. **Co-evolution of tumor and their supportive niches during breast cancer progression and metastasis.** Yibin Kang, Princeton, NJ

8:31 a.m. **Disrupting the "soil": Exploring and targeting the pre-metastatic niche.** Dihua Yu, Houston, TX

9:01 a.m. **Cancer-induced rewiring of distant organs' physiological state to promote tumor progression.** Ilaria Malanchi, London, United Kingdom

Ballroom 6 CF - Upper Level - Convention Center

CART Therapy: Transforming the Landscape of Adult and Pediatric Blood Cancers

Chair: Stephen Gottschalk, Memphis, TN

8:00 a.m. **Chair Introduction.** Stephen Gottschalk, Memphis, TN

8:20 a.m. **CAR T cell therapy in myeloma: Durability, design and path to functional cure.** Krina Patel, Houston, TX

8:49 a.m. **Emerging approaches in CAR T cell therapy for B-cell leukemia and lymphoma.** Matthew J. Frank, Stanford, CA

9:19 a.m. **Advancing CAR T cell therapy for pediatric blood cancers.** Stephen Gottschalk, Memphis, TN

Ballroom 20 CD - Upper Level - Convention Center

Chemistry to the Clinic Part 1 of 4: The Next Generation of Conjugates—Innovative Chemistry and Beyond-Cytotoxic Payloads in Cancer Therapy

NOT ELIGIBLE FOR CME CREDIT

Chair: Xueqing Wang, San Carlos, CA

8:00 a.m. **Chair Introduction.** Xueqing Wang, San Carlos, CA

8:01 a.m. **The peril and promise of immune stimulating ADCs.** L. Nathan Tumey, Binghamton, NY

8:31 a.m. **Kinase inhibitor ADCs: Leveraging tumor-intrinsic vulnerabilities for the treatment of hematological and solid Tumors.** Xueqing Wang, San Carlos, CA

9:01 a.m. **Beyond conventional payloads: Unlocking new therapeutic landscapes with targeted protein degrader-antibody conjugates (DACs).** Norman Fultang, Wilmington, DE

Room 29 - Upper Level - Convention Center

Dose Optimization in Early-Phase Oncology Trials: Implementing the Vision of FDA's Project Optimus

NOT ELIGIBLE FOR CME CREDIT

Chair: Gideon Blumenthal, New York, NY

8:00 a.m. **Chair Introduction.** Gideon Blumenthal, New York, NY

8:01 a.m. **Carrying dosage optimization forward: Project Optimus at 5 years.** Mirat Shah, Silver Spring, MD

8:16 a.m. **Utilizing randomization, backfill and expansion cohorts to gain greater understanding of dose- and exposure-response relationships.** Alexia Iasonos, New York, NY

8:31 a.m. **Ensuring tolerability by incorporating patient reported outcomes in dose finding clinical trials.** Shing M. Lee, New York, NY

8:46 a.m. **Towards finding a more optimal dose - Project Optimus at 5 years from an industry perspective.** Gideon Blumenthal, New York, NY

Room 5 - Upper Level - Convention Center

From Bench to Buzz: Making Your Research Resonate for More Funding and Attention

Chair: Kristen Dahlgren, Middlebury, VT

8:00 a.m. **Chair Introduction.** Kristen Dahlgren, Middlebury, VT

8:01 a.m. **Anatomy lesson: Finding the heart in your science.** Kristen Dahlgren, Middlebury, VT

8:30 a.m. **Translational research: Practical tools to turn complex science, simple.** Jaye Gardiner, Medford, MA

9:00 a.m. **Communications clinic: Amplifying with AI for broader engagement.** Saranne Rothberg, Tenafly, NJ

Ballroom 6 B - Upper Level - Convention Center

Improving Cancer Outcomes by Shaping the Tumor Macroenvironment

Chair: Ayelet Erez, Rehovot, Israel

8:00 a.m. **Chair Introduction.** Dafna Bar-Sagi, New York, NY

8:01 a.m. **Moving the macroenvironment: How physical activity remodels tumors.** Dafna Bar-Sagi, New York, NY

8:30 a.m. **The role of pks+ E. Coli in intestinal stem cell plasticity and early onset colorectal cancer.** Karuna Ganesh, New York, NY

9:00 a.m. **Deciphering the tumor host cross talk to improve cancer therapy.** Ayelet Erez, Rehovot, Israel

Room 30 - Upper Level - Convention Center

Senescence in Cancer: Identifying, Measuring, and Targeting a Double-Edged Sword

Chair: Marcus Ruscetti, Worcester, MA

8:00 a.m. **Chair Introduction.** Marcus Ruscetti, Worcester, MA

8:01 a.m. **Defining senescence and implications for cancer.** Jennifer H. Elisseeff, Baltimore,

8:31 a.m. **The SASP: How the non-cell autonomous arm of senescence impacts cancer immunity and therapy for better or worse.** Marcus Ruscetti, Worcester, MA

9:00 a.m. **Targeting (pre-)cancer cell senescence: Not so double-edged, perhaps?** Clemens A. Schmitt, Berlin, Germany

Room 33 - Upper Level - Convention Center

Targeted Alpha- and Beta-Emitter Radiopharmaceuticals: Multidisciplinary Precision Radiation Medicine

Chair: Zachary S. Morris, Madison, WI

8:00 a.m. **Chair Introduction.** Zachary S. Morris, Madison, WI

8:01 a.m. **Quantitative molecular imaging to enable personalized radiopharmaceutical therapy with alpha and beta emitting isotopes.** Delphine L. Chen, Seattle, WA

8:30 a.m. **Clinical advances and opportunities in the treatment of prostate cancer using alpha- and -beta emitting radiopharmaceuticals.** Neil K. Taunk, Philadelphia, PA

9:00 a.m. **Integrating alpha- and beta-emitting radiopharmaceuticals in combined modality treatment of patients with cancer.** Zachary S. Morris, Madison, WI

Ballroom 6 DE - Upper Level - Convention Center

The Impact of Lifestyle, Diet and the Microbiome on Cancer Onset and Spread

Chair: Karen H. Vousden, London, United Kingdom

8:00 a.m. **Chair Introduction.** Karen H. Vousden, London, United Kingdom

8:01 a.m. **Precision diets to augment cancer therapy.** Karen H. Vousden, London, United Kingdom

8:30 a.m. **Physical activity as a therapeutic for cancer treatment.** Mark Febbraio, Victoria, Australia

9:00 a.m. **Harnessing diet-microbiome interactions for cancer prevention.** Mingyang Song, Boston, MA

Ballroom 6 A - Upper Level - Convention Center

Unraveling the Role of Extrachromosomal DNA in Cancer Evolution and Therapy Response

Chair: Paul S. Mischel, Stanford, CA

8:00 a.m. **Chair Introduction.** Paul S. Mischel, Stanford, CA

8:01 a.m. **Breaking the chromosomal mold - ecDNA and its role in cancer.** Paul S. Mischel, Stanford, CA

8:30 a.m. **Building a repository of ecDNA structures.** Vineet Bafna, La Jolla, CA

9:00 a.m. **The landscape of structural variants in lung cancer and ecDNA across the TRACERx and PEACE studies.** Mariam Jamal-Hanjani, London, United Kingdom

SATURDAY, APRIL 18

Methods Workshop
8:00 a.m.–9:30 a.m.

Room 31 - Upper Level - Convention Center

The AACR Project GENIE® Data Model: A Foundation for Scalable, Structured Data Collection to Support the Precision Oncology Revolution

NOT ELIGIBLE FOR CME CREDIT

Chair: Jeremy L. Warner, Providence, RI

8:00 a.m. **Chair Introduction.** Jeremy L. Warner, Providence, RI

8:01 a.m. **AACR Project GENIE® data model: The who, what, why, and how.** Jeremy L. Warner, Providence, RI

8:20 a.m. **Building the model: Ensuring cross-functional utility.** Jennifer Hoppe, Philadelphia, PA

8:40 a.m. **Implementing the AACR Project GENIE® data model: Lessons from the field.** Jake VanCampen, Portland, OR

9:00 a.m. **Integrating the GDM in Europe: AACR Project GENIE® lessons for genomDE, CANDLE in the quest for a European health data space.** Hauke Busch, Lübeck, Germany

Professional Development Session
9:00 a.m.–4:00 p.m.

Grand Hall BCD - Manchester Grand Hyatt San Diego

21st AACR Undergraduate Student Caucus and Poster Competition

Chair: Brian M. Rivers, Atlanta, GA

9:00 a.m. **Welcome remarks.** Brian M. Rivers, Atlanta, GA

9:45 a.m. **Understanding Cancer.** John M. Carethers, San Diego, CA

10:05 a.m. **Personal Message from a Cancer Survivor.** Carlos Sandi, Frederick, MD

10:20 a.m. **Lead judge.** Sandra Ryeom, New York, NY

10:35 a.m. **Lead judge.** Beverly D. Lyn-Cook, Jefferson, AR

11:00 a.m. **Poster Session**

1:30 p.m. **Professional Developent Panel and Q&Z**

Moderator: Christopher M. Sistrunk, Duarte, CA

Panelists: Heather Beasley, Nashville, TN; Rui Li, Los Angeles, CA; Greisha Ortiz Hernandez, Duarte, California; Harsha Sanaka, Columbus, OH

3:15 p.m. **Navigating the AACR Annual Meeting.** Paul S. Mischel, Stanford, CA

3:30 p.m. **Remarks from AACR President.** Lillian. L. Siu, Toronto, Canada

3:40 p.m. **Announcement of prizes.** Margaret Foti, Philadelphia, PA

3:50 p.m. **Closing remarks and evaluation.** Brian M. Rivers, Atlanta, GA

Educational Sessions
10:00 a.m.–11:30 a.m.

Room 11 - Upper Level - Convention Center

Academic Entrepreneurship: Getting Your Discovery to Patients, Part 2— Preparing for a Perfect Landing

NOT ELIGIBLE FOR CME CREDIT

Chair: William N. Hait, New Brunswick, NJ

10:00 a.m. **Chair Introduction.** William N. Hait, New Brunswick, NJ

Panelists: Christian Hinrichs, New Brunswick, NJ; Levi A. Garraway, South San Francisco, CA; Avrum E. Spira, Boston, MA

Room 1 - Upper Level - Convention Center

Regulatory Science and Policy Session

Advancing Patient-Centered Clinical Trials: Bringing Trials to Patients and Patients to Trials

NOT ELIGIBLE FOR CME CREDIT

Moderator: Roy S. Herbst, New Haven, CT

10:05 a.m. **The impact of a community-focused approach.** Robert A. Winn, Richmond, VA

10:15 a.m. **Pragmatic clinical trials in action: Lessons from Pragmatica-Lung.** Konstantin H. Dragnev, Lebanon, VT

10:25 a.m. **Hybrid decentralized clinical trials: Connecting community-based screening to early-phase trial access.** Patricia M. LoRusso, New Haven, CT

Panelists: Electra D. Paskett, Columbus, OH; Camille Campbell, Fairfax, VA

Room 29 - Upper Level - Convention Center

Beyond Sex: The Y Chromosome in Cancer

Chair: Dan Theodorescu, Tucson, AZ

10:00 a.m. **Chair Introduction.** Dan Theodorescu, Tucson, AZ

10:01 a.m. **Hematopoietic loss of Y in male health and cancer.** Lars Forsberg, Uppsala, Sweden

10:31 a.m. **Mechanisms of LOY driven cancer.** Dan Theodorescu, Tucson, AZ

11:00 a.m. **Y chromosome loss as a driver of cancer.** Esther Rheinbay, Boston, MA

Room 31 - Upper Level - Convention Center

Biology, Mechanisms, and Models of Cachexia

Chair: Teresa A. Zimmers, Portland, OR

10:00 a.m. **Chair Introduction.** Teresa A. Zimmers, Portland, OR

10:01 a.m. **Mechanisms of self-consumption and support of tumor growth during cancer cachexia.** Tor Erik Rusten, Oslo, Norway

10:31 a.m. **Cancer-induced systemic reprogramming of cellular identity in cachexia.** Teresa A. Zimmers, Portland, OR

11:01 a.m. **From VHL loss to cachexia: Targeting the HIF2-PTHrP axis in kidney cancer.** Muhannad Abu-Remaileh, Boston, MA

Ballroom 20 CD - Upper Level - Convention Center

Chemistry to the Clinic Part 2 of 4: Beyond Inhibition—The Next Frontier in Proximity-Inducing Therapies

Chair: Michael A. Erb, La Jolla, CA

10:00 a.m. **Chair Introduction.** Michael A. Erb, La Jolla, CA

10:01 a.m. **Rewiring DNA repair using proximity pharmacology.** Michael A. Erb, La Jolla, CA

10:30 a.m. **Progress in induced proximity therapeutics beyond degradation.** William J. Gibson, Boston, MA

11:00 a.m. **Next-generation molecular discovery for induced proximity approaches.** Steven Banik, Stanford, CA

Room 33 - Upper Level - Convention Center

Epistasis and Evolution: How Genetic Interactions Shape Cancer Trajectories

Chair: Jeffrey Peter Townsend, New Haven, CT

10:00 a.m. **Chair Introduction.** Jeffrey Peter Townsend, New Haven, CT

10:01 a.m. **Detecting and modeling genetic interactions in cancer evolution.** Jamie Iranzo, Madrid, Spain

10:25 a.m. **Quantifying epistasis and evolutionary trajectories in cancer.** Jorge Alfaro-Murillo, San José, Costa Rica

10:50 a.m. **Tobacco smoking and the somatic selective epistasis in lung adenocarcinoma: Gene-by-environment interactions and clinical implications.** Jeffrey Peter Townsend, New Haven, CT

Ballroom 6 B - Upper Level - Convention Center

From Mechanisms to Real-World Evidence: The Emerging Role of GLP-1 Receptor Agonists in Cancer Prevention and Outcomes

Chair: Jiang Bian, Indianapolis, IN

10:00 a.m. **Chair Introduction.** Jiang Bian, Indianapolis, IN

10:01 a.m. **Obesity and cancer: A modifiable risk factor?** Jennifer Ligibel, Boston, MA

10:24 a.m. **Preclinical evidence for the anticancer effects and mechanisms of GLP-1 receptor agonists.** Stephen D. Hursting, Chapel Hill, NC

10:47 a.m. **Real-world evidence on GLP-1 receptor agonists and cancer: Risk, outcomes, and open questions.** Jiang Bian, Indianapolis, IN

Ballroom 6 CF - Upper Level - Convention Center

Mapping Neural-Immune Circuits: Spatial Multi-Omics in the Tumor Microenvironment

Chair: Moran Amit, Houston, TX

10:00 a.m. **Chair Introduction.** Moran Amit, Houston, TX

10:03 a.m. **Pearls and pitfalls in spatial multiomics: Platform selection, tissue handling, and advanced image analysis for neuroimmune characterization.** Logan Alexander Walsh, Montreal, QC, Canada

10:33 a.m. **From tissue to insight: Real-world applications of spatial multiomics in neuroimmune tumor biology.** William L. Hwang, Boston, MA

11:03 a.m. **Translating spatial multiomics into clinical action: Integration of spatial, clinical, and population data.** Moran Amit, Houston, TX

Room 30 - Upper Level - Convention Center

Metastatic Organotropism: Clues from Primary Tumors and Metastatic Niches

Chair: Massimo Loda, New York, NY

10:00 a.m. **Chair Introduction.** Massimo Loda, New York, NY

10:05 a.m. **The stromal microenvironment as a determinant of metastatic organotropism.** Massimo Loda, New York, NY

10:30 a.m. **Learning the metabolic code of metastatic organotropism.** George Poulogiannis, London, United Kingdom

10:55 a.m. **How circulating tumor cells find their way to distant sites.** Cory Abate-Shen, New York, NY

Room 28 - Upper Level - Convention Center

Small Patients, Big Problems: Precision Medicine Approaches for Childhood Cancer

Chair: Sarah K. Tasian, Philadelphia, PA

10:00 a.m. Chair Introduction. Sarah K. Tasian, Philadelphia, PA

10:01 a.m. **Impact of precision medicine in childhood CNS tumors and beyond.** David Ziegler, Randwick, NSW, Australia

10:30 a.m. **Approaching molecular stratification for bone sarcomas through collaboration.** Katherine A. Janeway, Boston, MA

11:00 a.m. **Therapeutic potential of targeted inhibitors for children with high risk leukemias.** Sarah K. Tasian, Philadelphia, PA

Ballroom 20 AB - Upper Level - Convention Center

Tumor Immunology For Non Immunologists: Back to Basics

Chair: Greg M. Delgoffe, Pittsburgh, PA

10:00 a.m. **Chair Introduction.** Greg M. Delgoffe, Pittsburgh, PA

10:05 a.m. **Tumor-induced immune suppression and its targeting with checkpoint blockade.** Greg M. Delgoffe, Pittsburgh, PA

10:30 a.m. **From T cell biology to cancer therapy: Programming immunity for durable responses.** Chrystal Mary Paulos, Atlanta, GA

10:55 a.m. **Tumor immunology in clinical practice: responses, biomarkers, toxicities.** Dmitriy Zamarin, New York, NY

Methods Workshop
10:00 a.m.–11:30 a.m.

Room 5 - Upper Level - Convention Center

Bayesian and Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Efficiency

NOT ELIGIBLE FOR CME CREDIT

Chair: Ying Yuan, Houston, TX

10:00 a.m. **Chair Introduction.** Ying Yuan, Houston, TX

10:00 a.m. **Early-phase clinical trial designs: Balancing complexity, data, and information for dose optimization.** Sumithra J. Mandrekar, Rochester, MN

10:30 a.m. **Revolutionizing phase I oncology trials using BOIN framework and backfill: Implementation and regulatory feedback.** Philip He, Basking Ridge, NJ

11:00 a.m. **Bayesian designs for safety and futility monitoring in early-phase clinical trials.** Ying Yuan, Houston, TX

Clinical Trials Minisymposium
10:00 a.m.–12:00 p.m.

Ballroom 6 A - Upper Level - Convention Center

Updates in Anticancer Immunotherapies

NOT ELIGIBLE FOR CME CREDIT

Cochairs: Edward B. Garon, Los Angeles, CA; Michael Cecchini, New Haven, CT

10:00 a.m. **Chair Introduction.** Edward B. Garon, Los Angeles, CA

10:05 a.m. **CT001 Evaluation of pharmacodynamic and potential predictive biomarkers for GV20-0251, an anti-IGSF8 antibody, as monotherapy from ongoing Phase 1/2a study.** Xingfeng Bao, Newton, MA

10:20 a.m. **CT002 First-in-human phase I study of PLN-101095, a first-in-class dual $\alpha v\beta 8/\alpha v\beta 1$ integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI).** Timothy A. Yap, Houston, TX

10:35 a.m. **CT003 Initial results of a phase 1 study of a.m.G 355, a novel anti-CCR8 antibody as a single agent and in combination with pembrolizumab in patients with solid tumors.** Antoine Hollebecque, Villejuif, France

10:50 a.m. **CT004 Safety of prolonged checkpoint inhibitor exposure in alveolar soft part sarcoma (ASPS) patients.** Alice P. Chen, Bethesda, MD

11:05 a.m. **CT006 Phase 1 DKY709A12101C study in patients with advanced solid tumors treated with DKY709, an IKZF2 degrader, alone or in combination with PDR001, a PD-1 inhibitor.** Elena Garralda, Barcelona, Spain

11:20 a.m. **CT007 A phase 2 study of tislelizumab (TIS) + investigational agents as first-line (1L) treatment in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC).** Hye Ryun Kim, Seoul, Republic of Korea

11:35 a.m. **CT008 Ten-year survival and cell-free DNA methylation profiling of melanoma patients with asymptomatic brain metastases treated with nivolumab plus ipilimumab: The multicenter phase III NIBIT-M2 trial.** Anna Maria Di Giacomo, Siena, Italy

11:50 a.m. **Closing remarks.** Michael Cecchini, New Haven, CT

Awards and Lectures
12:30 p.m.–2:00 p.m.

Ballroom 6 DE - Upper Level - Convention Center

AACR Team Science Award Lecture

NOT ELIGIBLE FOR CME CREDIT

Chair: Amina Zoubeidi, Vancouver, BC, Canada

Building the Cancer Dependency Map. Francisca Vazquez, Cambridge, MA

Perspectives: Cancer Dependency Map (DepMap) Team Members

ABIM CME MOC ACCREDITED

Educational Sessions
12:30 p.m.–2:00 p.m.

Room 28 - Upper Level - Convention Center

3D Tissue Imaging and Cancer

Chair: Peter Karl Sorger, Boston, MA

12:30 p.m. **Chair Introduction.** Peter Karl Sorger, Boston, MA

12:31 p.m. **High-plex 3D imaging to dissect mechanisms of immunosurveillance in immunosuppression in human tumors.** Peter Karl Sorger, Boston, MA

1:05 p.m. **AI approaches for 3D imaging in cancer.** Ashley Kiemen, Baltimore, MD

1:40 p.m. **Quantitative 3D views of whole cells with soft x-ray tomography.** Carolyn A. Larabell, San Francisco, CA

Ballroom 20 AB - Upper Level - Convention Center

AI in Biomarker Discovery and Drug Development

NOT ELIGIBLE FOR CME CREDIT

Chair: Jakob Nikolas Kather, Dresden, Germany

12:30 p.m. **Chair Introduction.** Jakob Nikolas Kather, Dresden, Germany

12:31 p.m. **Multimodal and agentic AI in biomarker discovery.** Jakob Nikolas Kather, Dresden, Germany

1:00 p.m. **AI in practice: From biological insight to clinical strategy.** Teeru Bihani, New York, NY

1:30 p.m. **AI transformation of pharmaceutical R&D.** Jorge S. Reis-Filho, Wilmington, DE

Room 5 - Upper Level - Convention Center

Beyond Cardiotoxicity: How Cardiovascular Disease and Systemic Risk Factors Drive Tumorigenesis

Chair: Javid J. Moslehi, San Francisco, CA

12:30 p.m. **Chair Introduction.** Javid J. Moslehi, San Francisco, CA

12:31 p.m. **Cardio-oncology: Beyond toxicology.** Javid J. Moslehi, San Francisco, CA

12:41 p.m. **Hyperlipidemia as a cancer risk factor.** Donald P. McDonnell, Durham, NC

1:01 p.m. **The bidirectional relationship between cancer and cardiovascular disease.** Nicholas J. Leeper, Stanford, CA

1:21 p.m. **Cardiovascular disease and cancer: A dangerous liaison.** Kathryn Moore, New York, NY

Ballroom 6 B - Upper Level - Convention Center

Cancer Metabolism as a Therapeutic Frontier

NOT ELIGIBLE FOR CME CREDIT

Chair: Ping-Chih Ho, Lausanne, Switzerland

12:30 p.m. **Chair Introduction.** Ping-Chih Ho, Lausanne, Switzerland

12:31 p.m. **Metabolic vulnerabilities in cancer.** Gina M. DeNicola, Tampa, FL

1:00 p.m. **DDRiving til exhausted!** Ping-Chih Ho, Lausanne, Switzerland

1:30 p.m. **Metabolic checkpoints in tumor macrophages for cancer immunotherapy.** Stanley Ching-Cheng Huang, Columbus, OH

Ballroom 20 CD - Upper Level - Convention Center

Chemistry to the Clinic Part 3 of 4: Novel Modalities, Targets, and Mechanisms in Drugging Oncogenic Pathways

NOT ELIGIBLE FOR CME CREDIT

Chair: Aimee Usera, Cambridge, MA

12:30 p.m. **Chair Introduction.** Aimee Usera, Cambridge, MA

12:31 p.m. **Orally bioavailable peptide macrocycles disrupting intracellular protein-protein interactions: Selective inhibitors of the RxL-binding site of cyclin family proteins.** Justin A. Shapiro, San Francisco, CA

1:00 p.m. **Structure-guided small-molecule inhibition of DHX8, a DEAH-box RNA helicase involved in mRNA splicing.** Robert L. Van Montfort, Sutton, United Kingdom

1:30 p.m. **Activation lethality: A new therapeutic strategy toward drugging oncogenic signaling pathways.** Aimee Usera, Cambridge, MA

Room 15 - Mezzanine Level - Convention Center

Clinical and Molecular Phenotyping of Cancer Cachexia

NOT ELIGIBLE FOR CME CREDIT

Chair: Marcus DaSilva Goncalves, New York, NY

12:30 p.m. **Chair Introduction.** Marcus DaSilva Goncalves, New York, NY

12:31 p.m. **A health-system-scale, episode-resolved multimodal atlas of cancer cachexia.** Eduard Reznik, New York, NY

1:01 p.m. **Observational research study to uncover subtypes of cancer cachexia.** Richard Dunne, Rochester, NY

1:31 p.m. **Microbiome-driven myeloid remodeling as a mechanism of cachexia and immunotherapy resistance in lung cancer.** Marcus DaSilva Goncalves, New York, NY

Room 29 - Upper Level - Convention Center

Fibroblast Dynamics: How Heterogeneity Shapes the Tumor Microenvironment

Chair: Stephanie K. Dougan, Boston, MA

12:30 p.m. **Chair Introduction.** Stephanie Dougan, Boston, MA

12:31 p.m. **Fibroblasts and anti-tumor immunity.** Stephanie Dougan, Boston, MA

1:00 p.m. **Identifying stromal barriers to pancreatic tumorigenesis.** Mara H. Sherman, New York, NY

1:30 p.m. **Mapping tumor promoting and restrictive features of the tumor microenvironment.** Claus Jorgensen, Manchester, United Kingdom

Room 11 - Upper Level - Convention Center

From Risk Awareness to Informed Action: Advancing Cancer Communication Across Prevention and Genomic Care

Chair: Anita Y. Kinney, New Brunswick, NJ

12:30 p.m. **Chair Introduction.** Anita Y. Kinney, New Brunswick, NJ

12:30 p.m. **Strategies for effective health communication in a complex information environment.** Jeffrey Niederdeppe, Ithaca, NY

1:00 p.m. **If you aim at nothing, you will hit it every time: Using audience segmentation and commercial marketing techniques to understand how to effectively develop health communication messages.** Sara Bauerele Bass, Philadelphia, PA

1:30 p.m. **Bridging genomic knowledge and patient action: Strategies for risk communication and guideline-based care.** Anita Y. Kinney, New Brunswick, NJ

Room 30 - Upper Level - Convention Center

Hematological Malignancies: Undruggable Targets and New Frontiers

Chair: Faith E. Davies, New York, NY

12:30 p.m. **Chair Introduction.** Faith E. Davies, New York, NY

12:31 p.m. **Functional genomic and drug screening for precision medicine approaches in acute leukemia.** Yana Pikman, Boston, MA

1:00 p.m. **Bruton's tyrosine kinase inhibitor resistance in chronic lymphocytic leukemia: Implications for therapeutic sequencing.** Jennifer A. Woyach, Columbus, OH

1:30 p.m. **Novel molecular targets in multiple myeloma.** Faith E. Davies, New York, NY

Ballroom 6 CF - Upper Level - Convention Center

Multi-modal Platforms for Early Cancer Detection

Chair: Kara N. Maxwell, Philadelphia, PA

12:30 p.m. **Chair Introduction.** Kara N. Maxwell, Philadelphia, PA

12:31 p.m. **LINE-1: A "pan-cancer" biomarker of carcinoma and high-risk precursors.** Martin Samuel Taylor, Providence, RI

1:00 p.m. **Humoral immunity in early cancer detection and prognosis.** Chi Van Dang, New York, NY

1:30 p.m. **Multi-modal early detection in patients with inherited cancer risk.** Kara N. Maxwell, Philadelphia, PA

Room 33 - Upper Level - Convention Center

New Insights from TCGA Whole-Genome Sequencing

Chair: Gad Getz, Boston, MA

12:30 p.m. **Chair Introduction.** Gad Getz, Boston, MA

12:37 p.m. **Representation learning over cancer genomes: Scaling petabytes to prediction.** Jason J. Pitt, Singapore, Singapore

1:05 p.m. **Dimensions of structural chromosomal instability in human cancer.** Marcin Imielinski, New York, NY

1:33 p.m. **Systematic analysis of >8,000 TCGA whole-genomes.** Gad Getz, Boston, MA

Room 1 - Upper Level - Convention Center

Regulatory Science and Policy Session

Where Expedited Pathways, Innovation, Safety, and Patient Access Collide: A KRAS Case Study

NOT ELIGIBLE FOR CME CREDIT

Moderators: Elizabeth M. Jaffee, Baltimore, MD; Timothy A. Yap, Houston, TX

12:40 p.m. **Promise vs. access in KRAS therapies: Navigating trials, evidence, and patient demand.** Ignacio Garrido-Laguna, Tampa, FL

12:55 p.m. **Panel discussion.**

Panelists: Andrew Rakeman, Woodbury, NY; Lola A. Fashoyin-Aje, Silver Spring, MD; Cristian Massacesi, Princeton, NJ; Mark Wicclair, Pittsburgh, PA; Mark Lee, Redwood City, CA

ABIM CME MOC ACCREDITED

Methods Workshop
12:30 p.m.–2:00 p.m.

Room 31 - Upper Level - Convention Center

Bridging the Gap: Multilevel Strategies to Expand Access to Cancer Clinical Trials

Chair: Electra D. Paskett, Columbus, OH

12:30 p.m. **Chair Introduction.** Electra D. Paskett, Columbus, OH

12:30 p.m. **The Ohio State University accrual to clinical trials (ACT's) initiative.** Electra D. Paskett, Columbus, OH

12:45 p.m. **Advancing clinical trials: Working through outreach, navigation and digitally enabled referral and recruitment strategies (ACT WONDER2S).** Susan T. Vadaparampil, Tampa, FL

1:00 p.m. **The SUPPORT trial: The ECOG ACRIN - NCI NCORP community oncology practice sites clinical trial referral initiative.** Melissa A. Simon, Chicago, IL

1:15 p.m. **Meet ALEX: A tailored intervention to build trust and facilitate cancer clinical trial referrals.** Janice Raup-Krieger, Gainesville, FL

1:30 p.m. **Enabling a cross-site network in CP2CT through a learning collaborative, data coordination, and evaluation.** Folakemi T. Odedina, Jacksonville, FL

SATURDAY, APRIL 18

Clinical Trials Minisymposium
12:30 p.m.–2:30 p.m.

Ballroom 6 A - Upper Level - Convention Center

Aiming for Cure: Perioperative Clinical Trials
NOT ELIGIBLE FOR CME CREDIT

Cochairs: Alice Y. Ho, Houston, TX; Kenneth Kenji Tanabe, Boston, MA

12:31 p.m. **Chair Introduction.** Alice Y. Ho, Houston, TX

12:36 p.m **CT011 Genomic HER2 amplification predicts for complete clinical response in a phase II study of induction tucatinib and trastuzumab combined with chemotherapy in locally advanced rectal adenocarcinoma.** Michael B. Foote, New York, NY

12:51 p.m. **CT012 A phase 2 single-arm open-label trial evaluating zanidatamab in patients with early stage HER2 positive breast cancer: The NeoZanHER Study.** Funda Meric-Bernstam, Houston, TX

1:06 p.m **CT013 Whole-exome sequencing tumor-informed circulating tumor DNA detection after completion of neoadjuvant treatment predicts non-pCR and distant recurrence in patients with early triple-negative breast cancer (TNBC) — Results from a sub-study of the NSABP B-59/GBG-96-GeparDouze Trial.** Marija Balic, Pittsburgh, PA

1:21 p.m. **CT014 Perioperative adebrelimab (A) plus chemotherapy (chemo) in resectable stage II-III NSCLC: Phase 3 EFS interim analysis (IA) and molecular residual disease (MRD) analysis.** Yi-Long Wu, Guangzhou, China

1:36 p.m. **CT015 Clinical outcomes by genomic markers and ctDNA dynamics with perioperative nivolumab (NIVO) for resectable NSCLC from CheckMate 77T.** Tina Cascone, Houston, TX

1:51 p.m. **CT016 Feasibility and efficacy of perioperative nivolumab with or without relatlimab for patients with potentially resectable hepatocellular carcinoma.** Howard L. Li, Baltimore, MD

2:06 p.m. **CT017 Neoadjuvant IL-1β and PD-1 inhibition in localized clear-cell renal cell carcinoma: Clinical and correlative analyses of the phase 1b SPARC-1 trial.** Patrick J. McCann, New York, NY

2:20 p.m. **Closing Remarks.** Kenneth Kenji Tanabe, Boston, MA

Educational Sessions
2:30 p.m.–4:00 p.m.

Room 28 - Upper Level - Convention Center

Cancer Systems Biology, Ecology, and Evolution

Chair: Jason A. Somarelli, Durham, NC

2:30 p.m. **Chair Invitation.** Jason A. Somarelli, Durham, NC

2:31 p.m. **Measuring cancer evolution with mathematical modelling and machine learning.** Andrea Sottoriva, Milan, Italy

2:51 p.m. **Phase I trials in cancer: From board to bench to bedside and back again.** Alexander R.A. Anderson, Tampa, FL

3:11 p.m. **Targeting drug-induced quiescence and pro-survival phenotypes to prevent the evolution of resistance.** Jason A. Somarelli, Durham, NC

Ballroom 20 CD - Upper Level - Convention Center

Chemistry to the Clinic Part 4 of 4: From Transcript to Protein—New Frontiers in Drug Discovery
NOT ELIGIBLE FOR CME CREDIT

Chair: Ryan Potts, Thousand Oaks, CA

2:30 p.m. **Chair Introduction.** Ryan Potts, Thousand Oaks, CA

2:31 p.m. **Reimagining druggability using chemoproteomic platforms.** Daniel K. Nomura, Berkeley, CA

3:00 p.m. **RIPTACs: A novel, powerful modality to treat patients with prostate cancer and other diseases.** Katherine J. Kayser-Bricker, New Haven, CT

3:30 p.m. **Controlling protein fate as a therapeutic strategy.** Ryan Potts, Thousand Oaks, CA

Ballroom 6 B - Upper Level - Convention Center

Chromosomal Instability in Cancer: From Mechanism to Therapy and Clinical Translation
NOT ELIGIBLE FOR CME CREDIT

Chair: Samuel F. Bakhoum, Hanover, NH

2:30 p.m. **Chair Introduction.** Samuel F. Bakhoum, Hanover, NH

2:31 p.m. **Cell-intrinsic vulnerabilities of chromosomally unstable cancers.** Uri Ben-David, Tel Aviv, Israel

3:01 p.m. **Invited Speaker.** Ashley M. Laughney, New York, NY

3:31 p.m. **Targeting chromosomal instability in the clinic.** Samuel F. Bakhoum, Hanover, NH

Room 29 - Upper Level - Convention Center

Comparison of Solid and Liquid Tumors

Chair: Hugues De Thé, Paris, France

2:30 p.m. **Chair Introduction.** Hugues De Thé, Paris, France

2:31 p.m. **What makes acute promyelocytic leukemia cured by targeted therapies?** Hugues De Thé, Paris, France

3:00 p.m. **Cell death regulation distinguishes hematologic malignancies from solid tumors and drives divergent therapy responses.** Kristopher A. Sarosiek, Boston, MA

3:30 p.m. **Mapping a new function for an old tumor suppressor: How NF1 and microtubule damage differentially regulate genome stability and drug response depending on tumor context.** Luca Mazzarella, Milano, Italy

Room 1 - Upper Level - Convention Center

Regulatory Science and Policy Session

Contextual Challenges in Interpreting Performance of Blood-Based Early Cancer Detection Tests

NOT ELIGIBLE FOR CME CREDIT

Moderators: Christina Clarke Dur, Menlo Park, CA; Bree L. Mitchell, San Carlos, CA

Panelists: Anand Pathak, Silver Spring, MD; Gary Puckrein, Washington, DC

2:40 p.m. **Definitions and Interpretations of Target Conditions of SCED and MCED.** Nima Nabavizadeh, Portland, OR

2:55 p.m. **Defining the Intended Use Population and Ensuring Real-World Generalizability.** Aasma Shaukat, New York, NY

3:10 p.m. **Performance Statistics in Single- and Multi-Cancer Tests.** Robert A. Smith, Atlanta, GA

Room 16 - Mezzanine Level - Convention Center

Continuous Oncology: Wearables, Digital Biomarkers, and the Future of Cancer Interception

NOT ELIGIBLE FOR CME CREDIT

Chair: Peter Kuhn, Los Angeles, CA

2:30 p.m. **Chair Introduction.** Peter Kuhn, Los Angeles, CA

2:35 p.m. **Consumer wearable devices for remote patient monitoring during cancer treatment.** Carissa Low, Pittsburgh, PA

3:00 p.m. **Wearable devices and AI in digital medicine.** Giorgio Quer, La Jolla, CA

3:25 p.m. **Integrating sensor data and AI into clinical decision making.** Jorge J. Nieva, Los Angeles, CA

Room 15 - Mezzanine Level - Convention Center

Identification and Management of Reduced Penetrance High-risk Cancer Gene Variants

Chair: Alvaro N. Monteiro, Tampa, FL

2:30 p.m. **Chair Introduction.** Alvaro N. Monteiro, Tampa, FL

2:31 p.m. **Consideration of inherited cancer risk on a continuum.** Tuya Pal, Nashville, TN

3:00 p.m. **Functional approaches to identify reduced penetrance pathogenic variants (RPPVs).** Alvaro N. Monteiro, Tampa, FL

3:30 p.m. **Challenges associated with clinical management of RPPVs.** Bryson William Katona, Philadelphia, PA

Room 5 - Upper Level - Convention Center

Innovations in Translating Social and Structural Determinants of Health Across Population, Community, and Basic Cancer Research

Chair: Adana A. M. Llanos, New York, NY

2:30 p.m. **Chair Introduction.** Adana A. M. Llanos, New York, NY

2:35 p.m. **Motivating social and structural drivers in cancer research: Frameworks, concepts, and why.** Adana A. M. Llanos, New York, NY

2:50 p.m. **Social and built environmental measures: Novel spatiotemporal approaches in population science.** Jesse J. Plascak, Columbus, OH

3:10 p.m. **Social and structural drivers of health at the intersection of community and basic science research.** Shannon M. Lynch, Philadelphia, PA

Ballroom 20 AB - Upper Level - Convention Center

KRAS Inhibitors: From Discovery to Patient Outcomes

NOT ELIGIBLE FOR CME CREDIT

Chair: Frank McCormick, San Francisco, CA

2:30 p.m. **Chair Introduction.** Frank McCormick, San Francisco, CA

2:31 p.m. **Targeting active KRAS and its effectors.** Frank McCormick, San Francisco, CA

3:30 p.m. **Direct targeting of multiple KRAS alleles and EGFR toward durable therapy.** Cameron Pitt, San Francisco, CA

3:00 p.m. **Targeting the oncogenic state of RAS: lessons from tri-complex inhibitors.** Mallika Singh, San Francisco, CA

Room 33 - Upper Level - Convention Center

Macrophages as Therapeutic Gatekeepers: From Biology to Clinical Application

Chair: Jennifer L. Guerriero, Boston, MA

2:30 p.m. **Chair Introduction.** Jennifer Guerriero, Boston, MA

2:31 p.m. **From complexity to therapy: Targeting tumor-promoting lipid macrophages.** Jennifer Guerriero, Boston, MA

3:00 p.m. **Redefining and targeting immunosuppressive myeloid cells in solid tumors.** Tyler E. Miller, Cleveland, OH

3:30 p.m. **The macrophage makeover: Tailoring innate immunity for cancer therapy.** Thomas Urban Marron, New York, NY

Room 30 - Upper Level - Convention Center

Manufacturing and Engineering the Next Generation of Immune Effectors

NOT ELIGIBLE FOR CME CREDIT

Chair: H. Trent Spencer, Atlanta, GA

2:30 p.m. **Chair Introduction.** H. Trent Spencer, Atlanta, GA

2:31 p.m. **Engineering effective CAR T cell therapy beyond B cell malignancy, lessons learned and applied.** Rimas J. Orentas, Gaithersburg, MD

3:00 p.m. **Manufacturing and engineering strategies to enhance the anti-cancer effective of innate immune effectors.** H. Trent Spencer, Atlanta, GA

3:30 p.m. **Advancements in vivo CAR T cell delivery.** Ryan P. Larson, Seattle, WA

Room 31 - Upper Level - Convention Center

Mechanotransduction in Tumor Development, Metastasis, and Therapy Resistance

Chair: Jing Yang, La Jolla, CA

2:30 p.m. **Chair Introduction.** Jing Yang, La Jolla, CA

2:31 p.m. **Engineered models of glioblastoma: Discovery, screening, and validation.** Sanjay Kumar, Berkeley, CA

3:00 p.m. **Forcing through metastasis: Regulation of epithelial-mesenchymal plasticity by ECM stiffness.** Jing Yang, La Jolla, CA

3:30 p.m. **Mechanical inputs from the microenvironment-Implications for diagnostics and therapeutic applications.** Kandice Tanner, Bethesda, MD

Ballroom 6 DE - Upper Level - Convention Center

New Technologies in the Metabolism of Cancer

Chair: Matthew G. Vander Heiden, Cambridge, MA

2:30 p.m. **Chair Introduction.** Matthew G. Vander Heiden, Cambridge, MA

2:31 p.m. **Spatial metabolomics of pancreatic and breast cancer.** Joshua D. Rabinowitz, Princeton, NJ

3:01 p.m. **Metabolic regulation of cancer cell growth.** Gerta Hoxhaj, Dallas, TX

3:31 p.m. **How metabolism influences cancer progression.** Matthew G. Vander Heiden, Cambridge, MA

Room 11 - Upper Level - Convention Center

Radiotheranostics: Nuts and Bolts

Chair: Kayvan R. Keshari, New York, NY

2:30 p.m. **Chair Introduction.** Kayvan R. Keshari, New York, NY

2:31 p.m. **CMIT and the state of radiotheranostics.** Kayvan R. Keshari, New York, NY

2:40 p.m. **Radiotheranostics: What's important for choosing and producing an isotope for theranostics.** Cathy S. Cutler, Upton, NY

3:05 p.m. **Radiotheranostics in routine use and on the horizon.** Jonathan McConathy, Birmingham, AL

SATURDAY, APRIL 18

Methods Workshop
2:30 p.m.–4:00 p.m.

Ballroom 6 CF - Upper Level - Convention Center

Deep Learning in Digital Pathology: From Morphology to Multimodal Biomarkers

Chair: Alexander T. Pearson, Chicago, IL

2:30 p.m. **Chair Introduction.** Alexander T. Pearson, Chicago, IL

2:31 p.m. **Fundamentals of deep learning for digital pathology.** Alexander T. Pearson, Chicago, IL

3:00 p.m. **Implementing computational biomarkers for real world translation.** Gabriele Campanella, New York, NY

3:30 p.m. **AI pathology meets spatial omics: Decoding tissue architecture for biomarkers.** Linghua Wang, Houston, TX

Plenary Session
4:15 p.m.–6:15 p.m.

Hall H - Ground Level - Convention Center

Discovery Science Plenary. The Next Frontier in Minimal Residual Disease: Solid Tumors

NOT ELIGIBLE FOR CME CREDIT

Chair: Maximilian Diehn, Stanford, CA

4:15 p.m. **Chair Introduction.** Maximilian Diehn, Stanford, CA

4:20 p.m. **From persistence to relapse: Evolution of drug resistance in lung cancer.** Aaron N. Hata, Boston, MA

4:47 p.m. **Therapeutic strategies to address cancer cell heterogeneity and plasticity.** Jean-Christophe Marine, Leuven, Belgium

5:14 p.m. **The hidden lives of cancer cells: Somatic evolution, cellular plasticity, and the detection of residual disease.** Dan A. Landau, New York, NY

5:41 p.m. **MRD-directed treatment strategies in colorectal cancer.** Jeanne Tie, Melbourne, VIC, Australia

6:08 p.m. **Closing remarks.** Maximilian Diehn, Stanford, CA

SUNDAY, APRIL 19

Opening Ceremony
7:45 a.m.–9:30 a.m.

Hall H - Ground Level - Convention Center

Additional seating to view the Opening Ceremony will be available in Room 20 AB and Room 20 CD.

Join us on Sunday for the Annual Meeting Opening Ceremony, a yearly tradition marking the start of four days filled with outstanding and innovative science. Highlights of this year's Opening Ceremony include:

- Remarks from AACR CEO Margaret Foti and AACR President Lillian L. Siu
- Presentation of Fellows of the AACR Academy 2026
- AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
- AACR Award for Lifetime Achievement in Cancer Research
- AACR June L. Biedler Prizes for Cancer Journalism
- Remarks from NCI Director Anthony Letai

Don't miss this exciting event!

Plenary Session
9:30 a.m.–11:30 a.m.

Additional seating to the Opening Plenary will be available in Room 20 AB and Room 20 CD.

Hall H - Ground Level - Convention Center

Opening Plenary. Precision, Partnership, Purpose: Advancing Cancer Science to Save Lives Globally

Cochairs: Paul S. Mischel, Stanford, CA; Alice T. Shaw, Boston, MA

9:30 a.m. **Chair Introductions.** Paul S. Mischel, Stanford, CA; Alice T. Shaw, Cambridge, MA

9:40 a.m. **How cancer cells escape targeted therapy by changing identity.** Charles L. Sawyers, New York, NY

10:07 a.m. **Beyond blood: The evolution of CAR T therapy for solid malignancies.** Carl H. June, Philadelphia, PA

10:34 a.m. **Chemical rewiring of biological circuits for cancer therapy: Targeted protein degradation and beyond.** Georg E. Winter, Vienna, Austria

11:01 a.m. **Rethinking cancer diagnosis and treatment with AI: From molecular mechanisms to clinical management.** Regina Barzilay, Cambridge, MA

Meet and Greet
12:00 p.m.–1:00 p.m.

AACR Publications Booth 3537 - Hall D

Meet the Editor-in-Chief of *Molecular Cancer Therapeutics:* Daniel K. Nomura, PhD

Awards and Lectures
12:00 p.m.-12:45 p.m.

Ballroom 20 CD - Upper Level - Convention Center

Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research

Chair: Jos Jonkers, Amsterdam, Netherlands

Funder Remarks: Enzo Galligioni, Trento, Italy

The HPV Vaccines Continue to Surprise. Douglas R. Lowy, Bethesda, MD; John T. Schiller, Bethesda, MD

Major Symposium
12:00 p.m.–1:30 p.m.

Ballroom 6 B - Upper Level - Convention Center

Human Cancer Models: From Patient-Derived Systems to Clinical Translation

Chair: Pier Paolo Claudio, Jackson, MS

12:00 p.m. **Chair Introduction.** Pier Paolo Claudio, Jackson, MS

12:05 p.m. **Ex vivo functional testing to support development of new therapeutic regimens in leukemia.** Jeffrey W. Tyner, Portland, OR

12:30 p.m. **SY36-02 Organoids for personalizing pancreatic cancer care.** David A. Tuveson, Cold Spring Harbor, NY

12:55 p.m. **SY36-03 Functional precision oncology: Predicting therapeutic response using live patient tumor models.** Pier Paolo Claudio, Jackson, MS

NCI-NIH-Selected Session
1:00 p.m.–2:00 p.m.

Room 2 - Upper Level - Convention Center

NCI Opportunities to Support Early Career Cancer Researchers and Research Specialists

Moderator: Nastaran Zahir, Rockville, MD

1:01 p.m. **Overview of NCI support for cancer research training and workforce development.** Nastaran Zahir, Rockville, MD

1:03 p.m. **Training at NCI.** Chanelle Borden, Rockville, MD

1:15 p.m. **Fellowship funding opportunities.** Mark Damico, Rockville, MD

1:27 p.m. **Career development award funding opportunities.** Susan Lim, Rockville, MD

1:39 p.m. **Research specialist award for laboratory and core scientists.** Kelly Crotty, Rockville, MD

1:45 p.m. **Clinician research scientist award.** Wolf Lindwasser, Rockville, MD

Advances in Hematologic Malignancies
1:00 p.m.–2:30 p.m.

Room 28 - Upper Level - Convention Center

Epigenetics in Hematologic Malignancies

Chair: Steven Josefowicz, New York, NY

1:00 p.m. **Chair Introduction.** Steven Josefowicz, New York, NY

1:05 p.m. **Signaling to chromatin and epigenetic switches in hematopoietic cells.** Steven Josefowicz, New York, NY

1:30 p.m. **Targeting epigenetic dependencies in myeloid malignancies.** Ross L. Levine, New York, NY

1:55 p.m. **Epigenetic priming as a strategy for enhancing T cell-directed therapies.** Jennifer E. Amengual, New York, NY

Advances in Organ Site Research
1:00 p.m.–2:30 p.m.

Room 11 - Upper Level - Convention Center

Advances in Bladder Cancer Research and Treatment: Pathways to Precision Medicine

Chair: Bishoy Faltas, New York, NY

1:00 p.m. **Chair Introduction.** Bishoy Faltas, New York, NY

1:05 p.m. **Advances in risk stratification and appropriate management of non-muscle invasive bladder cancer.** Ashish M. Kamat, Houston, TX

1:30 p.m. **Advances in the treatment of muscle-invasive bladder cancer.** Matthew Galsky, New York, NY

1:55 p.m. **The evolving landscape of bladder cancer care: Clinical breakthroughs and translational priorities.** Bishoy Faltas, New York, NY

Room 31 - Upper Level - Convention Center

Advances in Understanding Disseminated Tumor Cells: An Emerging Opportunity to Prevent Lethal Breast Cancer?

Chair: Lewis A. Chodosh, Philadelphia, PA

1:00 p.m. **Chair Introduction.** Lewis A. Chodosh, Philadelphia, PA

1:05 p.m. **Strategies to prevent lethal breast cancer recurrence by targeting disseminated tumor cells.** Lewis A. Chodosh, Philadelphia, PA

1:30 p.m. **NG02 Residual breast cancer cells co-opt SOX5-driven endochondral ossification to maintain dormancy.** Amulya Sreekumar, Philadelphia, PA

1:50 p.m. **Molecular characterization of patient-derived disseminated cancer cells identifies putative metastasis founder cells.** Christoph A. Klein, Regensburg, Germany

Room 33 - Upper Level - Convention Center

Gastric/Gastroesophageal Cancer Dynamics: Pre-Cancer Evolution, Metastasis, Microenvironment, and Therapeutic Breakthroughs

Chair: Suet Yi Leung, Pok Fu Lam, Hong Kong, SAR

1:00 p.m. **Chair Introduction.** Suet Yi Leung, Pok Fu Lam, Hong Kong, SAR

1:05 p.m. **Recent advances in pre-cancer evolution of the upper gastrointestinal tract.** Suet Yi Leung, Pok Fu Lam, Hong Kong, SAR

1:50 p.m. **Molecular heterogeneity in primary vs metastases and advances in Her2-directed therapeutics.** Jaffer A. Ajani, Houston, TX

1:25 p.m. **Resectable gastroesophageal cancer: Time to rewrite the standard.** Yelena Yuriy Janjigian, New York, NY

Advances in Population Sciences
1:00 p.m.–2:30 p.m.

Room 17 - Mezzanine Level - Convention Center

Advances in the Use of Geospatial and Neighborhood Data for Cancer Population Sciences Research and Translation

Chair: Trang VoPham, Seattle, WA

1:00 p.m. **Chair Introduction.** Trang VoPham, Seattle, WA

1:05 p.m. **A primer for geospatial science analytics in cancer research and translation.** Trang VoPham, Seattle, WA

1:25 p.m. **The impact of the environment and your neighborhood on cancer risk and survival.** Jaime E. Hart, Boston, MA

1:45 p.m. **The impact of structural and social drivers of health on cancer risk and survival. I**ona C. Cheng, San Francisco, CA

Advances in Prevention Research
1:00 p.m.–2:30 p.m.

Room 5 - Upper Level - Convention Center

Precision Screening: Opportunities to Enhance the Benefits of Cancer Screening

Chair: Christopher I. Li, Seattle, WA

1:00 p.m. **Chair Introduction.** Christopher I. Li, Seattle, WA

1:05 p.m. **Translating absolute risk of breast cancer into screening frequency: A framework to guide precision screening.** Graham A. Colditz, St. Louis, MO

1:30 p.m. **Discovery and validation of novel blood-based biomarkers to improve the screening and early detection of breast cancer.** Christopher I. Li, Seattle, WA

1:55 p.m. **Precision screening for colorectal cancer: premises, challenges, and opportunities.** Mingyang Song, Boston, MA

Advances in Survivorship Research
1:00 p.m.–2:30 p.m.

Ballroom 6 DE - Upper Level - Convention Center

Early-Onset Cancers: Interventions, Survivorship, and Novel Treatment Approaches

Chair: David B. Solit, New York, NY

1:00 p.m. **Chair Introduction.** David B. Solit, New York, NY

1:05 p.m. **Early onset colorectal Cancer: A new era of insight and intervention.** Cathy Eng, Nashville, TN

1:30 p.m. **From genetic risk to long-term outcome: A precision framework for survivorship in early-onset cancer.** Sogol Mostoufi-Moab, Philadelphia, PA

1:55 p.m. **Advancing target discovery for rare cancers through institutional-scale molecular profiling and social media outreach.** David B. Solit, New York, NY

SUNDAY, APRIL 19

Advances in Technologies
1:00 p.m.–2:30 p.m.

Ballroom 6 A - Upper Level - Convention Center
Shaping the Future of AI: The Role of Pathology in the Development of Foundational Models

Chair: Jeroen van der Laak, Nijmegen, Netherlands

1:00 p.m. **Chair Introduction.** Jeroen van der Laak, Nijmegen, Netherlands

1:05 p.m. **AI in pathology: State of the art.** Jeroen van der Laak, Nijmegen, Netherlands

1:30 p.m. **Foundational models for survival prediction in oncology.** Jana Lipkova, Irvine, CA

1:55 p.m. **Pathology foundation models in cancer research.** Jakob Nikolas Kather, Dresden, Germany

Major Symposia
1:00 p.m.–2:30 p.m.

Room 1 - Upper Level - Convention Center
Regulatory Science and Policy Session
Approaches to Drug Development for Rare Malignancies

Moderators: Elizabeth Dianne Pulte, Silver Spring, MD; Martha Donoghue, Silver Spring, MD

1:00 p.m. **Moderator Introduction.** Elizabeth Dianne Pulte, Silver Spring, MD

1:05 p.m. **Title to be announced.** Martha Donoghue, Silver Spring, MD

1:15 p.m. **Barriers to clinical development of therapeutics for chronic myelomonocytic leukemia.** Eric Padron, Tampa, FL

1:30 p.m. **Development of first treatment FDA approved for women with low grade serous ovarian cancer (LGSOC).** Rachel N. Grisham, New York, NY

1:45 p.m. **Panel Discussion**

Panelists: Stephanie Wethington, Silver Spring, MD; Joshua H. Bilenker, Watertown, MA; Denise K. Reinke, Ann Arbor, MI; Nicole Andrews, Chicago, IL

Ballroom 20 AB - Upper Level - Convention Center
Beyond Chromosomes: Mechanisms, Consequences, and Therapeutic Opportunities of Extrachromosomal DNA (ecDNA)

Chair: Anton G. Henssen, Berlin, Germany

1:00 p.m. **Chair Introduction.** Anton G. Henssen, Berlin, Germany

1:05 p.m. **SY20-01 Intercellular DNA transfer drives the emergence of ecDNA-like elements.** Peter Ly, Dallas, TX

1:30 p.m. **SY20-02 Cancer genes beyond chromosomes.** Howard Y. Chang, Stanford, CA

1:55 p.m. **When ecDNA leaves the nucleus: consequences of extrachromosomal DNA micronucleation.** Anton G. Henssen, Berlin, Germany

Ballroom 6 CF - Upper Level - Convention Center
Mechanisms of Immune Evasion and Immune Dysregulation

Chair: E. John Wherry, Philadelphia, PA

1:00 p.m. **Chair Introduction.** E. John Wherry, Philadelphia, PA

1:05 p.m. **Metabolic reprogramming and engineering of cancer immunity.** Hongbo Chi, Memphis, TN

1:35 p.m. **NG01 BACH1 drives hypoxia-induced stem-like transition states and immune evasion in breast cancer.** Long Chi Nguyen, Chicago, IL

1:55 p.m. **Immunopharmacology of anti-PD-1 and reinvigoration of exhausted CD8 T cells.** E. John Wherry, Philadelphia, PA

Room 15 - Mezzanine Level - Convention Center
Neural-Immune Crosstalk in Cancer

Chair: Tak W. Mak, Toronto, ON, Canada

1:00 p.m. **Chair Introduction.** Tak W. Mak, Toronto, ON, Canada

1:05 p.m. **Cholinergic lymphocytes revitalize the tumor immune microenvironment: TIME to ChAT.** Tak W. Mak, Toronto, ON, Canada

1:30 p.m. **SY04-02 Neuronal innervation of pancreatic cancer.** Andreas Trumpp, Heidelberg, Germany

1:55 p.m. **Nociceptor neurons impact ant-tumor immunity.** Sébastien Talbot, Kingston, ON, Canada

2:20 p.m. **General Discussion**

Room 30 - Upper Level - Convention Center

Spatial and Single-Cell Omics at Scale: Technologies for Decoding Cancer Ecosystems

Chair: Fei Chen, Cambridge, MA

1:00 p.m. **Chair Introduction.** Fei Chen, Cambridge, MA

1:05 p.m. **High-resolution spatial genomics for dissecting tumor ecosystems.** Fei Chen, Cambridge, MA

1:30 p.m. **When form meets function: Decoding tissue architecture.** Dana Pe'er, New York, NY

1:55 p.m. **Spatial analysis of tumor organization in glioma and in head and neck cancer.** Itay Tirosh, Rehovot, Israel

Room 29 - Upper Level - Convention Center

Synthetic Biology Approaches to Cancer and Immune Cell Therapy

Chair: Michel Sadelain, New York, NY

1:00 p.m. **Chair Introduction.** Michel Sadelain, New York, NY

1:05 p.m. **First line CAR T cell therapy for adults with ALL is supported by distinct inflammatory and immunometabolic features.** Stephen J. Forman, Duarte, CA

1:30 p.m. **Synthetic biology: A means to rewire T cells for success in the TME.** Philip D. Greenberg, Seattle, WA

1:55 p.m. **Optimizing the antigen sensitivity and functional persistence of CAR T cells.** Michel Sadelain, New York, NY

Room 14 - Mezzanine Level - Convention Center

The Necrotic Tumor Microenvironment as an Instigator of Metastatic Aggression and Immuno-evasion

Chair: Kevin J. Cheung, Seattle, WA

1:00 p.m. **Chair Introduction.** Kevin J. Cheung, Seattle, WA

1:05 p.m. **From guardians to foes: Cancer-induced host remodeling and neutrophil plasticity drive tumor necrosis and metastasis.** Jose M. Adrover, London, United Kingdom

1:30 p.m. **Tumor-immune interactions at the verge of necrotic cores.** Carlos Carmona-Fontaine, New York, NY

1:55 p.m. **Forged in the crucible: The necrotic niche as sculptor of tumor cell dissemination and metastasis.** Kevin J. Cheung, Seattle, WA

Room 16 - Mezzanine Level - Convention Center

Therapy-Induced Mutagenesis in Normal Tissues of Children: A Link to Late Effects?

Chair: Ruben van Boxtel, Utrecht, Netherlands

1:00 p.m. **Chair Introduction.** Ruben van Boxtel, Utrecht, Netherlands

1:05 p.m. **SY31-01 Therapy-related mutagenesis in long-term survivors of childhood cancer.** Jinghui Zhang, Memphis, TN

1:30 p.m. **SY31-02 Liver specific platinum mutagenesis in children.** Sam Behjati, Cambridge, United Kingdom

1:55 p.m. **Tracing molecular causes and consequences of treatment-induced mutagenesis using single-cell multiomics.** Ruben van Boxtel, Utrecht, Netherlands

Special Session
1:00 p.m.–2:30 p.m.

Ballroom 20 CD - Upper Level - Convention Center

New Drugs on the Horizon: Part 1

Cochairs: Lori S. Friedman, South San Francisco, CA; Lawrence G. Hamann, San Francisco, CA

1:00 p.m. **Introduction.** Lori S. Friedman, South San Francisco, CA

1:05 p.m. **ND01 Development of NEO-811, a molecular glue degrader of ARNT (HIF-1β) with potent single agent activity in ccRCC.** Philip Chamberlain, San Diego, CA

1:25 p.m. **ND02 AZD8359: A novel CD8biased T cell engager designed to deliver a wider therapeutic window in prostate cancer.** Suzanne I. Sitnikova, Cambridge, United Kingdom

1:45 p.m. **ND03 TNG961: A selective oral molecular glue degrader of HBS1L for the treatment of FOCAD-deficient cancers.** Hilary Elaine Nicholson, Boston, MA

2:05 p.m. **ND04 EPI-326: A novel mutation-independent and normal tissue-sparing EGFR bispecific antibody that degrades EGFR for the treatment of EGFR-driven solid tumors.** Shyra J. Gardai, San Mateo, CA

2:25 p.m. **Closing remarks.** Lawrence G. Hamann, San Francisco, CA

SUNDAY, APRIL 19

Clinical Trials Plenary Session
1:00 p.m.–3:00 p.m.

Hall H - Ground Level - Convention Center

New Frontiers in Precision Oncology

Cochairs: Jayesh Desai, Melbourne, VIC, Australia; Eileen M. O'Reilly, New York, NY

1:00 p.m. **CT020 Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in advanced non-small cell lung cancer (NSCLC) previously treated with or without a KRAS G12C inhibitor: Results from a phase 1/2 study.** Byoung Chul Cho, Seoul, Republic of Korea

1:15 p.m. **Discussant.** Adrian Sacher, Toronto, ON, Canada

1:30 p.m. **CT021 Preliminary safety and clinical activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC).** Jonathan Riess, Sacramento, CA

1:45 p.m. **Discussant.** Daniel S.W. Tan, Singapore, Singapore

2:00 p.m. **CT022 First data disclosure of the Phase I trial of the first in class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations.** Timothy A. Yap, Houston, TX

2:15 p.m. **Discussant.** Kathleen Moore, Omaha, NE

2:30 p.m. **CT023 Early clinical activity from the phase 1 evaluation of CID-078, a novel Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.** Afshin Dowlati, Cleveland, OH

2:40 p.m. **Discussant.** Alison Schram, New York, NY

Meet and Greet
1:15 p.m.–2:45 p.m.

AACR Central - Sails Pavilion – Convention Center

AACR-Minorities in Cancer Research Meet and Greet

Chair: Carmen E. Guerra, Philadelphia, PA

Meet and Greet
1:30 p.m.–3:00 p.m.

AACR Central - Sails Pavilion – Convention Center

AACR-Women in Cancer Research Meet and Greet

Chair: Mariana C. Stern, Los Angeles, CA

Meet and Greet
2:00 p.m.–3:00 p.m.

AACR Publications Booth 3537 - Hall D

Meet the Editor-in-Chief of *Cancer Discovery:* Luis A. Diaz, MD, FAACR

Poster Sessions
2:00 p.m.-5:00 p.m.

Halls B-G, Ground Level, San Diego Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

AACR Project GENIE®

Section 1 AACR Project GENIE®: Predictive Models and AI

Bioinformatics, Computational Biology, Artificial Intelligence, and Data Science

Section 2 Agentic AI in Cancer

Section 3 Application of Bioinformatics to Cancer Biology 1

Section 4 Digital Pathology 1

Section 5 Liquid Biopsy: Multi-Analyte and Multi-Omic

Immunology

Section 7	Alternative Cell Type and in Situ Cell Therapies
Section 8	Immune Cell Biology and Tumor-Immune Crosstalk
Section 9	Inflammation and Cancer Progression
Section 10	Virology and Cancer
Section 54	Late-Breaking Research: Immunology 1

Experimental and Molecular Therapeutics

Section 11	DNA Damage and Repair 1
Section 12	Gene and Vector-Based Therapy
Section 13	Innovative Therapeutic Modalities and Translational Platforms
Section 14	Kinase and Signaling Pathway Dependencies Driving Cancer Therapeutic Response
Section 15	Mechanism-Guided Development of Targeted Cancer Therapies
Section 16	Mechanisms of Drug Resistance 1
Section 17	Novel Antitumor Agents 1
Section 18	Novel Therapeutics and Drug Targets 1
Section 19	RNA, Gene and Cell Therapies, and Enabling Assay Technologies
Section 52	Late-Breaking Research: Experimental and Molecular Therapeutics 1

Molecular/Cellular Biology and Genetics

Section 20	Genomic Dissection to Define Novel Therapeutic Strategies
Section 21	Mechanisms and Targets in DNA Damage Repair
Section 22	Metabolite Control of Chromatin, Redox, and Cellular Stress Responses
Section 23	Targeting Mitochondria and Metabolic Vulnerabilities for Cancer Therapy
Section 24	Tumor Cell Plasticity, Microenvironment, and Stress-Response Pathways
Section 25	Tumor Suppressors
Section 55	Late-Breaking Research: Molecular/Cellular Biology and Genetics 1

Tumor Biology

Section 26	Developmental Origins, Drivers, and Heterogeneity in Pediatric Cancer
Section 27	Ex Vivo Systems: Patient-Derived, Patient-Specific Tumor Cultures
Section 28	Methods to Measure Tumor Evolution and Heterogeneity
Section 29	Molecular Pathology
Section 30	Noninvasive Imaging and Analysis of Animal and Tissue Models
Section 31	Physicochemical Modulation of Cancer Ecosystems: Mechanical Forces, Hypoxia, and Acidosis
Section 32	Spatial Protein Profiling and Multi-Modal Mapping of Tumor and Circulating Ecosystems
Section 33	Stem Cell Plasticity and Lineage Reprogramming in Cancer

Population Sciences

Section 34	Survivorship Research
Section 35	Survivorship Research Addressing Cancer Disparities

Prevention, Early Detection, and Interception

Section 36	Cancer in the Community: Epidemiology, Experimental Knowledge, Action, and Communication
Section 37	Experimental Chemoprevention and Interception: Data and Tools

Chemistry

Section 38	Computational, Technological, and Mechanistic Advances
Section 51	Late-Breaking Research: Chemistry

Clinical Research

Section 40	Biomarkers Predictive of Therapeutic Benefit 1
Section 41	Biomarkers Predictive of Therapeutic Benefit 2
Section 42	Circulating Tumor Cells, Metastasis, and Dissemination Biology 1
Section 43	Early Detection Biomarkers 1
Section 44	Liquid Biopsies: Circulating Nucleic Acids 1
Section 45	Mechanistic Insights for Targeted Therapies in Pediatric Cancer
Section 46	Prognostic Biomarkers 1
Section 47	Spatial Proteomics and Transcriptomics 1
Section 48	Survivorship, Supportive Care, and Quality of Life in Oncology
Section 49	Targeting DNA Repair, Cell Cycle, and Tumor Metabolism
Section 50	Late-Breaking Research: Clinical Research 1

NCI-NIH-Selected Session
2:30 p.m.–3:30 p.m.

Room 2 - Upper Level - Convention Center

NCI Drug Development Resources and Grant Writing Strategies for New and Early-Stage Investigators

Moderators: Sundar Venkatachalam, Rockville, MD; Christophe Marchand, Rockville, MD

2:32 p.m.	**Introduction.** Rosemarie Aurigemma, Rockville, MD
2:37 p.m.	**Research resources available at NCI.** Christophe Marchand, Rockville, MD
2:47 p.m.	**Stepping stones and DTP consultation service.** Morgan O'Hayre, Rockville, MD
2:57 p.m.	**Grant writing strategies and opportunities for new applicants.** Sundar Venkatachalam, Rockville, MD
3:07 p.m.	**Peer review process/updates.** Yali Fu, Rockville, MD

Meet and Greet
3:00 p.m.–4:00 p.m.

AACR Publications Booth 3537 - Hall D

Meet the Editor-in-Chief of *Cancer Research Communications:* Elaine R. Mardis, PhD, FAACR

Major Symposium
3:00 p.m.–4:30 p.m.

Room 1 - Upper Level - Convention Center

Science and Health Policy Session

Researcher Town Hall: Navigating Policy Challenges and Securing Funding

Moderator: Roy S. Herbst, New Haven, CT

Panelists: Jon G. Retzlaff, Washington, DC; Cornelia M. Ulrich, Salt Lake City, UT; E. John Wherry, Philadelphia, PA; Patricia Spears, Chapel Hill, NC

Awards and Lectures
3:00 p.m.-3:45 p.m.

Ballroom 6 B - Upper Level - Convention Center

AACR Award for Lifetime Achievement in Cancer Research

Chair: David G. Kirsch, Toronto, ON, Canada

Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanistic insights provide new therapeutic opportunities. James P. Allison, Houston, TX

Ballroom 6 A - Upper Level - Convention Center

AACR-Irving Weinstein Foundation Distinguished Lectureship

Chair: Lillian Siu, Toronto, ON, Canada

Funder Remarks: Steven M. Lipkin, New York, NY

Cell-free DNA: A window into our health. Dennis Lo, Ma Liu Shui, Hong Kong, SAR

SUNDAY, APRIL 19

Awards and Lectures
3:15 p.m.–4:00 p.m.

Room 29 - Upper Level - Convention Center

AACR James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research

Chair: Payal Kapur, Dallas, TX

Reading vs measuring: The next step for anatomic pathology. David L. Rimm, New Haven, CT

Special Session
3:00 p.m.–4:30 p.m.

Ballroom 20 CD - Upper Level - Convention Center

New Drugs on the Horizon: Part 2

Cochairs: Danette L. Daniels, Cambridge, MA; Monica Schenone, New York, NY

3:00 p.m. **Introduction.** Danette L. Daniels, Cambridge, MA

3:05 p.m. **ND05 A first-in-class human sialidase-armed anti-B7-H3 antibody that enhances innate and adaptive antitumor immune responses.** James Broderick, Waltham, MA

3:25 p.m. **ND06 ECI830, a potent and highly selective CDK2 inhibitor, for the treatment of HR+/HER2− breast cancer and CCNE1-amplified tumors.** Zainab Jagani, Cambridge, MA

3:45 p.m. **ND07 TRI-611, a potent, selective, CNS-penetrant ALK molecular glue degrader for the treatment of ALK-fusion protein positive non-small cell lung cancer.** Vito J. Palombella, Lexington, MA

4:05 p.m **ND08 Discovery and development of a CD30 dual-payload ADC that combines MTI and Top1i to overcome drug resistance.** Megan Rice, Gaithersburg, MD

4:25 p.m. **Closing remarks.** Monica Schenone, New York, NY

Minisymposium
3:00 p.m.–4:30 p.m.

Room 31 - Upper Level - Convention Center

Immunology

Combating T Cell Checkpoints

Cochairs: Megan L. Burger, Portland, OR; Justin Paul Kline, Chicago, IL

3:00 p.m. **Chair Introduction.** Megan L. Burger, Portland, OR

3:05 p.m. **1338 DPP-4: A CD8+ T cell metabolic checkpoint and cancer immunotherapy target.** Defne Bayik, Miami, FL

3:20 p.m. **1339 On-demand GLUT3 expression augments CAR-T cell metabolic fitness and antitumor efficacy while preventing toxicity in glioblastoma models.** Keisuke Watanabe, Tokyo, Japan

3:35 p.m. **1340 The zinc finger 7 motif of TNFAIP3/A20 enforces a critical block in exhausted CD8 T cell degranulation and represents a potent target for enhancing adoptive cellular therapies for cancer.** Adam Blaisdell, San Francisco, CA

3:50 p.m. **1342 Expression of Galectin-1 in exhausted CD8+T cells restrains their antitumor effector functions.** Marco A. Scheidegger, Buenos Aires, Argentina

4:05 p.m. **1344 PTPN2/N1 inhibition drives a STAT3-mediated response in exhausted T cells and underscores targetable counter-regulatory mechanisms for T cell improvement.** Yaiza Senent, Cambridge, MA

4:20 p.m. **Closing remarks.** Justin Paul Kline, Chicago, IL

Clinical Trials Minisymposium
3:00 p.m.–5:00 p.m.

Ballroom 20 AB - Upper Level - Convention Center

Advanced Cellular and Immune-Based Therapeutics

Cochairs: Benjamin Schlechter, Boston, MA; Lin Shen, Beijing, China

3:00 p.m. **Chair introduction.** Benjamin Schlechter, Boston, MA

3:05 p.m. **CT026 A phase I trial of intraperitoneal (IP) mesothelin (MSLN)-targeted CAR T-cell therapy in patients with MSLN-positive esophagogastric cancer (EGC) with peritoneal carcinomatosis.** Joan R. Choo, New York, NY

3:20 p.m. **CT027 Safety and preliminary efficacy of a novel LACO-Stim armored mesothelin-targeted CART therapy in advanced solid tumors.** Changsong Qi, Beijing, China

3:35 p.m. **CT028 Results of first-in-human, Phase 1 study of KSQ-001EX, an autologous tumor infiltrating lymphocyte therapy engineered to inactivate the SOCS1 gene, in patients with select advanced solid tumors.** Rodabe N. Amaria, Houston, TX

3:50 p.m. **CT029 Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial.** Paul Nathan, Northwood, United Kingdom

4:05 p.m. **CT030 A phase 1b/2a, open-label, multicenter, randomized, dose escalation study evaluating the safety, tolerability and efficacy of RZ-001 in combination with valganciclovir (VGCV) and atezolizumab/bevacizumab in subjects with hepatocellular carcinoma.** Yoon Jun Kim, Seoul, Republic of Korea

4:20 p.m. **CT031 A phase I/II trial evaluating LOAd703 in combination with nab-paclitaxel, gemcitabine, and atezolizumab for advanced pancreatic cancer.** Angelica Loskog, Uppsala, Sweden

4:35 p.m. **CT032 ABO2203, a messenger RNA encoding a CD3×CD19 T cell engager, for relapsed/refractory B cell non-Hodgkin lymphoma: Preliminary results from first-in-human study.** Li Wang, Shanghai, China

4:50 p.m. **Closing remarks.** Lin Shen, Beijing, China

Minisymposia
3:00 p.m.–5:00 p.m.

Room 30 - Upper Level - Convention Center

Bioinformatics, Computational Biology, Artificial Intelligence, and Data Science

Integrative Computational Approaches

Cochairs: Dimitrios Nikolaos Sidiropoulos, Baltimore, MD; Andrea Sottoriva, Milan, Italy

3:00 p.m. **Chair Introduction.** Dimitrios Nikolaos Sidiropoulos, Baltimore, MD

3:05 p.m. **1292 Multimodal modeling of detailed cancer subtypes and molecular features from >60,000 patients with co-registered H&E images and clinical tumor sequencing.** Kevin Michael Boehm, New York, NY

3:20 p.m. **1293 A multimodal AI framework integrating spatial omics and radiomics for recurrence prediction in glioblastoma.** Julia Louw, Durham, NC

3:35 p.m. **1294 Deciphering single-cell heterogeneity and cellular ecosystem dynamics during prostate cancer progression.** Faming Zhao, Portland, OR

3:50 p.m **1295 Deep-learning profiling of regulatory somatic variants across clonal cancer evolution.** Ksenia Sokolova, Princeton, NJ

4:05 p.m. **1296 Integrated single cell spatial multi-omics landscape of WHO grades 2-4 diffuse gliomas identifies locoregional metabolomic correlates of glioma plasticity and proliferation.** Yanxia Ma, Houston, TX

4:20 p.m. **1297 ADTnorm enables scalable and interpretable single cell proteomics integration across technologies for incorporating historical cancer data.** Ye Zheng, Houston, TX

4:35 p.m. **1298 Structure-sequence integration for peptide:MHC class II binding prediction using AI foundation models (AlphaFold 3 and ESM2).** Kamel Lahouel, Phoenix, AZ

4:50 p.m. **Closing remarks.** Andrea Sottoriva, Milan, Italy

Room 17 - Mezzanine Level - Convention Center
Clinical Research

From Real World Data to Medicine-based Evidence

Cochairs: Suzette Delaloge, Villejuif, France; Shivani Sud, Chapel Hill, NC

3:00 p.m. **Chair Introduction.** Suzette Delaloge, Villejuif, France

3:05 p.m. **1301 Real-world analysis of NSCLC variant-level frequencies from liquid biopsy testing in diverse U.S. populations.** Emma K. Longshore, Louisville, CO

3:20 p.m. **1302 Distinct Histology of Lung Cancer in people who have never smokedand Prognostic Determinants in Non-Mucinous Adenocarcinoma.** Thi-Van-Trinh Tran, Rockville, MD

3:35 p.m. **1303 Real-world overall survival with trastuzumab deruxtecan versus standard chemotherapy in HER2-amplified MSS metastatic colorectal cancer.** Zunairah Shah, Buffalo, NY

3:50 p.m. **1304 Cancer risk with initiation of angiotensin receptor blockers (ARBs) vs. angiotensin converting enzyme inhibitors (ACEIs).** Caroline Himbert, Salt Lake City, UT

4:05 p.m. **1305 Assisted reproductive technology and the risk of female sex hormone-related cancers.** Emily Pei-Ying Lin, Taipei, Taiwan

4:20 p.m. **1306 Developing a real-world clinical genomic platform to deliver precision oncology in underrepresented populations.** Shubhankar Sood, Heidelberg, Germany

4:35 p.m. **1307 Pan-cancer landscape of alternative lengthening of telomeres revealed by machine learning analysis of clinical sequencing data.** Harshit Sahay, New York, NY

4:50 p.m. **Closing remarks.** Shivani Sud, Chapel Hill, NC

Ballroom 6 DE - Upper Level - Convention Center
Clinical Research

Liquid Biopsy Frontiers: ctDNA, Fragmentomics, and MRD to Guide Precision Oncology

Cochairs: Scott V. Bratman, Toronto, ON, Canada; Ajay Goel, Duarte, CA

3:00 p.m. **Chair Introduction.** Scott V. Bratman, Toronto, ON, Canada

3:05 p.m. **1310 Serial plasma comprehensive genomic profiling detects therapy resistance and guides management of metastatic non-small cell lung cancer.** William Bowers, Baltimore, MD

3:20 p.m. **1311 Feasibility of plasma ctDNA for detecting brain metastasis-specific alterations in lung cancer.** Laura P. Stabile, Pittsburgh, PA

3:35 p.m. **1312 AXL mRNA overexpression in CTCs as a new potential liquid biopsy biomarker in NSCLC.** Evi Lianidou, Athens, Greece

3:50 p.m. **1313 Circulating tumor cell (CTC) informed pipeline for rapid personalization of synergistic cytokine-armed CAR-NK cell therapy in PDAC.** Yin Zou, Ann Arbor, MI

4:05 p.m. **1314 Circulating tumor DNA (ctDNA) clearance dynamics in microsatellite instability-high metastatic (MSI-H) colorectal cancer (CRC) treated with immune checkpoint inhibitors (ICI).** Hannah R. Robinson, Aurora, CO

4:20 p.m. **1315 Genomic signatures in red blood cell DNA enable early non-invasive detection of colorectal neoplasia: A multicenter clinical study.** Xingyun Yao, Hangzhou, China

4:35 p.m. **1316 A methylation-based molecular tumor typing classifier for tissue samples from cancers of unknown primary.** Yupeng He, Palo Alto, CA

4:50 p.m. **Closing remarks.** Ajay Goel, Duarte, CA

Ballroom 6 CF - Upper Level - Convention Center
Experimental and Molecular Therapeutics

Advanced Antibody, Conjugate, and Targeted Therapeutic Platforms

Cochairs: Danyelle Townsend, Charleston, SC; Xinyan Wu, Rochester, MN

3:00 p.m. **Chair Introduction.** Xinyan Wu, Rochester, MN

3:05 p.m. **1321 Synthbody™- A novel multivalent multispecific antibody drug conjugate platform demonstrates combinatorial logic-gated "synthetic" targeting of cancer antigens with log order enhanced internalization and potency.** Daniel S. Chen, San Carlos, CA

3:20 p.m. **1322 M7437, a novel anti-Ly6E antibody-drug conjugate (ADC) with topoisomerase 1 (TOP1) inhibitor payload: Preclinical antitumor activity and safety.** Felix Hart, Darmstadt, Germany

3:35 p.m. **1323 Preclinical evaluation of target-mediated clearance and alternative payloads in CDH17-directed antibody drug conjugates.** Neil A. O'Brien, Los Angeles, CA

3:50 p.m. **1324 Preclinical assessment of HWK-016, a next-generation, MUC16-targeting ADC with novel bioconjugation and linker-payload technology.** David Dornan, Morristown, NJ

4:05 p.m. **1325 Preclinical assessment of BT5528 anti-tumor activity in cell-line-derived xenograft (CDX) models of head and neck squamous cell carcinoma (HNSCC).** Gavin Bennett, Cambridge, United Kingdom

4:20 p.m. **1326 PRISM AIR: A high-throughput platform for functional validation of ADC targets and antibody candidate prioritization.** Jillian Eskra, Cambridge, MA

4:35 p.m. **4446 STRO-004, an exatecan-based next-generation tissue factor (TF)-targeted ADC, demonstrates superior efficacy across TF-expressing solid tumors in a comprehensive single-mouse PDX trial.** Genevive Hernandez, South San Francisco, CA

4:50 p.m. **Closing remarks.** Danyelle Townsend, Charleston, SC

Room 5 - Upper Level - Convention Center
Experimental and Molecular Therapeutics

Innovative Targeted and Cellular Therapies for Exploiting Cancer Vulnerabilities

Cochairs: Yaguang Xi, Athens, GA; William T. Beck, Chicago, IL

3:00 p.m. **Chair Introduction.** Yaguang Xi, Athens, GA

3:05 p.m. **1329 Preclinical development of EFTX-G12V, a first-in-class EGFR-directed KRAS G12V selective inhibitor.** Lyla J. Stanland, Morrisville, NC

3:20 p.m. **1330 Targeting Aurora kinase A for potentiating colorectal cancer to KRAS targeted therapy.** Zhaojin Liu, Los Angeles, CA

3:35 p.m. **1331 The Kinase Library: A global atlas of the human protein kinome and its applications in cancer.** Tomer M. Yaron-Barir, Boston, MA

3:50 p.m. **1332 Selective targeting of the $\alpha3\beta4$ nicotinic acetylcholine receptor by DISCO (dual interacting subunit complex) CAR T cells.** Patrick M. Schürch, Philadelphia, PA

4:05 p.m. **1333 REST represses neuroendocrine transcriptional programs and enables anti-tumor immunity in SCLC.** Jackson P. Fatherree, Seattle, WA

4:20 p.m. **1334 Age related phenotypic changes in melanoma create a tumor vulnerability to ferroptosis.** Murilo Ramos Rocha, Baltimore, MD

4:35 p.m. **1335 The ubiquitin E3 ligase SCFSkk2/Cks1complex: A critical node coupling cell cycle control, tumorigenesis, and lineage fidelity in small cell lung cancer (SCLC).** Saumen Karan, Bronx, NY

4:50 p.m. **Closing remarks.** William T. Beck, Chicago, IL

Room 14 - Mezzanine Level - Convention Center
Immunology

Modifiers of Inflammation and the Tumor Microenvironment

Cochairs: Jelani C. Zarif, Baltimore, MD; Sonikpreet Aulakh, Morgantown, VA

3:00 p.m. **Chair Introduction.** Jelani C. Zarif, Baltimore, MD

3:05 p.m. **1347 A bone repair external state program drives cancer cell dedifferentiation and immune evasion in melanoma.** Jackson A. Weir, Cambridge, MA

3:20 p.m. **1348 Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy.** Mathieu Rouanne, New York, NY

3:35 p.m. **1349 Deletion of host-derived GPNMB positively regulates anti-tumor response by reprogramming tumor-associated macrophages.** Ruxandra Tonea, Chicago, IL

3:50 p.m. **1350 Vaccine stimulation of bystander t cells in the lymph node unexpectedly promotes tumor-specific host immunity to regress solid tumors.** Leyuan Ma, Philadelphia, PA

4:05 p.m. **1351 IL-18 secreting CAR-T cells uncover divergent immune mechanisms of antigen-heterogeneous solid tumor clearance.** Audre May, Stanford, CA

4:35 p.m. **1353 Emergency myelopoiesis drives immunosuppressive monocyte programming in lymphoma-associated secondary hemophagocytic lymphohistiocytosis.** Hyunsoo Cho, Seoul, Republic of Korea

4:50 p.m. **Closing remarks.** Sonikpreet Aulakh, Morgantown, VA

Room 33 - Upper Level - Convention Center
Molecular/Cellular Biology and Genetics

Advances in Cancer Epigenetics

Cochairs: Eneda Toska, Baltimore, MD; Daria Gaykalova, Baltimore, MD

3:00 p.m. **Chair Introduction.** Daria Gaykalova, Baltimore, MD

3:05 p.m. **1356 Chromatin remodeler CHD7 drives lineage plasticity and chemoresistance in neuroendocrine prostate cancer.** Mingchen Shi, Vancouver, BC, Canada

3:20 p.m. **1357 The essential role of KDM5B/SOX9 signaling Axis in the development and progression of therapy-induced neuroendocrine prostate cancer.** Guoliang Li, Nashville, TN

3:35 p.m. **1358 Promoter methylation gains in aging and cancer are independent of replication.** Sara-Jayne Thursby, Baltimore, MD

3:50 p.m. **1359 Cooperativity between DNMT and EZH2 activity drives neuroendocrine phenotype in advanced prostate cancer.** Richa Singh, New York, NY

4:05 p.m. **1360 Targeting the ubiquitin reading function of DNMT1 as a next-generation approach for epigenetic cancer therapy.** Joshua A. Kuleape, Grand Rapids, MI

4:20 p.m. **1361 KDM2A-driven epigenetic reprogramming promotes barrett's esophagus progression to adenocarcinoma.** Shilpa S. Dhar, Houston, TX

4:35 p.m. **1362 KMT2D is a master epigenetic regulator of lineage plasticity in lung squamous cell carcinoma.** Manrong Wu, Houston, TX

4:50 p.m. **Closing remarks.** Eneda Toska, Baltimore, MD

Room 15 - Mezzanine Level - Convention Center
Molecular/Cellular Biology and Genetics

Noncoding RNA Regulation of Cancer Hallmarks, Therapeutic Resistance, and Biomarker Discovery

Cochairs: Manuela Ferracin, Bologna, Italy; Shailendra Dwivedi, Oklahoma City, OK

3:00 p.m. **Chair Introduction.** Manuela Ferracin, Bologna, Italy

3:05 p.m. **1365 Regulation of ribosomal RNA synthesis in acute myeloid leukemia.** Putzer J. Hung, Philadelphia, PA

3:20 p.m. **1366 CYP4A22-AS1-YBX1 axis drives radiation resistance in cervical adenocarcinoma via PGK1 transactivation.** Mingyi Zhou, Houston, TX

3:35 p.m. **1367 Dual remodeling of RCC-associated fibroblasts via miR-196b antagomir and COUP-TFII inhibitor ultrasmall lactoferrin-lipid nano-assemblies augments immunotherapy.** Ahmad Ziada, Amherst, MA

3:50 p.m. **1368 Mitochondrial tRNA fragments as modifiers of breast cancer development and metastasis.** Katy L. Swancutt, Kansas City, KS

4:05 p.m. **1369 Urinary extracellular vesicle microRNA profiling enables noninvasive early detection and prognostic stratification of lung cancer.** Yoriko Ando, Tokyo, Japan

4:20 p.m. **1370 Developing MTX-5-FU-Gem-miR-15a as a multimodal therapeutic strategy to overcome olaparib resistance in epithelial ovarian cancer.** Amartya Pal, Stony Brook, NY

4:35 p.m. **1371 POLR1B-derived circular RNA hsa-POLR1B_0014 orchestrates RNA polymerase I transcription and oncogenic hallmarks in lung adenocarcinoma through miR-181b-5p-mediated regulatory networks.** Deepika Antil, Rupnagar, India

4:50 p.m. **Closing remarks.** Shailendra Dwivedi, Oklahoma City, OK

Room 16 - Mezzanine Level - Convention Center
Multidisciplinary

Advances in Cancer Research

Cochairs: Naoko Takebe, Oklahoma City, OK; Edna Cukierman, Philadelphia, PA

3:00 p.m. **Chair Introduction.** Naoko Takebe, Oklahoma City, OK

3:05 p.m. **1283 Asymmetric emergence of cardiovascular disease in hematologic malignancy survivors: A national real-world analysis.** Yizhe Song, St. Louis, MO

3:21 p.m. **1284 Decoding melanoma immunogenicity: A comprehensive proteogenomic, immunopeptidomic, and metabolomic atlas.** Pei Wang, New York, NY

3:37 p.m. **1285 Endocrine therapy adherence and 10-year risk of cardiometabolic outcomes among women with hormone receptor-positive breast cancer.** Jorge R. Ledesma, Pleasanton, CA

3:53 p.m. **1286 Comprehensive phenotypic mapping of alternative lengthening of telomeres (ALT) regulation expands the landscape of targetable suppressors.** Bill Diplas, New York, NY

4:09 p.m. **1287 A spatiotemporal proteome map of chemotherapy response in metastatic breast cancer.** Xiaoyu Zhao, La Jolla, CA

4:25 p.m. **1288 The protein phosphatase EYA4 is a druggable target for the treatment of breast cancer.** Daniela A. Garcia, San Antonio, TX

4:41 p.m. **1289 ASP2998, a TROP2-targeted immunostimulatory antibody drug conjugate (iADC) with dual payloads, demonstrates potent efficacy and a favorable safety profile in nonclinical models.** Mark Orr, Seattle, WA

4:57 p.m. **Closing remarks.** Edna Cukierman, Philadelphia, PA

Room 11 - Upper Level - Convention Center
Population Sciences

Population Sciences at the Forefront 1: Risk Factors Influencing Cancer Incidence and Survival

Cochairs: Veronica Wendy Setiawan, Los Angeles, CA; Melissa Troester, Chapel Hill, NC

3:00 p.m. **Chair Introduction.** Veronica Wendy Setiawan, Los Angeles, CA

3:05 p.m. **1374 Adherence to the EAT-Lancet reference diet in adolescence and risk of invasive breast cancer among US women.** Phuong Anh Le, Boston, MA

3:20 p.m. **1375 Cardiorespiratory multimorbidity and lung cancer risk: A population-based cohort study.** Kexin Chen, Tianjin, China

3:35 p.m. **1377 Generational immigration status and gastric cancer incidence among Japanese descendants: An analysis of the Multiethnic Cohort study.** Haejin In, New Brunswick, NJ

3:50 p.m. **1378 Development and validation of a parsimonious electronic health record model for pancreatic cancer risk stratification.** Lucas A. Mavromatis, New York, NY

4:05 p.m. **1379 Age-related differences in predicted basal metabolic rate and survival outcomes after colorectal cancer in the ColoCare Study.** Sheetal Hardikar, Salt Lake City, UT

4:20 p.m. **1380 Patient-level and claim-level analysis of telehealth disparities in cancer care: Lower uptake but higher intensity among racial or ethnic minority groups and older adults.** Sakshith Reddy Chintala, San Diego, CA

4:35 p.m. **1381 The Confluence Project: Largest multi-ancestry genome-wide association study of breast cancer identifies 469 susceptibility loci in over two million participants.** The Confluence Project - National Cancer Institute, Bethesda, MD

4:50 p.m. **Closing remarks.** Melissa Troester, Chapel Hill, NC

Room 28 - Upper Level - Convention Center
Tumor Biology
Nonclinical Models of Cancer

Cochairs: Ming Chen, Durham, NC; Stephanie Dougan, Boston, MA

3:00 p.m. **Chair Introduction.** Ming Chen, Durham, NC

3:05 p.m. **1383 Defining the role of the Daam2 R414W germline variant in familial glioma.** Tiffany J. Choy, Houston, TX

3:20 p.m. **1384 Aging amplifies oncogenic mutant pik3ca 1047R signaling and accelerates mammary tumorigenesis.** Thangarajeswari Mohan, San Antonio, TX

3:35 p.m. **1385 Evaluation of kinase inhibitor efficacy and cancer-associated fibroblast-organoid crosstalk in a CRISPR-edited mouse model of bladder cancer.** Tahmina Haque, Philadelphia, PA

3:50 p.m. **1386 NSCLC patient-derived organoids recapitulate tissue signalling and impairment of infiltrated immune cell activation predicting patients' response to therapy.** Anna Pasto, Stevenage, United Kingdom

4:05 p.m. **1387 Live cell visualization of RNA splicing dynamics upon APOBEC3 lentiviral transduction in aged bone marrow using a 3D biosensing nanobioreactor.** Emma Klacking, La Jolla, CA

4:20 p.m. **1388 Ex vivo micro-tumor testing platform to guide patient stratification for clinical development of ADCs.** Esmee Koedoot, Leiden, Netherlands

4:35 p.m. **1389 Defining immune phenotypes of checkpoint inhibitor response in human live tumor fragments preserving the native tumor microenvironment.** Erika von Euw, Madison, WI

4:50 p.m. **Closing remarks.** Stephanie Dougan, Boston, MA

Clinical Trials Plenary Session
3:30 p.m.–5:30 p.m.

Hall H - Ground Level - Convention Center
Therapeutic Advances in ADCs

Cochairs: Ecaterina Dumbrava, Houston, TX; Manuel Hidalgo, New York, NY

3:30 p.m. **CT035 CTEP #10355 A phase 1 trial of DS-8201a and olaparib in HER2-expressing malignancies: Results from dose escalation.** Elizabeth K. Lee, Boston, MA

3:45 p.m. **Discussant.** Aditya Bardia, Los Angeles, CA

4:00 p.m. **CT036 A first-in-human study result of a novel EGFR-targeted antibody drug conjugate (ADC) in patients with advanced nasopharyngeal carcinoma (NPC) (SYS6010-001-NPC).** Haiqiang Mai, Guangzhou, China

4:15 p.m. **Discussant.** Anna Spreafico, Toronto, ON, Canada

4:30 p.m. **CT037 A first-in-human phase 1 trial of a novel claudin 6 (CLDN6)-targeting antibody drug conjugate (ADC) QLS5132 in patients (pts) with platinum-resistant ovarian cancer (PROC).** Tao Zhu, Hangzhou, China

4:45 p.m. **Discussant.** Ramez Eskander, San Diego, CA

5:00 p.m. **CT038 Combination of risvutatug rezetecan and adebrelimab in previously treated advanced nsq-NSCLC without actionable genomic alterations: Results from ARTEMIS-101, a phase 1 study.** Runbo Zhong, Shanghai, China

5:15 p.m. **Discussant.** Melissa Johnson, Nashville, TN

Meet and Greet
4:00 p.m.–5:00 p.m.

AACR Publications Booth 3537 - Hall D
Meet the Editor-in-Chief of *Cancer Research:* Christine A. Iacobuzio-Donahue, MD, PhD

NCI-NIH-Selected Session
4:00 p.m.–5:00 p.m.

Room 2 - Upper Level - Convention Center

NCI Opportunities in Technology Development for Cancer Research

Moderator: Michelle A. Berny-Lang, Bethesda, MD

4:01 p.m. **Introduction.** Michelle A. Berny-Lang, Bethesda, MD

4:06 p.m. **Innovative Molecular Analysis Technologies (IMAT) Program.** Kelly Crotty, Bethesda, MD

4:21 p.m. **Informatics Technology for Cancer Research (ITCR) Program.** Michelle A. Berny-Lang, Bethesda, MD

Awards and Lectures
4:30 p.m.-5:15 p.m.

Ballroom 6 B - Upper Level - Convention Center

AACR-Princess Takamatsu Memorial Lectureship

Chair: Lisa M. Coussens, Portland, OR

Funder Remarks: Yoshinori Murakami, Tokyo, Japan

Extracellular vesicles and particles drive the systemic complications of cancer. David C. Lyden, New York, NY

Room 29 - Upper Level - Convention Center

AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research

Chair: Johann S. de Bono, London, United Kingdom

Learning the molecular logic of cancer. Eliezer M. Van Allen, Boston, MA

Major Symposium
4:45 p.m.–6:15 p.m.

Room 1 - Upper Level - Convention Center

Regulatory Science and Policy Session

Modernizing Nonclinical Safety Assessment in Oncology Product Development: Current Progress and Future Directions

Moderator: Haleh Saber, Silver Spring, MD

4:45 p.m. **Moderator Introduction.** Haleh Saber, Silver Spring, MD

4:50 p.m. **Title to be announced.** Michael Manning, Silver Spring, MD

5:00 p.m. **Title to be announced.** Natalie E. Simpson, Silver Spring, MD

5:10 p.m. **Title to be announced.** Matthew Thompson, Silver Spring, MD

5:20 p.m. **Panel Discussion**

Panelists: Tiffany Ricks, Silver Spring, MD; Jacintha Shenton, Thousand Oaks, CA; Shannon M. Mumenthaler, Duarte, CA; Rodney Prell, South San Francisco, CA

SUNDAY, APRIL 19

Professional Development Session
5:00 p.m.–7:00 p.m.

Grand Hall ABC - Manchester Grand Hyatt San Diego

Personalized Career Conversations

Cochairs: Antonio T. Baines, Greensboro, NC; Cody L. Wolf, Charlottesville, VA; Lorna Rodriguez-Rodriguez, Duarte, CA; Melissa R. Junttila, South San Francisco, CA

Mentors: Janeen R. Azare, New York, NY; J. Carl Barrett, Boston, MA; John M. Carethers, San Diego, CA; John D. Carpten, Duarte, CA; Luis Carvajal-Carmona, Davis, CA; Raffaele Colombo, Vancouver, BC, Canada; Marcia R. Cruz-Correa, San Juan, PR; Johann Sebastian de Bono, London; Laura Fejerman, Davis, CA; Susan M. Galbraith, Gaithersburg, MD; Erica L. Jackson, South San Francisco, CA; Electron Kebebew, Stanford, CA; Reza Mazhari, Cambridge, MD; Ruben A. Mesa, Winston-Salem, NC; Coleman K. Obasaju, Indianapolis, IN; Folakemi T. Odedina, Jacksonville, FL; Thomas Paul, New York, NY; Elizabeth A. Platz, Baltimore, MD; Robert Radinsky, Cambridge, MA; Camille C. R. Ragin, Philadelphia, PA; Victoria M. Richon, Watertown, MA; Victoria L. Seewaldt, Duarte, CA; Sheila Kumari Singh, London, United Kingdom; Kedar S. Vaidya, London, United Kingdom; Arti P. Varanasi, Baltimore, MD; Tiffany A. Wallace, Rockville, MD; Robert A. Winn, Richmond, VA; Clayton Yates, Baltimore, MD

Awards and Lectures
5:30 p.m.–6:15 p.m.

Ballroom 20 CD - Upper Level - Convention Center

Presidential Address: Mapping the Molecular Landscape of Head and Neck Cancer to Inform Pan-Tumor Targeting

Chair: Michael A. Caligiuri, Duarte, CA

5:30 p.m. **Introduction.** Michael A. Caligiuri, Duarte, CA

5:40 p.m. **Mapping the molecular landscape of head and neck cancer to inform pan-tumor targeting.** Lillian L. Siu, Toronto, ON, Canada

Professional Development Session
6:00 p.m.–8:00 p.m.

Grand Hall A - Manchester Grand Hyatt San Diego

Building Your Effective Mentorship Team: Challenges, Successes, and Essential Strategies at Every Stage in Your Career

Cochairs: Heather Beasley, Nashville, TN; Electron Kebebew, Stanford, CA; Brian M. Rivers, Atlanta, GA; Katherine Y. Tossas, Richmond, VA

6:00 p.m. **Welcome.** Heather K. Beasley, Nashville, TN

6:05 p.m. **Moderated Panel Discussion.** Electron Kebebew, Stanford, California; Katherine Y. Tossas, Richmond, VA

Panelists: Phoung Khanh Morrow, Takeda Pharmaceuticals, LTD., Deerfield, IL

7:05 p.m. **Q&A with audience**

7:50 p.m. **Closing remarks**

Special Session
6:30 p.m.–8:00 p.m.

Indigo BFCG - Hilton Bayfront Hotel

Networking Hubs

CancerCareers.org: Scientific Careers Resource

Entrepreneurship and Innovation

Artificial Intelligence, Machine Learning, and Data Science

Novel Models for Cancer Research

Early Detection Screening

Spatial Integration of Multi-omics

Town Meetings
6:30 p.m.–8:30 p.m.

Room 33 - Upper Level - Convention Center
At the Breaking Point: The Interface of Radiation Science and Pediatric Oncology—A PCWG-RSM Town Hall

Cochairs: Meredith S. Irwin, Toronto, ON, Canada; Quynh-Thu Le, Palo Alto, CA

6:40 p.m. **Title to be announced.** Danielle S. Bitterman, Boston, MA

6:50 p.m. **Title to be announced.** Pippa Cosper, Madison, WI

7:00 p.m. **Title to be announced.** Lillian M. Guenther, Memphis, TN

7:10 p.m. **Panel Discussion**

7:30 p.m. **Networking Reception**

Room 28 - Upper Level - Convention Center
Integrating Population Science and Pathology to Transform Cancer Research: A PICR-PSWG Town Hall and Networking Meeting

Cochairs: Massimo Loda, New York, NY; Paul A. Scheet, Houston, TX

6:30 p.m. **Chair Introductions**

6:40 p.m. **The awesome potential of integrating molecular pathology and population sciences.** Mark E. Sherman, Jacksonville, FL

6:50 p.m. **From pixels to populations: computational pathoepidemiology of multistep mammary carcinogenesis.** Mustapha Abubakar, Bethesda, MD

7:00 p.m. **Title to be announced.** Sylvia K. Plevritis, Stanford, CA

Moderator: Melissa A. Troester, Chapel Hill, NC

7:10 p.m. **Panel Discussion**

7:30 p.m. **Networking Reception**

Room 30 - Upper Level - Convention Center
Resolution Biology in Cancer: A Vicious Cycle of Reversing Tissue Damage and Tumor Microenvironment Evolution for Enhanced Therapy Response—A CEWG-TME Town Hall and Networking Meeting

Cochairs: Edna Cukierman, Philadelphia, PA; Laura M. Heiser, Portland, OR

6:40 p.m. **Title to be announced.** Ignaty Leshchiner, Boston, MA

6:47 p.m. **Title to be announced.** Kit Curtius, La Jolla, CA

6:54 p.m. **Title to be announced.** Yash Chhabra, Philadelphia, PA

7:01 p.m. **Title to be announced.** Veena Padmanaban, Baltimore, MD

7:08 p.m. **Panel Discussion**

7:30 p.m. **Networking Reception**

Annual Reception
8:30 p.m.–11:30 p.m.

Sapphire Ballroom - Hilton Bayfront San Diego
AACR Annual Reception, Featuring The Checkpoints

MONDAY, APRIL 20

Plenary Session
8:00 a.m.–10:00 a.m.

Hall H - Ground Level - Convention Center

AI Revolution in Cancer Research

Chair: Jakob Nikolas Kather, Dresden, Germany

8:00 a.m. **Chair Introduction.** Jakob Nikolas Kather, Dresden, Germany

8:05 a.m. **From copilots to scientists: How agentic AI will transform cancer research.** Jure Leskovec, Stanford, CA

8:33 a.m. **Building biological foundation models that reason.** Bo Wang, Toronto, ON, Canada

9:01 a.m. **PL03-03 Real-time multimodal AI enables individualized care in challenging subpopulations.** Suchi Saria, Baltimore, MD

9:29 a.m. **Multimodal, generative, and agentic AI for oncology.** Faisal Mahmood, Boston, MA

9:57 a.m. **Closing remarks.** Jakob Nikolas Kather, Dresden, Germany

Poster Sessions
9:00 a.m.-12:00 p.m.

Halls B-G, Ground Level, San Diego Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

Science Education

Section 1 2026 AACR Undergraduate Scholars and Margaret Foti Undergraduate Prize Recipients

Regulatory Science and Policy

Section 2 Regulatory Science and Policy

Bioinformatics, Computational Biology, Artificial Intelligence, and Data Science

Section 3 Application of Bioinformatics to Cancer Biology 2

Section 4 Digital Pathology 2

Section 5 Integrative Computational Approaches 1

Section 6 Sequence Analysis

Section 54 Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1

Immunology

Section 7 CAR T Cell Targets and TME Reprogramming

Section 8 Combination Immunotherapies

Section 9 Innate Immunity in Cancer

Section 10 T Cell Engagers 1

Section 53 Late-Breaking Research: Immunology 2

Experimental and Molecular Therapeutics

Section 11 Antibody Technologies and Platforms 1

Section 12 Antibody-Drug Conjugates and Linker Engineering 1

Section 13 Antibody-Drug Conjugates and Linker Engineering 2

Section 14 DNA Damage and Repair 2

Section 15 Engineering the Next Wave of Antibody-Based Cancer Therapeutics

Section 16 Mechanisms of Drug Resistance 2

Section 17 Quantitative Pharmacology and Translational Modeling

Section 18 Targeting Drug Resistance 1: Apoptosis and Autophagy

Section 19 Targeting Drug Resistance 2: RAS Signaling

Molecular/Cellular Biology and Genetics

Section 20 Cell Cycle

Section 21 Chromatin Structure and Function

Section 22 DNA Methylation

Section 23 Genomic Drivers of Cancer Pathogenesis

Section 24 Metabolic Regulation in Breast and Gynecologic Cancers

Section 25 MicroRNAs as Cancer Biomarkers, Therapeutic Targets, and Modulators of Treatment Response

Tumor Biology

Section 26 Aging and Host Determinants of Tumor Progression: The Macroenvironmental Axis

Section 27 Characterization of Metastases by Imaging and Profiling

Section 28 In Vivo Imaging

Section 29 In Vivo Models 1: Mouse, Zebrafish, and Alternative Species

Section 30 Metabolic and Transcriptional Control of Cancer Stem Cell Plasticity

Section 31 Tertiary Lymphoid Structures in Cancer

Section 32 Therapies Targeting Metastasis

Section 33 Tumorigenesis and Early Microenvironmental Trajectories

Endocrinology

Section 34 Hormone Receptor Signaling and Therapeutic Targeting

Population Sciences

Section 35 Biomarkers of Endogenous or Exogenous Exposures, Early Detection, Biological Effects, and Prognosis

Section 36 Epidemiology: Cancer Incidence, Mortality, Patterns, and Methodology

Prevention / Early Detection / Interception

Section 37 Cancer Disparities

Chemistry

Section 38 Antibodies, Antibody-Drug Conjugates, and Nucleic Acids

Section 39 Structural and Chemical Biology

Clinical Research

Section 40 Biomarkers Predictive of Therapeutic Benefit 3

Section 41 Cancer and Aging: Implications for Outcomes

Section 42 Community-Engaged Approaches to Equity Across the Cancer Journey: From Prevention to Trial Design

Section 43 Data-Driven Approaches to Precision Oncology

Section 44 Early Detection Biomarkers 2

Section 45 Immunomodulatory Effects of Targeted Therapies

Section 46 Liquid Biopsies: Circulating Nucleic Acids 2

Section 47 Molecular Imaging, Radiomics, and Theranostics

Section 48 Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates 1

Section 49 Targeted Antigen Therapies and Immunity

Section 52 Late-Breaking Research: Clinical Research 2

Clinical Trials

Section 50 First-in-Human Phase I Clinical Trials

Section 51 Phase I Clinical Trials in Progress

Meet and Greet

9:15 a.m.–10:15 a.m.

AACR Publications Booth 3537 - Hall D

Meet the Editors-in-Chief of *Blood Cancer Discovery:* Ross L. Levine, MD, FAACR, and Riccardo Dalla-Favera, MD, FAACR

NCI-NIH-Selected Session
10:15 a.m.–11:15 a.m.

Room 2 - Upper Level - Convention Center
From Data Commons to Knowledge Engine: AI Enablement Across CRDC and CCDI

Moderator: Erika Kim, Rockville, MD

10:16 a.m. **Introduction.** Erika Kim, Rockville, MD

10:21 a.m. **NCI's Cancer Research Data Commons (CRDC): Infrastructure to Support Cancer Data Sharing and Analysis.** Tanja M. Davidsen, Rockville, MD

10:36 a.m. **CCDI Data Ecosystem: Advancing Pediatric Cancer Research.** Subhashini Jagu, Rockville, MD

10:46 a.m. **ARPA-H BDF tool integration with CRDC.** Erika Kim, Rockville, MD

Advances in Diagnostics and Therapeutics
10:15 a.m.–11:45 a.m.

Room 33 - Upper Level - Convention Center
Next-Generation Radioligand Therapy

Chair: Julie L. Sutcliffe, Davis, CA

10:15 a.m. **Chair Introduction.** Julie L. Sutcliffe, Davis, CA

10:16 a.m. **Out of the fume hood and into the clinic.** Julie L. Sutcliffe, Davis, CA

10:36 a.m. **New questions and new opportunities in theranostics.** Jason S. Lewis, New York, NY

10:56 a.m. **Beyond PSMA and SSTR2: Expanding the radioligand therapy frontier.** Markus Reschke, Basel, Switzerland

Ballroom 20 AB - Upper Level - Convention Center
Role of the Intestinal Microbiome in CAR T-Cell Therapy

Chair: Robert R. Jenq, Durante, CA

10:15 a.m. **Chair Introduction.** Robert R. Jenq, Durante, CA

10:16 a.m. **The impact of the intestinal microbiome on CAR T cell therapy: Preclinical and clinical insights.** Melody Smith, Stanford, CA

10:46 a.m. **CAR-T response rates - how to harness the microbiome for our patients?** Robert R. Jenq, Durante, CA

11:15 a.m. **Chemical dissection of microbiota mechanisms in cancer immunotherapy.** Howard Hang, La Jolla, CA

Advances in Organ Site Research
10:15 a.m.–11:45 a.m.

Room 15 - Mezzanine Level - Convention Center
Advances in Glioblastoma Research and Experimental Therapies

Chair: Mario L. Suva, Boston, MA

10:15 a.m. **Chair Introduction.** Mario L. Suva, Boston, MA

10:16 a.m. **Targeting brain tumor networks in glioblastoma.** Varun Venkataramani, Heidelburg, Germany

10:35 a.m. **NG03 Screening for tumor microtube-targeting drugs identifies PKC modulators as multipotent inhibitors of glioblastoma progression.** Daniel Azorín, Zurich, Switzerland

10:55 a.m. **Immune microenvironment in glioblastoma.** Dolores Hambardzumyan, New York, NY

11:15 a.m. **High-definition spatial analysis of glioblastoma.** Mario L. Suva, Boston, MA

Room 16 - Mezzanine Level - Convention Center
Precision Liver Cancer Care Across the Continuum: From Prevention to Therapy

Chair: Valerie Chew, Singapore, Singapore

10:15 a.m. **Chair Introduction.** Valerie Chew, Singapore, Singapore

10:20 a.m. **Biomarker-guide precision prevention of HCC.** Yujin Hoshida, Dallas, TX

10:45 a.m. **Single-cell omics-driven biomarker and therapeutic discovery in hepatocellular carcinoma.** Valerie Chew, Singapore, Singapore

11:10 a.m. **Personalized care in hepatocellular carcinoma: Integrating tumor biology and patient factors.** Manon Allaire, Paris, France

Room 14 - Mezzanine Level - Convention Center

Reframing Gynecologic Cancer Prevention: From STIC Discovery to Salpingectomy - Translating the Fallopian Tube Paradigm into Ovarian Cancer Prevention

Chair: Rebecca L. Stone, Baltimore, MD

10:15 a.m. **Chair Introduction.** Rebecca L. Stone, Baltimore, MD

10:20 a.m. **Bringing population-level ovarian cancer prevention into practice.** Rebecca L. Stone, Baltimore, MD

10:45 a.m. **Making the invisible visible: New imaging tchnologies for detecting tubal precursors.** Angela M. Belcher, Cambridge, MA

11:05 a.m. **The ovarian pre-cancer atlas: Charting a path to clinical interception.** Ronny I. Drapkin, Philadelphia, PA

Advances in Survivorship Research
10:15 a.m.–11:45 a.m.

Room 17 - Mezzanine Level - Convention Center

Cancer Cachexia: Tumor Signals, Systemic Impact, and Translational Opportunities

Chair: Tobias Janowitz, Cold Spring Harbor, NY

10:15 a.m. **Chair Introduction.** Tobias Janowitz, Cold Spring Harbor, NY

10:17 a.m. **Pancreatic cancer cachexia: Rethink the biology, rebuild the body.** Min Li, Oklahoma City, OK

10:37 a.m. **Mechanisms of behavioral changes in cachexia.** Tobias Janowitz, Cold Spring Harbor, NY

10:57 a.m. **Cachexia phenotypes in patients with advanced cancer.** Elizabeth M. Cespedes Feliciano, Oakland, CA

11:17 a.m. **Tumor- and liver-derived mediators of cancer cachexia.** Mauricio Berriel Diaz, Neuherberg, Germany

Advances in Technologies
10:15 a.m.–11:45 a.m.

Ballroom 6 B - Upper Level - Convention Center

Single Cell Multi-omic Technologies for Resolving Genotype-Phenotype Relationships in Cancer

Chair: Nicholas E. Navin, Houston, TX

10:15 a.m. **Linking genotypes and phenotypes of single cells to decode breast cancer progression.** Nicholas E. Navin, Houston, TX

11:05 a.m. **High-content single-cell multiomics can resolve molecular determinants of cancer cell phenotypes.** Charles Gawad, Stanford, CA

10:40 a.m. **Advances in single-cell DNA methylation and multiomic technologies and analysis.** Andrew Adey, Portland, OR

Advances in the Science of Cancer Disparities
10:15 a.m.–11:45 a.m.

Room 5 - Upper Level - Convention Center

Addressing Cancer Mortality in Areas of Persistent Poverty

Chair: Rulla M. Tamimi, New York, NY

10:15 a.m. **Chair Introduction.** Rulla M. Tamimi, New York, NY

10:20 a.m. **Building social capital to advance cancer control in persistent poverty areas.** Rulla M. Tamimi, New York, NY

10:45 a.m. **A common-sense framework for community-engaged research partnerships.** David W. Wetter, Salt Lake City, UT

11:10 a.m. **Upstream: Targeting persistent poverty to advance cancer equity discussion.** Melissa L. Bondy, Stanford, CA

Major Symposia
10:15 a.m.–11:45 a.m.

Ballroom 6 CF - Upper Level - Convention Center

AACR-Bayard D. Clarkson Symposium on Plasticity and Cancer Progression: Mechanisms and Consequences

Chair: Lynne-Marie Postovit, Kingston, ON, Canada

10:15 a.m. **Chair Introduction.** Lynne-Marie Postovit, Kingston, ON, Canada

10:20 a.m. **From epigenetic heterogeneity to cancer plasticity.** Mathieu Lupien, Toronto, ON, Canada

10:45 a.m. **Epigenomic heterogeneity and transcriptional instability, rather than cellular reprogramming, underpin the emergence of dedifferentiated endometrial cancer.** Lynne-Marie Postovit, Kingston, ON, Canada

11:10 a.m **SY28-03 Intrinsic and extrinsic inflammatory signaling spatiotemporally orchestrate lung cancer adeno-to-squamous transition and RAS(ON) inhibitor resistance.** Hongbin Ji, Hangzhou Shi, China

Room 30 - Upper Level - Convention Center

Clonal Hematopoiesis: Aging and Drivers of Blood Cancer and Solid Tumors

Chair: Jyoti Nangalia, Cambridge, United Kingdom

10:15 a.m. **Chair Introduction.** Jyoti Nangalia, Cambridge, United Kingdom

10:20 a.m. **Determinants of pre-malignant clonal expansion rate and implications for blood cancers.** Siddhartha Jaiswal, Stanford, CA

10:45 a.m. **Epigenetic histories of blood over the human lifespan.** Jyoti Nangalia, Cambridge, United Kingdom

11:10 a.m. **Clonal hematopoiesis, inflammation, and cancer development.** Benjamin L. Ebert, Boston, MA

Ballroom 6 DE - Upper Level - Convention Center

Decoding Cancer's Complex Ecosystem: The Pathology of Tumor Microenvironment and Heterogeneity

Chair: Hoifung Poon, Redmond, WA

10:15 a.m. **Chair Introduction.** Hoifung Poon, Redmond, WA

10:20 a.m. **SY29-01 Tracing the eco-evolutionary path of tumors to understand cancer.** Kenneth J. Pienta, Baltimore, MD

10:55 a.m. **Multimodal generative AI for decoding the tumor microenvironment grammar.** Hoifung Poon, Redmond, WA

Room 31 - Upper Level - Convention Center

DNA Damage Response and Synthetic Lethality in Cancer

Chair: Alan D. D'Andrea, Boston, MA

10:15 a.m. **Chair Introduction.** Alan D. D'Andrea, Boston, MA

10:20 a.m. **SY19-01 Synthetic lethality opportunities for tumors with MMEJ deficiency.** Alan D. D'Andrea, Boston, MA

10:45 a.m. **SY19-02 Exploiting replication gaps for cancer therapy.** Sharon B. Cantor, Worcester, MA

11:10 a.m. **Synthetic lethality beyond BRCA.** Pamela N. Munster, San Francisco, CA

Room 28 - Upper Level - Convention Center

Exploiting Cancer Evolution for Clinical Impact

Chair: Carlo C. Maley, Tempe, AZ

10:15 a.m. **Chair Introduction.** Carlo C. Maley, Tempe, AZ

10:20 a.m. **Recognizing intrinsic and evolved drug resistance in ER+ advanced breast cancer.** Trey Ideker, La Jolla, CA

10:45 a.m. **Measuring clonal evolution in inflammatory bowel disease for early detection of colorectal cancer risk.** Trevor Graham, London, United Kingdom

11:10 a.m. **Evolutionary approaches to cancer therapy.** Carlo C. Maley, Tempe, AZ

Room 29 - Upper Level - Convention Center

Immunometabolism in Cancer

Chair: Greg M. Delgoffe, Pittsburgh, PA

10:15 a.m. **Chair Introduction.** Greg M. Delgoffe, Pittsburgh, PA

10:20 a.m. **Examining immunometabolism in cancer models.** Owen Sansom, Glasgow, United Kingdom

10:45 a.m. **Mitochondrial reprogramming in T cell exhaustion.** Greg M. Delgoffe, Pittsburgh, PA

11:10 a.m. **Reprogramming NK cell metabolism to enhance adoptive cellular therapy.** May Daher, Houston, TX

Ballroom 6 A - Upper Level - Convention Center

Presidential Select Symposium. Targeting Stage 0: Precision-Based Prevention

Chair: Raymond N. DuBois, Charleston, SC

10:15 a.m. **Remarks.** Lillian L. Siu, Toronto, ON, Canada

10:17 a.m. **Introduction.** Raymond N. DuBois, Charleston, SC

10:20 a.m. **Risk for pediatric cancer is finally being included in newborn screening trials.** Sharon E. Plon, Houston, TX

10:35 a.m. **Therapeutic precision cancer prevention: The power of canaries.** John Burn, Newcastle-upon-Tyne, United Kingdom

10:50 a.m. **Vaccines for cancer prevention and interception.** Mary L. Disis, Seattle, WA

11:05 a.m. **AI in cancer diagnosis: Promise, performance, and the human-AI factor.** Joann G. Elmore, Los Angeles, CA

11:20 a.m. **Panel Discussion**

Room 1 - Upper Level - Convention Center

Regulatory Science and Policy Session

Strengthening the Oncology Trial Ecosystem Through Operational and Regulatory Innovation

Moderator: Lola A. Fashoyin-Aje, Silver Spring, MD

10:15 a.m. **Moderator Introduction.** Lola A. Fashoyin-Aje, Silver Spring, MD

10:20 a.m. **U.S. Site Activation in Global Oncology Trials: Operational Realities.** Mark D. Stewart, Washington, DC

10:30 a.m. **Bespoke or Ready-to-Wear Activation? A Site's Perspective.** Jason Lebsack, Tampa, FL

10:40 a.m. **Panel Discussion.**

Panelists: Judith A. Fitzgerald, West Palm Beach, FL; Terrell Baptiste, San Francisco, CA; Bea Lavery, San Francisco, CA; Funda Meric-Bernstam, Houston, TX

Special Session
10:15 a.m.–11:45 a.m.

Ballroom 20 CD - Upper Level - Convention Center

New Drugs on the Horizon: Part 3

Cochairs: Katrina L. Jackson, Watertown, MA; Daniel Seungduk La, Lexington, MA

10:15 a.m. **Introduction.** Katrina L. Jackson, Watertown, MA

10:20 a.m. **ND09 Discovery of CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, for the treatment of cancers with RB1 loss or hyperactivated E2F.** Marie Evangelista, South San Francisco, CA

10:40 a.m. **ND10 Discovery of AMX-883: an orally bioavailable, novel degrader of BRD9 as a karyotype-independent pro-differentiation agent for the potential treatment of AML.** Martin Pass, Cambridge, United Kingdom

11:00 a.m. **ND11 Discovery and preclinical characterization of a novel ENPP3-Targeted ADC, JNJ-89862175 to treat advanced solid tumors.** Smruthi Vijayaraghavan, Spring House, PA

11:20 a.m. **ND12 Development of IPN01203, a dual T cell agonist activating Vβ6/Vβ10 TCR-expressing T cells.** Stephan G. Klinz, Cambridge, MA

11:40 a.m. **Closing remarks.** Daniel Seungduk La, Lexington, MA

MONDAY, APRIL 20

Clinical Trials Plenary Session
10:15 a.m.–12:15 p.m.

Hall H - Ground Level - Convention Center

Cellular Therapies and Complex Immunotherapies

Cochairs: James L. Gulley, Takoma Park, MD; Robert H. Vonderheide, Philadelphia, PA

10:15 a.m. **CT103 Ciltacabtagene autoleucel in high-risk smoldering myeloma: Results from the CAR-PRISM trial.** Omar Nadeem, Boston, MA

10:30 a.m. **Discussant.** Krina Patel, Houston, TX

10:45 a.m. **CT104 Initial results of a first in human dose-escalation study of KIR-CAR in patients with advanced mesothelin-expressing solid tumors.** Janos L. Tanyi, Philadelphia, PA

11:00 a.m. **Discussant.** Sandip Pravin Patel, San Diego, CA

11:15 a.m. **CT105 FAP-targeted 4-1BBL trimeric costimulation amplifies T-cell activation and antitumor efficacy of a CEA-directed T-cell engager in MSS colorectal cancer.** Ignacio Melero, Pamplona/Oxford, Spain

11:30 a.m. **Discussant.** Anthony El-Khoueiry, Los Angeles, CA

11:45 a.m **CT106 First-Line mRNA-4359 plus pembrolizumab (pembro) in locally advanced or metastatic melanoma: Results from the phase 1/2 mRNA-4359-P101 study.** Pavlina Spiliopoulou, Glasgow, United Kingdom

12:00 p.m. **Discussant.** Allison Betof, Stanford, CA

Meet and Greet
11:30 a.m.–12:30 p.m.

AACR Publications Booth 3537 - Hall D

Meet the Editor-in-Chief of *Molecular Cancer Research:* Massimo Loda, MD

NCI-NIH-Selected Session
12:30 p.m.–1:30 p.m.

Room 2 - Upper Level - Convention Center

Modernizing Clinical Trial Communication: NCI's AI-Enabled Toolkit for Research Protocols and Participant Materials

Moderator: Juli Klemm, Rockville, MD

12:35 p.m. **AI innovation at CBIIT: NCI›s clinical trial modernization initiative.** Umit Topaloglu, Rockville, MD

12:45 p.m. **Tools in action: Consent generation, lay summaries, and translation.** Tanna Nelson, Rockville, MD

12:55 p.m. **Implications for the scientific community.** James L. Gulley, Bethesda, MD

Special Session
12:30 p.m.–1:45 p.m.

Room 5 - Upper Level - Convention Center

AACR Annual Business Meeting of Members

AACR Chief Executive Officer. Margaret Foti, Philadelphia, PA

AACR President. Lillian L. Siu, Toronto, ON, Canada

AACR Immediate Past President. Patricia M. LoRusso, New Haven, CT

AACR Treasurer. Michael A. Caligiuri, Duarte, CA

President-Elect. Keith Thomas Flaherty, Cambridge, MA

Advances in Diagnostics and Therapeutics
12:30 p.m.–2:00 p.m.

Room 33 - Upper Level - Convention Center

El Camino de la Pediatría: Finding Our Way Through the Chasm of Pediatric Oncology Drug Development

Chair: Samuel C. Blackman, Seattle, WA

12:30 p.m. **Chair Introduction.** Samuel C. Blackman, Seattle, WA

12:31 p.m. **Targeting tomorrow: ADCs and novel small molecules in clinical development for children with cancer.** Elizabeth Fox, Memphis, TN

12:56 p.m. **Precision immunotherapy: CAR T-cell and bispecific antibody therapies for childhood cancers.** Theodore W. Laetsch, Philadelphia, PA

1:21 p.m. **From the mountaintop to the promised land: On making novel therapies a reality for childhood cancer.** Samuel C. Blackman, Seattle, WA

Advances in Early Detection and Interception
12:30 p.m.–2:00 p.m.

Ballroom 20 CD - Upper Level - Convention Center

Non-invasive Early Detection of Single-Site Cancers

Chair: Diane M. Simeone, San Diego, CA

12:30 p.m. **Chair Introduction.** Diane M. Simeone, San Diego, CA

12:31 p.m. **The strategy of making early detection of pancreatic cancer a reality.** Diane M. Simeone, San Diego, CA

12:56 p.m. **Biomarker based early detection of Barrett's esophagus and it's cancer progression.** Sanford D. Markowitz, Cleveland, OH

1:21 p.m. **Image-based models for personalized cancer screening.** Adam Yala, Berkeley, CA

Advances in Hematologic Malignancies
12:30 p.m.–2:00 p.m.

Room 17 - Mezzanine Level - Convention Center

Population Sciences for Hematological Malignancies

Chair: Kenan Onel, Buffalo, NY

12:30 p.m. **Chair Introduction.** Kenan Onel, Buffalo, NY

12:35 p.m. **Title to be announced.** Kenan Onel, Buffalo, NY

1:00 p.m. **Leveraging genetic diversity to improve knowledge and survival in acute myeloid leukemia.** Ann-Kathrin Eisfeld, Columbus, OH

1:25 p.m. **Unlocking genetic ancestry to address disparities in hematological malignancies.** Nicholas Pannunzio, Irvine, CA

Advances in Organ Site Research
12:30 p.m.–2:00 p.m.

Room 29 - Upper Level - Convention Center

Microbiota-Host Interactions in Colorectal Cancer Development and Therapy

Chair: Lars Vereecke, Ghent, Belgium

12:30 p.m. **Chair Introduction.** Lars Vereecke, Ghent, Belgium

12:35 p.m. **Sticky situation: How colibactin-driven genotoxicity requires epithelial adhesion.** Lars Vereecke, Ghent, Belgium

1:25 p.m. **Intratumoral bacteria reprogram tumor cell state and therapy response in colorectal cancer.** Susan Bullman, Houston, TX

1:00 p.m. **Modulating the gut microbiome to enhance anti-tumor immunity in colorectal cancer.** Wendy Sarah Garrett, Boston, MA

Room 28 - Upper Level - Convention Center

Prostate Cancer: Basic to Clinical Advances

Chair: Arul M. Chinnaiyan, Ann Arbor, MI

12:30 p.m. **Chair Introduction.** Arul M. Chinnaiyan, Ann Arbor, MI

12:36 p.m. **Heterobifunctional reprogramming of androgen receptor complexes in prostate cancer.** Arul M. Chinnaiyan, Ann Arbor, MI

1:04 p.m. **A golden age for prostate cancer drug development.** Johann S. de Bono, London, United Kingdom

1:24 p.m. **Therapeutic vulnerabilities in neuroendocrine prostate cancer.** Himisha Beltran, Boston, MA

Advances in Technologies
12:30 p.m.–2:00 p.m.

Hall H - Ground Level - Convention Center

Dharma Master Jiantai Symposium in Biomarkers: Next-Gen Tools for ADCs - Defining Biomarkers of Response through Technological Innovation

Chair: Barbara Pistilli, Villejuif, France

12:30 p.m. **Chair Introduction.** Barbara Pistilli, Villejuif, France

12:35 p.m. **Pathologist's perspective. Quantitative and reproducible assessment of ADC targets: Moving beyond conventional pathology.** David L. Rimm, New Haven, CT

1:00 p.m. **Biomathematician's perspective. Computational methods and integration of multiomics data for predicting ADC activity.** Maria Vakalopoulou, Orsay, France

1:25 p.m. **Clinician's perspective. From exploratory biomarkers to validated companion diagnostics in ADC precision oncology.** Barbara Pistilli, Villejuif, France

Ballroom 6 DE - Upper Level - Convention Center

Using AI and Spatial Transcriptomics Data to Predict Spatial Gene Expression from Histopathology Slides

Chair: Eytan Ruppin, Los Angeles, CA

12:30 p.m. **Chair Introduction.** Eytan Ruppin, Los Angeles, CA

12:35 p.m. **AI-powered tissue maps: uniting spatial omics and pathology imaging.** Mingyao Li, Philadelphia, PA

1:00 p.m. **Agentic AI for pathology and transcriptomic analysis.** James Y. Zou, Stanford, CA

1:25 p.m. **Towards fast and accessible precision oncology.** Eytan Ruppin, Los Angeles, CA

Major Symposia
12:30 p.m.–2:00 p.m.

Room 1 - Upper Level - Convention Center

Science and Health Policy Session

Cancer Prevention and Screening: Exploring Policy Solutions

Moderator: Gilbert S. Omenn, Ann Arbor, MI

Panelists: Suchitra Krishnan-Sarin, New Haven, CT; Timothy Rebbeck, Boston, MA; Electra D. Paskett, Columbus, OH; Douglas E. Wood, Seattle, WA; Philip E. Castle, Rockville, MD

Ballroom 6 A - Upper Level - Convention Center

Cancer Vaccines: The Next Immunotherapy Breakthrough?

Chair: Vinod P. Balachandran, New York, NY

12:30 p.m. **Chair Introduction.** Vinod P. Balachandran, New York, NY

12:31 p.m. **A personalized neoantigen vaccine reprograms the immune landscape of glioblastoma.** Catherine J. Wu, Boston, MA

12:55 p.m. **NG05 Mechanisms by which mRNA vaccines augment responses to immune checkpoint blockade.** Adam Grippin, Houston, TX

1:15 p.m. **Spatiotemporal dynamics of adoptively transferred stem-like CD8+ T cells in the tumor microenvironment following vaccination.** Robert Seder, Bethesda, MD

1:35 p.m. **Personalized neoantigen vaccines for pancreatic cancer.** Vinod P. Balachandran, New York, NY

Room 11 - Upper Level - Convention Center

Does Adherence to Oral Cancer Therapy Matter?

Chair: Smita Bhatia, Birmingham, AL

12:30 p.m. **Chair Introduction.** Smita Bhatia, Birmingham, AL

12:31 p.m. **Challenges and facilitators of adherence to oral therapies in breast cancer.** Katherine Reeder-Hayes, Chapel Hill, NC

12:56 p.m. **Patient before pill- strategies for improving outcomes for standard therapies and clinical trials for colorectal cancer.** Van K. Morris, Houston, TX

1:21 p.m. **Adherence to oral 6MP in children with acute lymphoblastic leukemia: Lessons learned over the past two decades.** Smita Bhatia, Birmingham, AL

Ballroom 6 CF - Upper Level - Convention Center

Glues and Heterobifunctionals as Novel Therapeutics

Chair: Benjamin F. Cravatt, San Diego, CA

12:30 p.m. **Chair Introduction.** Benjamin F. Cravatt, San Diego, CA

12:35 p.m. **Molecular glues that lead to gain-of-function pharmacology.** Nathanael S. Gray, Stanford, CA

12:55 p.m. **Chemical and genetic glues of the E3 ligase substrate adapter KBTBD4.** Brian Liau, Cambridge, MA

1:15 p.m. **NG07 Discovery of TRIM21 molecular glues that drive potent anti-tumor efficacy via nuclear pore complex degradation.** Steven M. Corsello, Stanford, CA

1:35 p.m. **Developing selective degraders of disease-associated proteoforms.** Fleur M. Ferguson, La Jolla, CA

Room 14 - Mezzanine Level - Convention Center

Metabolic Reprogramming in Metastasis: Nucleotide Pathways as Drivers and Therapeutic Targets

Chair: Raul Mostoslavsky, Boston, MA

12:30 p.m. **Chair Introduction.** Raul Mostoslavsky, Boston, MA

12:35 p.m. **Linking metabolism and epigenetics in metastatic disease, one gene at a time.** Raul Mostoslavsky, Boston, MA

1:00 p.m. **Key Vulnerabilities to nucleotide metabolism inhibition in cancer and metastasis.** Pankaj Kumar Singh, Oklahoma City, OK

1:25 p.m. **NUDT5 allows cells to regulate purine nucleotide synthesis and respond to thiopurine chemotherapy.** Ralph J. DeBerardinis, Dallas, TX

Room 31 - Upper Level - Convention Center

Programmed Cell Death: Mechanisms and Therapeutic Opportunities

Chair: Kristopher A. Sarosiek, Boston, MA

12:30 p.m. **Chair Introduction.** Kristopher A. Sarosiek, Boston, MA

12:35 p.m. **SY35-01 Boosting the efficacy of BH3 mimetic drugs for cancer therapy.** Andreas Strasser, Parkville, VIC, Australia

1:00 p.m. **The influence of intrinsic and extrinsic factors in targeting apoptosis.** Lawrence H. Boise, Atlanta, GA

1:25 p.m. **SY35-03 Targeting apoptosis to overcome cancer chemoresistance in solid tumors.** Kristopher A. Sarosiek, Boston, MA

Ballroom 20 AB - Upper Level - Convention Center

RAS Inhibitors, Mechanisms of Resistance, and Drug Combinations

Chair: Channing J. Der, Chapel Hill, NC

12:30 p.m. **Chair Introduction.** Channing J. Der, Chapel Hill, NC

12:35 p.m. **SY27-01 Combination therapies to enhance RAS inhibitor efficacy: Thinking outside the box.** Channing J. Der, Chapel Hill, NC

12:55 p.m. **NG04 BMAL2 is a KRAS-driven master regulator of hypoxic adaptation and EMT in pancreatic ductal adenocarcinoma.** Alvaro Curiel Garcia, New York, NY

1:15 p.m. **Rewiring under pressure: Adaptive resistance to KRAS inhibitors in PDAC, mechanisms and therapeutic opportunities.** Sandra Misale, Baltimore, MD

1:35 p.m. **Mechanisms of resistance to RAS inhibition in pancreatic cancer.** Andrew J. Aguirre, Boston, MA

Room 30 - Upper Level - Convention Center

Signaling Pathways in Cancer: Dedicated to the Memory of J. Michael Bishop

Chair: Benjamin G. Neel, New York, NY

12:30 p.m. **Chair Introduction.** Benjamin G. Neel, New York, NY

12:35 p.m. **New insights into SHP2 signaling to RAS.** Benjamin G. Neel, New York, NY

12:55 p.m. **Dietary Omega-3/6 fatty acids, mTOR, and breast cancer progression.** John Blenis, New York, NY

1:15 p.m. **Regulation of RAF kinases in RAS-driven cancers.** Deborah K. Morrison, Frederick, MD

1:35 p.m **NG06 Autocrine LIF signaling: A novel therapeutic target to eliminate inflammatory and immunosuppressive cancer stem cells in LKB1 mutant lung adenocarcinoma.** Ray Pillai, New York, NY

Room 16 - Mezzanine Level - Convention Center

Stress Across Scales in Cancer: From Societal Burden to Microenvironmental and Cellular Mechanisms

Chair: Mikala Egeblad, Baltimore, MD

12:30 p.m. **Chair Introduction.** Mikala Egeblad, Baltimore, MD

12:35 p.m. **Stress and mutation dependencies in the tumor microenvironment.** Ruth Scherz-Shouval, Rehovot, Israel

1:00 p.m. **Chronic stress-induced remodeling of the tumor microenvironment in cancer progression.** Mikala Egeblad, Baltimore, MD

1:25 p.m. **Change in cancer survivors› stressors and stress biomarkers.** Jesse J. Plascak, Columbus, OH

Ballroom 6 B - Upper Level - Convention Center

The Epitranscriptome in Cancer: Modifying RNA to Shape the Future of Oncology

Chair: Lucia Altucci, Naples, Italy

12:30 p.m. **Chair Introduction.** Lucia Altucci, Naples, Italy

12:35 p.m. **Targeting RNA methylation against cancer.** Lucia Altucci, Naples, Italy

1:00 p.m. **The functional significance of RNA modifications in blood malignancies.** Kamil Kranc, London, United Kingdom

1:25 p.m. **Chromatin regulation by RNA methylation in leukemia.** Chuan He, Chicago, IL

Special Session
12:30 p.m.–2:00 p.m.

Room 15 - Mezzanine Level - Convention Center

Stand Up To Cancer Scientific Session: Strategies Towards Overcoming Cancer Health Disparities

Moderator: Shawna V. Hudson, New Brunswick, NJ

12:30 p.m. **Introduction.** Shawna V. Hudson, New Brunswick, NJ

12:33 p.m. **Mailed outreach for colorectal cancer screening in community health centers: The CARES pragmatic cluster randomized clinical trial.** Jennifer Haas, Boston, MA

1:02 p.m. **Disrupting how we recruit to cancer clinical trials.** Nina A. Bickell, New York, NY

1:31 p.m. **Bold approaches to lung cancer screening.** Robert A. Winn, Richmond, VA

Meet and Greet
2:00 p.m.–3:00 p.m.

AACR Publications Booth 3537 - Hall D

Meet the Editor-in-Chief of *Clinical Cancer Research:* Timothy A. Yap, MBBS, PhD

Major Symposium
2:15 p.m.–3:45 p.m.

Room 1 - Upper Level - Convention Center

Regulatory Science and Policy Session

Advancing Early-Phase Pediatric Cancer Trials to Turn Promising Agents into Actionable Evidence

Chair: Meredith S. Irwin, Toronto, ON, Canada

2:20 p.m. **Title to be announced.** Brenda J. Weigel, Memphis, TN

2:35 p.m. **Regulatory considerations for early-phase pediatric cancer trials.** Nicole Drezner, Silver Spring, MD

2:50 p.m. **Title to be announced.** Gerard McGeehan, Newtown Square, PA

MONDAY, APRIL 20

Poster Sessions
2:00 p.m.-5:00 p.m.

Halls B-G, Ground Level, San Diego Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

Bioinformatics, Computational Biology, Artificial Intelligence, and Data Science

Section 1 Application of Bioinformatics to Cancer Biology 3

Section 2 Integration of Clinical and Research Data

Section 3 Large Language Models in the Clinic

Section 4 Radiomics and AI in Medical Imaging

Survivorship

Section 5 Advocates Poster Session 1

Section 6 Advocates Poster Session 2

Immunology

Section 7 Immune Checkpoints

Section 8 Immune Mechanisms Invoked by Other Therapies and Exposures

Section 9 Microbiome, Inflammation, and Response to Immunotherapy in Cancer

Section 10 Modifiers of Inflammation and the Tumor Microenvironment

Experimental and Molecular Therapeutics

Section 11 Cellular Responses to Anticancer Drugs

Section 12 Drug Resistance 1: Antibodies and ADCs

Section 13 Molecular Targets 1

Section 14 Nanocarriers and Drug Delivery Systems

Section 15 Novel Targets and Pathways

Section 16 Novel Therapeutics and Drug Targets 2

Section 17 Overcoming Chemotherapy Resistance

Section 18 Pharmacogenomics and Translational Biomarkers for Precision Cancer Therapy

Section 19 Targeting Cell Surface Vulnerabilities to Overcome Therapeutic Resistance

Section 53 Late-Breaking Research: Experimental and Molecular Therapeutics 2

Molecular/Cellular Biology and Genetics

Section 20 Epigenetic Changes as Molecular Markers of Cancer

Section 21 Epigenomics

Section 22 Genomic Profiling to Understand Cancer Biology

Section 23 Metabolic Studies in Brain, Pediatric, and Hematologic Cancers

Section 24 RTK-ERBB-PI3K and New Targets in Therapeutic Resistance

Section 25 Tumorigenesis Drivers

Tumor Biology

Section 26 Extracellular Vesicles and Long-Range Tumor-Host Communication

Section 27 Humanized Mouse Models

Section 28 In Vitro Models 1: 2D and 3D

Section 29 Microenvironmental Determinants of Therapy Response and Resistance 1

Section 30 Migration and Invasion

Section 31 Pediatric Cancer Genomics and Epigenomics

Section 32 Therapeutic Modulation of the Tumor Microenvironment: New Targets and Approaches 1

Section 33 Tumor Evolution

Section 55 Late-Breaking Research: Tumor Biology 1

Population Sciences

Section 34 Cancer Surveillance: Emerging Cancer Trends and Population Differences

Section 35 Genetic Epidemiology 1: GxE, GWAS, Polygenic Risk Scores, and Post-GWAS

Prevention, Early Detection, and Interception

Section 36 Metabolism and Microbiome in Cancer Initiation and Prevention

Section 54 Late-Breaking Research: Prevention, Early Detection, and Interception

Chemistry

Section 38 Natural Products

Science and Health Policy

Section 39 Science and Health Policy 1

Clinical Research

Section 40 Adoptive Cell Therapy 1

Section 41 Biomarkers Predictive of Therapeutic Benefit 4

Section 42 Circulating Tumor Cells, Metastasis, and Dissemination Biology 2

Section 43 Combination Immunotherapies

Section 44 Diagnostic Biomarkers 1

Section 45 Liquid Biopsies: Circulating Nucleic Acids 3

Section 46 Molecular Classification and Tumor Biology in Cancer

Section 47 Molecular Targeted Therapy

Section 48 Prognostic Biomarkers 2

Section 49 Spatial Proteomics and Transcriptomics 2

Clinical Trials

Section 51 Phase 0 and First-in-Human Phase I Clinical Trials

Section 52 Phase II and Phase III Clinical Trials

Meet and Greet
2:30 p.m.–3:30 p.m.

Room 26 - Upper Level - Convention Center

Meet the Research Grant Reviewers

Moderator: Adham Halaoui, San Diego, CA

Panelists: Greg M. Delgoffe, Pittsburgh, PA; Rulla M. Tamimi, New York, NY

Awards and Lectures
2:30 p.m.–3:45 p.m.

Ballroom 6 A - Upper Level - Convention Center

NCI Director's Address and Fireside Chat

2:30 p.m. **Introductions.** Lillian L. Siu, Toronto, ON, Canada; Keith Thomas Flaherty, Cambridge, MA

2:32 p.m. **NCI Director's Address.** Anthony G. Letai, Bethesda, MD

3:02 p.m. **Fireside Chat**

Clinical Trials Minisymposium
2:30 p.m.–4:30 p.m.

Hall H - Ground Level - Convention Center

Focus on ctDNA

Cochairs: Scott Kopetz, Houston, TX; Aadel A. Chaudhuri, Rochester, MN

2:30 p.m. **Chair introduction.** Scott Kopetz, Houston, TX

2:35 p.m. **CT170 Neoadjuvant pembrolizumab stratified by tumor mutation burden in high-risk stage II-III dMMR/MSI colorectal cancer (NEOPRISM-CRC): Perioperative ultrasensitive ctDNA monitoring and tumor-infiltrating TCR repertoire for treatment response prediction.** Yanrong Jiang, London, United Kingdom

2:50 p.m. **CT171 Early findings from MONITOR-Breast: ctDNA dynamics during neoadjuvant therapy using an ultrasensitive MRD assay.** Julia Foldi, Pittsburgh, PA

3:05 p.m. **CT172 A phase II trial of adjuvant PD-1 blockade with endocrine therapy in hormone receptor positive inflammatory breast cancer: Circulating biomarkers and molecular correlates of clinical outcomes.** Ranjan Upadhyay, Houston, TX

3:20 p.m. **CT173 Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): The MERIDIAN Phase II trial.** Enrique Sanz Garcia, Toronto, ON, Canada

3:35 p.m. **CT174 Unlocking endocrine resistance: Co-targeting KAT6 and ER with prifetrastat (PF-07248144) and fulvestrant drives tumor and ctDNA response in ER+/HER2− metastatic breast cancer.** Li Liu, San Diego, CA

3:50 p.m. **CT175 ctDNA clearance as a prognostic biomarker in ES-SCLC: Insights from the LUMINANCE phase IIIb study.** Gozde Kar, Cambridge, United Kingdom

4:05 p.m. **CT176 ctDNA as a prognostic and pharmacodynamic biomarker following first- or later-line treatment of advanced NSCLC with BNT116 + cemiplimab.** Janet L. Markman, Cambridge, MA

4:20 p.m. **Closing Remarks.** Aadel A. Chaudhuri, Rochester, MN

Minisymposia
2:30 p.m.–4:30 p.m.

Room 31 - Upper Level - Convention Center
Bioinformatics, Computational Biology, Artificial Intelligence, and Data Science
Digital Pathology

Cochairs: Pallavi Tiwari, Madison, WI; Satish Easwar Viswanath, Atlanta, GA

2:30 p.m. **Chair Introduction.** Pallavi Tiwari, Madison, WI

2:35 p.m. **3997 Elucidating broad cell-cell interactions via 3D super-cell graphs for prostate cancer risk stratification.** Yujie Zhao, Seattle, WA

2:50 p.m. **3998 AI-driven spatial analysis of 1100 head and neck squamous cell carcinoma patients H&E slides uncovers three sub-types with markedly distinct tumor microenvironments and survival patterns.** Sumona Biswas, Bethesda, MD

3:05 p.m. **3999 Pan-cancer prediction of response to immune checkpoint blockade from histopathology.** Danh-Tai Hoang, Bethesda, MD

3:20 p.m. **4000 A large-scale, multi-target deep learning model for virtual genomic profiling in colorectal cancer.** Erik N. Bergstrom, Austin, TX

3:35 p.m. **4001 AI-driven spatial cell classification and tumor-infiltrating lymphocyte (TIL) patch analysis reveal spatial immunoarchitecture in arsenic-associated bladder cancer.** Sonalika Singhal, Grand Forks, ND

3:50 p.m. **4002 Peritumoral collagen microarchitecture is differently prognostic of biochemical recurrence across populations in prostate cancer.** Ajay Rajaraman Subramanian, Atlanta, GA

4:05 p.m. **4003 Path-IO: A deep learning pathomics framework for personalized immunotherapy selection and outcome prediction in metastatic non-small cell lung cancer.** Rukhmini Bandyopadhyay, Houston, TX

4:20 p.m. **Closing remarks.** Satish Easwar Viswanath, Atlanta, GA

Ballroom 20 AB - Upper Level - Convention Center
Clinical Research
Adoptive T Cell Therapy

Cochairs: Ryan H. Moy, New York, NY; Michelle Choe, Seattle, WA

2:30 p.m. **Chair Introduction.** Ryan H. Moy, New York, NY

2:35 p.m. **4006 Iterative engineering of GPC-3 targeted synthetic TCR and antigen receptor (STAR) cells in advanced solid tumors.** Changsong Qi, Beijing, China

2:50 p.m. **4007 The cellular architecture of the infused T cell predicts efficacy of autologous tumor-infiltrating lymphocyte therapy (LM-103) in acral melanoma.** Chao Zhang, Tianjin, China

3:05 p.m. **4008 A novel, first in class chimeric antigen receptor dendritic cell platform driving broad and durable antitumor immunity in solid tumors.** Carl DeSelm, St. Louis, MO

3:20 p.m. **4009 Decoding the medulloblastoma surfaceome prioritizes the oncofetal antigen GPC2 for potent CAR-T cell therapy.** Sabine Heitzeneder, Stanford, CA

3:35 p.m. **4010 NK-TCR cells: A next-generation platform expanding NK-cell therapeutic potential.** Nadima Uprety, Houston, TX

3:50 p.m. **4011 Universal T cell therapy screening library in preclinical models of CAR T cell therapy.** Alexander Eapen, Stanford, CA

4:05 p.m. **4012 Triple disruption of CCDC6, CBLB, and ASB2 promotes the therapeutic efficacy of Glypican 3 targeted T cells.** Azlann Arnett, Houston, TX

4:20 p.m. **Closing remarks.** Michelle Choe, Seattle, WA

Room 29 - Upper Level - Convention Center
Clinical Research

Biomarkers That Change Management: Predicting Therapy Benefit, Progression, and Metastatic Risk

Cochairs: Montserrat Garcia-Closas, London, United Kingdom; Tejas Patil, Aurora, CO

2:30 p.m. **Chair Introduction.** Montserrat Garcia-Closas, London, United Kingdom

2:35 p.m. **4015 Whole-genome duplication predicts metastasis risk and timing across human cancers.** Jierui Xu, New York, NY

2:50 p.m. **4016 Tissue-based homologous recombination deficiency status prediction in patients with breast, ovarian, and pancreatic cancers.** Pegah Safabakhsh, Palo Alto, CA

3:05 p.m. **4017 Integrated multi-omics approaches in resectable hepatocellular carcinoma with microvascular invasion for revealing therapeutic target.** Jisun So, Seongnam, Republic of Korea

3:20 p.m. **4018 Stromal immune composition significantly contributes to adenomatous polyp recurrence or progression to cancer.** Mrunal Dehankar, Rochester, MN

3:35 p.m. **4019 Clinical validation of WES-based HRD scoring and its prognostic value for PARP inhibitor maintenance therapy in ovarian cancer.** DongSoo Kyung, Seoul, Republic of Korea

3:50 p.m. **4020 Utility of CA19-9 for prediction of asymptomatic pancreatic cancer among patients with new onset diabetes.** Johannes Fahrmann, Houston, TX

4:05 p.m. **4021 Precision diagnostics for early melanoma detection using spatial biology and AI guided image analysis.** Yung-Ching Kao, Brisbane, Australia

4:20 p.m. **Closing remarks.** Tejas Patil, Aurora, CO

Room 11 - Upper Level - Convention Center
Clinical Research

Pediatric Cancer from Mechanism to Translation

Cochairs: Sneha Ramakrishna, Stanford, CA; Mark E. Hatley, Memphis, TN

2:30 p.m. **Chair Introduction.** Sneha Ramakrishna, Stanford, CA

2:35 p.m **4024 Dysregulated AKT signaling reprograms osteosarcoma to drive selective reliance on EP300.** Adam D. Durbin, Memphis, TN

2:50 p.m. **4025 Sequential cell free DNA analysis reveals genetic heterogeneity in patients with relapsed neuroblastoma enrolled in the SIOPEN-ITCC BEACON study.** Gudrun Schleiermacher, Paris, France

3:05 p.m. **4026 Spatial T-cell receptor profiling uncovers barriers to T-cell engagement and shared tumor-reactive clonotypes in high-risk neuroblastoma.** Yiyue (January) Jiang, Toronto, ON, Canada

3:20 p.m. **4027 Co-targeting GPC2 and B7-H3 with CAR T cells achieves durable responses in preclinical high-risk neuroblastoma and medulloblastoma models.** Patrick M. Schürch, Philadelphia, PA

3:35 p.m. **4028 Surface localized nuclear envelope proteins define a therapeuticvulnerability in MYC-driven Group 3 medulloblastoma.** Sheila Kumari Singh, Hamilton, ON, Canada

3:50 p.m. **4029 Neuronal activity-regulated mechanisms promoting growth of diffuse hemispheric glioma, H3G34-mutant.** Samuel H. Wu, Stanford, CA

4:05 p.m. **4030 Targeting MYB with REM-422 for the treatment of pediatric T-cell acute lymphoblastic leukemia - A report from the Pediatric Preclinical Testing Consortium (PIVOT).** Richard B. Lock, Sydney, Australia

4:20 p.m. **Closing remarks.** Mark E. Hatley, Memphis, TN

Room 28 - Upper Level - Convention Center

Experimental and Molecular Therapeutics

Cracking Adaptive Resistance: AI-Enabled, Screen-Guided Targets in Tumor Plasticity, DNA Damage, Metabolism, and CTC-Associated Immunity

Cochairs: Huiping Liu, Chicago, IL; John Tainer, Houston, TX

2:30 p.m. **Chair Introduction.** Huiping Liu, Chicago, IL

2:35 p.m. **4033 Chemical trapping of inactive GRB2 dimer unveils a novel cancer vulnerability by coupling replication stress to anti-tumor immunity.** Zamal Ahmed, Houston, TX

2:50 p.m. **4034 Computational ranking-guided discovery of Plexin-B2 as a driver of circulating tumor cell clusters and AI-facilitated neutralization to prevent and inhibit metastasis.** Fangjia Tong, Chicago, IL

3:05 p.m. **4035 SWELL1 controls epigenetic methylation, mitochondrial metabolism, and anti-tumor immunity in IDH-mutant gliomas.** Henry Yi Cheng, Baltimore, MD

3:20 p.m. **4036 Deciphering regulatory drivers of lineage plasticity and resistance to antibody-drug conjugates in urothelial bladder cancer.** Jiaqian Luo, New York, NY

3:35 p.m. **4037 Pharmacological inhibition of eIF4A1 suppresses leukemogenesis via specifically rewiring amino acid biosynthesis.** Xiaoxu Zhang, Monrovia, CA

3:50 p.m. **4038 Anti-ROR2 therapies target cancer stem cells in triple-negative breast cancer.** Emanuela M. Ghia, La Jolla, CA

4:05 p.m. **4039 Deletion of peroxiredoxin 3 (PRX3) impairs mitochondrial bioenergetics and tumor growth in mesothelioma, supporting the first in human clinical testing of the PRX3 inhibitor RSO-021.** Brian Cunniff, Burlington, VT

4:20 p.m. **Closing remarks.** John Tainer, Houston, TX

Room 33 - Upper Level - Convention Center

Experimental and Molecular Therapeutics

Tumor Microenvironment, Immunomodulation, and Enabling Delivery and Models

Cochairs: Ahmed Aman, Toronto, ON, Canada; Elena Garralda, Barcelona, Spain

2:30 p.m. **Chair Introduction.** Ahmed Aman, Toronto, ON, Canada

2:35 p.m. **4044 GPNMB CAR-T cells target both glioblastoma and the tumor microenvironment to relieve immune suppression.** Sheila Kumari Singh, Hamilton, ON, Canada

2:50 p.m. **4042 Tumor-tailored ionizable lipid nanoparticles facilitate IL-12 circular RNA delivery for enhanced lung cancer immunotherapy.** Yue Xu, Houston, TX

3:05 p.m. **4043 A novel TAM-targeted therapeutic for rare and aggressive solid tumors.** Faith H. Barnett, San Diego, CA

3:20 p.m. **4045 Collagen binding enhances anti-CTLA4 therapy in recurrent glioblastoma.** Lewis Barr, Birmingham, AL

3:35 p.m. **4046 A novel DLL3 trispecific T cell engager antibody integrating the CD2/CD58 co-stimulatory pathway demonstrates superior antitumor efficacy and balanced safety profile.** Yu Liang, Pennington, NJ

3:50 p.m. **4047 CBP/p300 and PARP inhibitor combination treatment synergistically enhances anti-tumor efficacy in models of advanced prostate cancer.** Orly I. Richter, Bethesda, MD

4:05 p.m. **4048 3D bioprinted cancer models for drug screening versus 2D and in vivo models: A comparison study.** Aurélie Cadiou, Lyon, France

4:20 p.m. **Closing remarks.** Elena Garralda, Barcelona, Spain

Ballroom 20 CD - Upper Level - Convention Center
Immunology

Advances in Therapeutic Antibodies

Cochairs: Juan C. Osorio, New York, NY; Thomas Frank Gajewski, Chicago, IL

2:30 p.m. **Chair Introduction.** Juan C. Osorio, New York, NY

2:35 p.m. **4051 BHB299: An AI/ML-optimized high avidity/low affinity CEACa.m.6-directed T cell engager for diverse solid tumors.** Ryan Henrici, San Mateo, CA

2:50 p.m. **4052 ENA101: A first-in-class bispecific T cell engager targeting a DARKFOX peptide presented by solid tumors.** Joseph Dukes, Oxford, United Kingdom

3:05 p.m. **4053 NRP1 drives a novel cross-presentation pathway exploitable by peptide-linked antibodies to redirect viral memory T-cells against solid tumors.** Jeffrey J. Molldrem, Houston, TX

3:20 p.m. **4054 Tumor-activated PrimeBody biologics platform enables more potent CD47 targeting and superior therapeutic index in preclinical models.** Aaron Springer, San Diego, CA

3:35 p.m. **4055 Integrated CD2-costimulation on CD3 T cell engager EVOLVE platform yields differentiated and superior T cell effector profile.** Emma Stewart, Branford, CT

3:50 p.m. **4056 Preclinical evaluation and safety of CBX-250 in acute myeloid leukemia: A bispecific T cell engager targeting Cathepsin-G peptide/HLA complex.** Jennifer Helble, Cambridge, MA

4:05 p.m. **4057 Gastrointestinal tumor-associated target: A first-in-class therapeutic monoclonal antibody.** Unbyeol Goh, Seoul, Republic of Korea

4:20 p.m. **Closing remarks.** Thomas Frank Gajewski, Chicago, IL

Room 30 - Upper Level - Convention Center
Molecular/Cellular Biology and Genetics

Oncogenic Transcriptional Control: From Chromatin to Cell Fate

Cochairs: Ling Cai, Durham, NC; Christoph Kuppe, Aachen, Germany

2:30 p.m. **Chair Introduction.** Christoph Kuppe, Aachen, Germany

2:40 p.m. **4060 SOX2 is a master regulator of classical squamous cell carcinoma.** Reilly Falter, Salt Lake City, UT

2:55 p.m. **4061 Single cell transcriptomic analysis of T-SCLC patients identifies PHOX2B as a factor in NE transformation.** Amin Sabet, New York, NY

3:10 p.m. **4062 MBD4 regulates FOXA1 lineage-specific enhancers to promote prostate tumorigenesis and progression.** Xuanrong Chen, New York, NY

3:25 p.m. **4063 Oral small-molecule condensate modulator (c-mod) inhibits MYC activity and demonstrates robust anti-tumor activity across diverse tumor models.** Ann Boija, Boston, MA

3:40 p.m. **4064 NSD3 is a critical cofactor that enables fusion oncoprotein-driven 3D genome reorganization and activation of oncogenic transcriptional programs.** Kyle P. Eagen, Houston, TX

3:55 p.m. **4065 EcDNA-borne structural variants drive oncogenic fusion transcript amplification.** Hyerim Yi, Stanford, CA

4:10 p.m. **4066 Epidemiology meets epitranscriptomics: Uncovering a novel TERT-antisense transcript regulated by RNA methylation and its role in cancer cell growth and proliferation.** Brenen Papenberg, Bethesda, MD

4:25 p.m. **Closing remarks.** Ling Cai, Durham, NC

Room 14 - Mezzanine Level - Convention Center
Multidisciplinary

Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE® Use Cases

Cochairs: Todd R. Golub, Cambridge, MA; David B. Solit, New York, NY

2:30 p.m. **Chair Introduction.** Todd R. Golub, Cambridge, MA

2:35 p.m. **3988 Beyond G12C: Pan-cancer landscape and co-mutational architecture of rare RAS alleles across 211,526 patients.** Niamh Coleman, Dublin, Ireland

2:50 p.m. **3989 Mutant p53 neomorphic activities drive organ-specific metastatic programs through distinct transcriptional networks.** Gizem Efe, New York, NY

3:05 p.m. **3990 Real-world evidence of KMT2C mutation as a biomarker of sensitivity to platinum-based therapy in solid cancers.** Bruno Bockorny, Boston, MA

3:20 p.m. **3991 BRAF N486_P490del and fusions as distinctive gene alterations in pancreatic ductal adenocarcinomas: Analysis of C-CAT and AACR Project GENIE® data.** Kiyoaki Ochi, Tokyo, Japan

3:35 p.m. **3992 Leveraging Ultima Genomics ppmSeq WGS-cfDNA to accurately detect clonal evolution over sequential blood biopsies.** Elizabeth E. Martin, Cambridge, MA

3:50 p.m. **3993 Artificial intelligence-integrated analysis of the gut microbiome in early- and late-onset colorectal cancer among populations at increased risk using clinical, genomic, and social determinants data.** Sophia Manjarrez, Duarte, CA

4:05 p.m. **3994 Differences in the mutational landscape across race and sex highlight distinct TP53-associated risk in multiple myeloma.** Chidiebube Ugwu, Philadelphia, PA

4:20 p.m. **Closing remarks.** David B. Solit, New York, NY

Room 15 - Mezzanine Level - Convention Center
Multidisciplinary

Cutting-Edge Advances in Hematology

Cochairs: Rong Fan, New Haven, CT; Ann-Kathrin Eisfeld, Columbus, OH

2:30 p.m. **Chair Introduction.** Rong Fan, New Haven, CT

2:35 p.m. **3979 Targeting nicotinamide metabolism with Na.m.PT-inhibitor OT-82 potentiates venetoclax in preclinical models of pediatric and adult acute myeloid leukemia.** Michelle Haber, Sydney, Australia

2:50 p.m. **3980 Non-canonical CAR T cell states correlate with durable therapeutic responses in multiple myeloma patients.** Kai Wu, Seattle, WA

3:05 p.m. **3981 A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death.** Meredith Nicole Nix, Stanford, CA

3:20 p.m. **3982 FGFR1+ cancer-associated fibroblasts contribute to the failure of CAR-T cell therapy in B-cell lymphoma through the secretion of TGFβ.** Nicolas Di Siervi, New York, NY

3:35 p.m. **3983 Condensate dynamics drive adaptive METTL3 inhibitor resistance.** Xuejing Yang, New York, NY

3:50 p.m. **3984 Lymphotoxin alpha induces myeloid differentiation and programmed cell death in myeloid leukemic stem cells resulting in deep and sustained remission in vivo.** Philipp J. Jost, Graz, Austria

4:05 p.m. **3985 MED12L: A novel player in platelet dysfunction in myeloid neoplasms.** Matteo Brindisi, Rozzano (MI), Italy

4:20 p.m. **Closing remarks.** Ann-Kathrin Eisfeld, Columbus, OH

Room 16 - Mezzanine Level - Convention Center

Prevention, Early Detection, and Interception

Precision Prevention: Advances in Early Detection and Risk Assessment

Cochairs: Elizabeth M. Swisher, Seattle, WA; Melissa Amy Merritt, Sydney, NSW, Australia

2:30 p.m. **Chair Introduction.** Melissa Amy Merritt, Sydney, NSW, Australia

2:35 p.m. **4069 Therapy-associated clonal hematopoiesis and risk of hematologic malignancy after primary cancer treatment.** Kara Marie Barnao, Rockville, MD

2:50 p.m. **4070 APC mosaicism and colibactin-associated signature as key factors in unexplained colorectal polyposis.** Keltouma Driouch, Paris, France

3:05 p.m. **4071 The impact of patient biology on racial disparities in breast cancer outcome.** Jerry DeWitt, San Diego, CA

3:20 p.m. **4072 Single-cell pathology of the normal breast uncovers occult cytomorphologic signatures that signal future cancer risk and etiologic origins.** Mustapha Abubakar, Bethesda, MD

3:35 p.m. **4073 Deep plasma proteomics for early-stage breast cancer detection.** Pooja Advani, Jacksonville, FL

3:50 p.m. **4074 Non-invasive early detection of cancer-predisposing liver diseases using genome-wide cfDNA fragmentomes.** Akshaya Vijaya Annapragada, Baltimore, MD

4:05 p.m. **4075 Enhanced early detection of pancreatic cancer using a multi-analyte liquid biopsy approach.** Anna Bergamaschi, San Diego, CA

4:20 p.m. **Closing remarks.** Elizabeth M. Swisher, Seattle, WA

Ballroom 6 CF - Upper Level - Convention Center

Tumor Biology

Microenvironmental Determinants of Tumor Evolution and Immune Escape

Cochairs: Sergei Grivennikov, Los Angeles, CA; Elizabeth A. Repasky, Buffalo, NY

2:30 p.m. **Chair Introduction.** Sergei Grivennikov, Los Angeles, CA

2:35 p.m. **4078 Vagal sensory neuronal inflammatory memory promotes gastric tumorigenesis through ILC2-mediated epigenetic signaling and the CGRP/Ramp1 axis.** Yi Zeng, New York, NY

2:50 p.m. **4079 Unique mechanism of MASLD-associated hepatocarcinogenesis: LSEC-derived CXCL9 facilitates T-cell exhaustion in steatotic tumor microenvironment.** Naoko Ohtani, Osaka, Japan

3:05 p.m. **4080 The neural bridge: Stress-remodeled enteric nervous system (ENS) in the colitis-cancer transition.** Xue-Yan He, St. Louis, MO

3:20 p.m. **4081 A multimodal single-cell atlas reveals a pathogenic epithelial-myeloid circuit driving HNSCC progression.** De-Chen Lin, Los Angeles, CA

3:35 p.m. **4082 The gut microbiota influences chronic sleep deprivation-induced colorectal cancer progression and treatment response.** Maria Carolina Hernandez, Gainesville, FL

3:50 p.m. **4083 The impact of obesity-induced changes in adipose tissue on ovarian cancer progression.** Sofia Howe, San Diego, CA

4:05 p.m. **4084 Dissecting myeloid-driven mechanisms of immunotherapy resistance in prostate cancer bone metastases.** Aram Lyu, Seattle, WA

4:20 p.m. **Closing remarks.** Elizabeth A. Repasky, Buffalo, NY

Ballroom 6 B - Upper Level - Convention Center
Tumor Biology
Novel Molecular Mechanisms Driving Cancer Metastasis

Cochairs: Richard Carpenter, Bloomington, IN; Eran Andrechek, East Lansing, MI

2:30 p.m. **Chair Introduction.** Richard Carpenter, Bloomington, IN

2:35 p.m. **4087 Senescent cancer cells facilitate metastasis by adhesion-mediated clustering and immune modulation.** Seyedehalaleh Anvar, Gainesville, FL

2:50 p.m. **4088 Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction.** Zhimin Hu, La Jolla, CA

3:05 p.m. **4089 Immunosuppressive cellular topography and genomic adaptations sustain colorectal cancer metastasis to the brain.** Anuja Sathe, Stanford, CA

3:20 p.m. **4090 ADAR1 acts as a metastatic switch by sustaining survival programs in breast cancer brain metastasis.** Teresa Sposito, San Diego, CA

3:35 p.m. **4091 KPC1 regulates mesenchymal reprogramming in metastatic melanoma through ubiquitin-dependent degradation of ZEB1.** Dave Hoon, Santa Monica, CA

3:50 p.m. **4092 Tumor cell JAG1 promotes lymph node metastasis and predicts recurrence in lymph node positive breast cancer patients.** Jan Kitajewski, Chicago, IL

4:05 p.m. **4093 Lipocalin-2 drives brain metastatic progression through reciprocal tumor-microenvironment interactions in lung cancer.** Danming He, Beijing, China

4:20 p.m. **Closing remarks.** Eran Andrechek, East Lansing, MI

Special Session
2:30 p.m.–4:30 p.m.

Ballroom 6 DE - Upper Level - Convention Center
AACR-JCA Joint Session: Lung Cancer in Never-Smokers

Cochairs: Maria Teresa Landi, Bethesda, MD; Takashi Kohno, Tokyo, Japan

2:30 p.m. **Chair Introduction.** Maria Teresa Landi, Bethesda, MD

2:34 p.m. **SS03-01 Unraveling the genetic and environmental risk factors for lung adenocarcinoma in Asia.** Takashi Kohno, Tokyo, Japan

3:02 p.m. **Germline variation in oncogene-driven, young-onset, and familial lung cancer.** Jaclyn LoPiccolo, Boston, MA

3:30 p.m. **Differential response to anti-cancer treatment depending on smoking status in lung cancer.** Se-Hoon Lee, Seoul, Republic of Korea

3:58 p.m. **Sherlock-Lung: Charting the landscape of lung cancer in never smokers.** Maria Teresa Landi, Bethesda, MD

4:26 p.m. **Closing Remarks.** Takashi Kohno, Tokyo, Japan

Awards and Lectures
3:00 p.m.–3:45 p.m.

Room 5 - Upper Level - Convention Center
AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship

Chair: Camille C.R. Ragin, Philadelphia, PA

Funder Remarks: Lynette A. Badu, Charlotte, NC

Use of surveillance data to promote cancer prevention and control: Examples from American Cancer Society. Ahmedin M. Jemal, Atlanta, GA

MONDAY, APRIL 20

Meet and Greet
3:30 p.m.–4:30 p.m.

AACR Publications Booth 3537 - Hall D

Meet the Editors-in-Chief of *Cancer Prevention Research:* Raymond N. DuBois, MD, PhD, FAACR, and Nickolas Papadopoulos, PhD

NCI-NIH-Selected Session
4:00 p.m.–5:00 p.m.

Room 2 - Upper Level - Convention Center

Leveraging NCI-supported Cancer Epidemiology Cohorts to Advance Cancer Prevention and Control

Cochairs: Erin M. Siegel, Rockville, MD; Iona C. Cheng, San Francisco, CA

4:00 p.m. **Welcome and Overview of Current Cancer Epidemiology Cohorts Landscape.** Erin M. Siegel, Rockville, MD

4:05 p.m. **Welcome and Overview of Current Cancer Epidemiology Cohorts Landscape.** Sonia Rosenfield, Rockville, MD

4:10 p.m. **Panel Discussion.**

Panelists: James R. Cerhan, Rochester, MN; Iona C. Cheng, San Francisco, CA; Elena Martinez, San Diego, CA; Shelley S. Tworoger, Portland, OR; Wei Zheng, Brentwood, TN

Major Symposium
4:00 p.m.–5:30 p.m.

Room 1 - Upper Level - Convention Center

Regulatory Science and Policy Session

Power in Numbers: Leveraging Adult Data in Pediatric Cancer Drug Development

Moderator: Martha Donoghue, Silver Spring, MD

Moderator Introduction. Martha Donoghue, Silver Spring, MD

Panelists: Nicole Drezner, Silver Spring, MD; Mansi Dalal, Silver Spring, MD; Lauren Price, Silver Spring, MD; Jiang Liu, Silver Spring, MD; Adam Levy, Princeton, NJ; Vickie Buenger, Bryan, TX

Awards and Lectures
4:15 p.m.-5:00 p.m.

Ballroom 6 A - Upper Level - Convention Center

AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research

Chair: William Pao, New York, NY

How science turned metastatic melanoma from an untreatable cancer to a curable cancer. Antoni Ribas, Los Angeles, CA

Room 5 - Upper Level - Convention Center

AACR Award for Outstanding Achievement in Basic Cancer Research

Chair: Ruth Scherz-Shouval, Rehovot, Israel

RNA in Cancer: From Mechanism to Medicine. Housheng Hansen He, Toronto, ON, Canada

Special Session
4:45 p.m.–6:15 p.m.

Ballroom 6 CF - Upper Level - Convention Center

AACR-ASCO Joint Session: Next Generation of CAR T-Cell Therapies

Cochairs: Lillian L. Siu, Toronto, ON, Canada; Eric J. Small, San Francisco, CA

4:45 p.m. **Introduction by the AACR President.** Lillian L. Siu, Toronto, ON, Canada

4:46 p.m. **Introduction by the ASCO President.** Eric J. Small, San Francisco, CA

4:47 p.m. **Towards in vivo CART.** Saar Gill, Philadelphia, PA

5:12 p.m. **CAR T cells for pediatric brain tumors.** Crystal L. Mackall, Stanford, CA

5:37 p.m. **Precision targeted engineering of CAR T cells.** Phil K. Darcy, Melbourne, Australia

MONDAY, APRIL 20

Awards and Lectures
5:00 p.m.-5:45 p.m.

Ballroom 6 DE - Upper Level - Convention Center
AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research

Chair: Stephen J. Forman, Duarte, CA

Clinical applications of caner genomics. Luis A. Diaz Jr., New York, NY

Room 30 - Upper Level - Convention Center
AACR-St. Baldrick's Foundation Award for Outstanding Achievement in Pediatric Cancer Research

Chair: Meredith Irwin, Toronto, ON, Canada

Funder Remarks: Laura Chung, Los Angeles, CA

Toward mechanistic understanding and new therapies for childhood cancers. Kimberly Stegmaier, Boston, MA

Meet-the-Expert Sessions
5:00 p.m.–5:45 p.m.

Room 28 - Upper Level - Convention Center
Granulocyte Reprogramming in Gastric Metaplasia and the Tumor Immune Microenvironment

Juanita L. Merchant, Tucson, AZ

Room 29 - Upper Level - Convention Center
Integrating Digital Pathology and Molecular Pathology for Next-Generation Cancer Diagnostics

A. John Iafrate, Boston, MA

Forums
5:00 p.m.–6:30 p.m.

Ballroom 6 B - Upper Level - Convention Center
Pharma, Biotech and Academia: Advancing Drug Discovery and Development in an AI World

Chair: Susan M. Galbraith, Gaithersburg, MD

5:00 p.m. **Chair Introduction.** Susan M. Galbraith, Gaithersburg, MD

5:10 p.m. **Therapeutic approaches in chromatin and gene regulation informed by basic mechanisms.** Cigall Kadoch, Boston, MA

5:25 p.m. **Drug-like antibody design against challenging targets with atomic precision.** Joshua Meier, San Francisco, CA

5:40 p.m. **Panel Discussion**

Room 31 - Upper Level - Convention Center
Science of Community Outreach and Engagement: Navigating Change and Maintaining Impact

Chair: Kim F. Rhoads, Richmond, VA

5:00 p.m. **Chair Introduction.** Kim F. Rhoads, Richmond, VA

5:10 p.m. **Innovations in the science of community outreach and engagement through storytelling: Using patient stories to save lives.** Lourdes Baezconde-Garbanati, Los Angeles, CA

5:20 p.m. **Strategies for facilitating community involvement in cancer research to enhance community impact.** Pamela C. Hull, Lexington, KY

5:30 p.m. **Community engagement as sustainability: The secret sauce for lasting impact.** Lorna H. McNeill, Houston, TX

5:40 p.m. **Panel Discussion**

Professional Development Session
5:00 p.m.–7:00 p.m.

Harbor Ballroom GHI - Manchester Grand Hyatt San Diego

Navigating a Path to a Successful Career in Cancer Research

Cochairs: Christopher M. Sistrunk, Duarte, CA; Johnson Ung, Charlottesville, VA; Yamile Molina, Chicago, IL; Arti P. Varanasi, Baltimore, MD

Career transitioning: From undergraduate to graduate and medical school and other allied health professional schools. Gregory Adams, Rockville, MD

Careers in cancer: Patient advocacy and community. Kimlin Ashing, Duarte, CA

Harnessing the power of AI and pitfalls to avoid. Oliver Bogler, New York, NY

Careers in cancer: Biotechnology. Francesco Caiazza, South San Francisco, CA

Getting the grant: Investigator grants. Carlos A. Casiano, Loma Linda, CA

Career Objectives and Survival Skills: Clinical Fellows. Aimee Marie Crago, New York, NY

The art of effectively communicating your research and networking. Sophia HI George, Miami, FL

5How to advance from poster to paper: Challenges of publishing in peer-reviewed journals with high impact factor. Chanita Hughes-Halbert, Los Angeles, CA

Careers in cancer: Industry. Melissa R. Junttila, South San Francisco, CA

Career objectives and survival skills: Early-stage investigator (Junior faculty level). K. Sean Kimbro, Atlanta, GA

Effective management, communication, and negotiation skills. Christopher I. Li, Seattle, WA

The importance of sponsorship for women. Mariana C. Stern, Los Angeles, CA

Building effective collaborations: Working effectively in a team. Katherine Y. Tossas, Richmond, VA

Building a mentoring team. Danny R. Welch, Kansas City, KS

Putting yourself on the map: Strategies to increase your visibility and expand the impact of your research. Clayton Yates, Baltimore, MD

How NCI supports cancer researchers in training and in the early phase of their independent careers. Nastaran Zahir, Bethesda, MD

Special Session
5:00 p.m.–7:00 p.m.

Room 11 - Upper Level - Convention Center

The Making of Cancer: From Cellular Events to Systemic Disease—Breakthrough Discoveries from Cancer Grand Challenges

Chair: Charles Swanton, London, United Kingdom

5:00 p.m.	**Chair Introduction.** Charles Swanton, London, United Kingdom
5:08 p.m.	**Remarks.** Paul S. Mischel, Stanford, CA
5:10 p.m.	**Mutational signatures, normal tissue landscapes, and what they reveal about cancer risk.** Michael R. Stratton, Cambridge, United Kingdom
5:25 p.m.	**How tissue environments and tumor promoters conspire with mutations to drive carcinogenesis.** Allan Balmain, San Francisco, CA
5:40 p.m.	**Tissue-specific cooperativity of epigenetic and oncogenic defects in cancer provides tractable therapeutic opportunities.** Karen M. Cichowski, Boston, MA
5:55 p.m.	**Cachexia and cancer as a whole-body disease.** Eileen P. White, New Brunswick, NJ
6:10 p.m.	**Panel Discussion**
7:00 p.m.	**Networking Reception**

MONDAY, APRIL 20

Awards and Lectures
5:15-6:00 pm

Ballroom 6 A - Upper Level - Convention Center
AACR Award for Outstanding Achievement in Chemistry in Cancer Research

Chair: Lori S. Friedman, San Carlos, CA

Probing the epigenome for therapeutic opportunities. Cheryl H. Arrowsmith, Toronto, ON, Canada

Awards and Lectures
5:30 p.m.-6:15 p.m.

Room 5 - Upper Level - Convention Center
AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research

Chair: Ralph J. DeBerardinis, Dallas, TX

Epigenetic mechanisms of cancer progression. Andrew P. Feinberg, Baltimore, MD

Professional Development Session
5:30 p.m.–7:00 p.m.

Grand Hall A - Manchester Grand Hyatt San Diego
From Hypothesis to Headline: Publishing Your Research

5:30 p.m. **Editor-in-Chief of *Cancer Research.*** Christine A. Iacobuzio-Donahue, New York, NY

6:15 p.m. **Editor-in-Chief of *Clinical Cancer Research.*** Timothy A. Yap, Houston, TX

Town Meetings
6:30 p.m.–8:30 p.m.

Room 28 - Upper Level - Convention Center
From Molecules to Medicine: Driving Breakthroughs in Blood Cancer Treatment—A CICR-HMWG Town Hall

Cochairs: Lori S. Friedman, South San Francisco, CA; Kenneth C. Anderson, Boston, MA

Moderator: Ingo Hartung, Darmstadt, Germany

6:45 p.m. **Title to be announced.** Omar Abdel-Wahab, New York, NY

6:55 p.m. **Title to be announced.** Lynda Groocock, Cambridge, MA

7:05 p.m. **Title to be announced.** Gromek Smolen, Watertown, MA

7:15 p.m. **Panel Discussion**

7:35 p.m. **Networking Reception**

Room 30 - Upper Level - Convention Center
Immune-Driven Cancer Prevention: From Vaccines to Lifestyle Interventions—A CIMM-CPWG Town Hall and Networking Meeting

Cochairs: Catherine J. Wu, Brookline, MA; Marcia R. Cruz Correa, San Juan, PR

6:40 p.m. **Title to be announced.** Nicholas Arpaia, New York, NY

6:47 p.m. **Title to be announced.** Jennifer L. McQuade, Houston, TX

6:54 p.m. **Title to be announced.** Eduardo Vilar-Sanchez, Houston, TX

7:01 p.m. **Title to be announced.** Alison Epstein Ringel, Cambridge, MA

7:08 p.m. **Panel Discussion**

7:35 p.m. **Networking Reception**

TUESDAY, APRIL 21

Plenary Session
8:00 a.m.–10:00 a.m.

Hall H - Ground Level - Convention Center

Early-Onset Cancers

Chair: Andrew T. Chan, Boston, MA

8:00 a.m. **Chair Introduction.** Andrew T. Chan, Boston, MA

8:05 a.m. **Cancer trends in young adults: A birth cohort perspective and public health implications.** Hyuna Sung, Atlanta, GA

8:33 a.m. **Early-onset colorectal cancer: Advancing correlation to causation to prevention.** Andrew T. Chan, Boston, MA

9:01 a.m. **Early-life mutagenesis and the rise of early-onset colorectal cancer.** Ludmil B. Alexandrov, La Jolla, CA

9:29 a.m **PL04-02 Young-onset breast cancer: Lessons learned from postpartum diagnoses.** Pepper Schedin, Portland, OR

9:57 a.m. **Wrap-up and opportunities for the future.** Andrew T. Chan, Boston, MA

Poster Sessions
9:00 a.m.-12:00 p.m.

Halls B-G, Ground Level, San Diego Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

AACR Project GENIE®

Section 1 AACR Project GENIE®: Genomic Characterization

Bioinformatics, Computational Biology, Artificial Intelligence, and Data Science

Section 2 Application of Bioinformatics to Cancer Biology 4

Section 3 Digital Pathology 3

Section 4 Integrative Computational Approaches 2

Section 5 Machine Learning Approaches for Cancer Prediction

Immunology

Section 6 Adaptive Immunity in Cancer

Section 7 CAR T Cell Functional Enhancement

Section 8 Immunomodulatory Agents

Section 9 Monoclonal Antibodies and Antibody-Cytokine Platforms

Section 10 Vaccine Platforms and Target Identification

Section 53 Late-Breaking Research: Immunology 3

Experimental and Molecular Therapeutics

Section 11 Antibody Technologies and Platforms 2

Section 12 Antibody-Drug Conjugates and Linker Engineering 3

Section 13 Drug Combinations, Repurposing, and Differentiation

Section 14 Epigenetic Modulators 1

Section 15 Hematologic Malignancies and Novel Therapeutic Modalities

Section 16 Next-Generation Targeted Therapies Directed Against Tumor Surface Antigens

Section 17 Novel Antitumor Agents 2

Section 18 Proximity-Induced Drug Discovery 1

Section 19 Strategies to Enhance the Therapeutic Index of Radiotherapy

Molecular/Cellular Biology and Genetics

Section 20 Cell Death Regulation and Therapeutic Resistance in Cancer

Section 21 Insights into Genomic Instability

Section 22 Metabolic Alterations in Colorectal and Gastrointestinal Cancers

Section 23 Metabolic Features of Thoracic and Urologic Cancers

Section 24 Oncogenic Transcription Factors and Cancer Programs

Section 54 Late-Breaking Research: Molecular/Cellular Biology and Genetics 2

Tumor Biology

Section 25 Angiogenesis

Section 26 Contextual Determinants of Cancer Stemness and Tumor Aggressiveness

Section 27 Epithelial-to-Mesenchymal Transition

Section 28 In Vitro Models 2: 2D, 3D, Organoids, and Spheroids

Section 29 Microbiome-Tumor-Immune Crosstalk

Section 30 Novel Experimental Platforms and Causal Inference

Section 31 Spatial Niches and Functional Boundaries within the Tumor Microenvironment 1

Section 32 Tumor-Immune Crosstalk

Section 55 Late-Breaking Research: Tumor Biology 2

Endocrinology

Section 33 Signaling Pathways, Metabolism, and Emerging Therapeutic Targets

Population Sciences

Section 35 Diet, Alcohol, and Tobacco, and Other Lifestyle Factors

Section 36 Etiology and Molecular Epidemiology Approaches to Decipher Cancer Disparities

Prevention, Early Detection, and Interception

Section 37 Early Detection and Interception

Chemistry

Section 38 New Ligands and Inhibitors

Section 39 Targeted Protein Degradation and Induced Proximity

Clinical Research

Section 40 Adoptive Cell Therapy 2

Section 41 Biological and Clinical Consequences of Cancer Therapy

Section 42 Biomarkers Predictive of Therapeutic Benefit 5

Section 43 Effects of Ionizing Radiation on Normal Tissues and FLASH Radiation Research

Section 44 Epigenetics, Cytogenetics, and Clinical Molecular Genetics

Section 45 Liquid Biopsies: Circulating Nucleic Acids 4

Section 46 Precision Oncology and Real World Data

Section 47 Prognostic Biomarkers 3

Section 48 Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates 2

Section 49 Retrospective Observational Studies

Clinical Trials

Section 50 Phase I Clinical Trials

Section 51 Phase II and Phase III Clinical Trials in Progress

Professional Development Session
9:00 a.m.–3:00 p.m.

Grand Hall BCD - Manchester Grand Hyatt San Diego

Special Program for High School Students: The Conquest of Cancer and the Next Generation of Cancer Researchers

Chair: Brian M. Rivers, Atlanta, GA

9:00 a.m. **Welcome and opening remarks.** Brian M. Rivers, Atlanta, GA

9:30 a.m. **Remarks from AACR President.** Lillian L. Siu, Toronto, ON, Canada

9:45 a.m. **Introduction of mentors**

10:00 a.m. **Mentor escorted tour of posters and exhibit show**

11:15 a.m. **Understanding cancer.** Jose G. Trevino, Richmond, VA

11:35 a.m. **Personal message from a cancer advocate.** Melinda Bachini, Herriman, Utah

11:45 a.m. **Why cancer research needs you!** Christopher M. Sistrunk, Duarte, CA

12:30 p.m. **Networking lunch and career development panel with undergraduate scholars**

Moderator: Kathleen W. Scotto, New Brunswick, NJ

Panelists: AACR undergraduate scholars

1:30 p.m. **Student poster session**

2:30 p.m. **Presentation of student certificates**

Closing remarks, evaluation and adjournment

Meet and Greet
9:15 a.m.–10:15 a.m.

AACR Publications Booth 3537 - Hall D

Meet the New Editors-in-Chief of *Cancer Immunology Research:* Elizabeth M. Jaffee, MD, FAACR, and Antoni Ribas, MD, PhD, FAACR

NCI-NIH-Selected Session
10:15 a.m.–11:15 a.m.

Room 2 - Upper Level - Convention Center

NCI/NIH Consortia Initiative: Metabolic Dysregulation and Cancer Risk Program—A Transdisciplinary Approach to Obesity-Associated Cancers

Cochairs: Edward Richard Sauter. Rockville, MD; Anil Wali, Rockville, MD; Wanping Xu, Rockville, MD

10:15 a.m. **Overview of the NCI's history of funding research to address the role of obesity in cancer risk.** Edward Richard Sauter. Rockville, MD

10:25 a.m. **Overview of MeDOC.** Marinella Temprosa, Rockville, MD

10:35 a.m. **Panel Discussion**

Panelists: Marinella Temprosa, Rockville, MD; Bing Li, Iowa City, IA; Liza Makowski, Memphis, TN; Mary Playdon, Salt Lake City, UT; Edward L. Giovannucci, Boston, MA

Advances in Organ Site Research
10:15 a.m.–11:40 a.m.

Room 30 - Upper Level - Convention Center

Latest Advances in Translational Research from the 2025 San Antonio Breast Cancer Symposium

Cochairs: Carlos L. Arteaga, Dallas, TX; Charles M. Perou, Chapel Hill, NC

10:15 a.m. **Remarks.** Carlos L. Arteaga, Dallas, TX

10:20 a.m. **Parity and breastfeeding and immune responses in breast cancer.** Sherene Loi, Melbourne, VIC, Australia

10:45 a.m. **When tumor suppressors activate: Rb drives an estrogen receptor target program that challenges its canonical tumor suppressor function.** Shom Goel, Melbourne, VIC, Australia

11:10 a.m. **Leveraging driver and truncal fusion RNAs as therapeutic triggers with a programmable nucleic acid sensing system.** Nolan Priedigkeit, Boston, MA

11:35 a.m. **Closing Remarks.** Charles M. Perou, Chapel Hill, NC

Advances in Diagnostics and Therapeutics
10:15 a.m.–11:45 a.m.

Room 16 - Mezzanine Level - Convention Center

Immune-Genomic Mechanisms and Treatment of Peritoneal Metastases

Chair: Sun Young Rha, Seoul, Republic of Korea

10:15 a.m. **Chair Introduction.** Sun Young Rha, Seoul, Republic of Korea

10:16 a.m. **Multimodal treatment strategies for gastric peritoneal carcinomatosis.** Sun Young Rha, Seoul, Republic of Korea

10:41 a.m. **Molecular heterogeneity in colorectal peritoneal metastases.** Raghav Sundar, New Haven, CT

11:06 a.m. **Mutational signatures and cellular phenotypes in ovarian peritoneal metastases.** Ignacio Vazquez-Garcia, Boston, MA

Ballroom 20 CD - Upper Level - Convention Center

New Advances in Bispecific Antibody Development

Chair: William R. Sellers, Cambridge, MA

10:15 a.m. **Chair Introduction.** William R. Sellers, Cambridge, MA

10:16 a.m. **The discovery of biparatopic antibodies and ADCs targeting FGFR2.** William R. Sellers, Cambridge, MA

10:41 a.m. **Unlocking novel biologies with bi- and trispecific antibodies: The importance of antibody format.** Nina E. Weisser, Vancouver, BC, Canada

11:06 a.m. **CD3 and CD28 T cell engagers for solid tumors.** John Desjarlais, Pasadena, CA

Room 31 - Upper Level - Convention Center

Synthetic Lethality in Oncology: Progress Made, Pitfalls Encountered, and the Path Forward

Chair: Timothy A. Yap, Houston, TX

10:15 a.m. **Chair Introduction.** Timothy A. Yap, Houston, TX

10:20 a.m. **Exploiting synthetic lethality to generate new cancer therapies.** Mark J. O'Connor, Cambridge, United Kingdom

10:40 a.m. **Targeting synthetic lethal paralogs in the clinic: Progress, pitfalls and the promise.** Timothy A. Yap, Houston, TX

11:00 a.m. **Leveraging paralog relationships for targeting chromatin modulators in cancer.** Steven F. Bellon, Cambridge, MA

Advances in Early Detection and Interception
10:15 a.m.–11:45 a.m.

Ballroom 6 A - Upper Level - Convention Center

Cancer Detection and Interception Across Tumor Types: Addressing Modifiable Risk Factors for Early Action

Chair: Adriana Albini, Milan, Italy

10:15 a.m. **Chair Introduction.** Adriana Albini, Milan, Italy

10:20 a.m. **Targeting precancerous oncogenic drivers: A promising strategy for cancer interception.** Margie Lee Clapper, Philadelphia, PA

10:45 a.m. **Building precision cancer interception: A transversal crosstalk from basic research to social sciences.** Suzette Delaloge, Villejuif, France

11:10 a.m. **From early detection to multicancer testing: Shifting cancer care toward proactive prevention and interception.** Adriana Albini, Milan, Italy

Advances in Organ Site Research
10:15 a.m.–11:45 a.m.

Ballroom 6 B - Upper Level - Convention Center

Dharma Master Jiantai Advances in Lung Cancer Research Session: Small Cell Lung Cancers (SCLC) and Neuroendocrine Cancers (NECs)

Chair: Lauren Averett Byers, Houston, TX

10:15 a.m. **Chair Introduction.** Lauren Averett Byers, Houston, TX

10:20 a.m. **Regulation and therapeutic vulnerabilities of lineage transcription factor programs in small cell lung cancer.** Matthew Gilbert Oser, Boston, MA

10:40 a.m. **On the verge of a watershed for small cell lung cancer and neuroendocrine malignancies.** Lauren Averett Byers, Houston, TX

11:00 a.m. **Microenvironmental determinants of SCLC progression: A role for the nervous system in tumor initiation and growth.** Humsa Venkatesh, Boston, MA

11:20 a.m. **Importance of advocacy foundations to the research process.** Ann Fish-Steagall, Chicago, IL

Advances in Population Sciences
10:15 a.m.–11:45 a.m.

Room 33 - Upper Level - Convention Center

Translating Epidemiology to the Clinic: Aspirin for the Prevention and Treatment of Colorectal Cancer—Dedicated to the Memory of Thomas W. Kensler

Chair: Omer H. Yilmaz, Cambridge, MA

10:15 a.m. **Chair Introduction.** Omer H. Yilmaz, Cambridge, MA

10:20 a.m. **Dietary control of stem cells in physiology and disease.** Omer H. Yilmaz, Cambridge, MA

10:45 a.m. **Platelet activation, aspirin and cancer.** Ruth Langley, London, United Kingdom

11:10 a.m. **Targeting cyclooxygenase for prevention and treatment of colorectal cancer.** Raymond N. DuBois, Charleston, SC

Advances in Prevention Research
10:15 a.m.–11:45 a.m.

Room 5 - Upper Level - Convention Center

HPV Vaccination and Self-Sampling for Cervical Cancer Prevention and Early Detection Globally and in Underserved Settings

Chair: Carmen E. Guerra, Philadelphia, PA

10:15 a.m. **Chair Introduction.** Carmen E. Guerra, Philadelphia, PA

10:20 a.m. **Single-dose HPV Vaccination: A shot in the arm for cancer prevention.** Aimée R. Kreimer, Bethesda, MD

10:45 a.m. **Advancing cervical cancer prevention through HPV self-sampling: Lessons from the NCI SHIP trial.** Carmen E. Guerra, Philadelphia, PA

11:10 a.m. **HPV self-sampling in safety net and low resource settings.** Jane R. Montealegre, Houston, TX

Advances in Technologies
10:15 a.m.–11:45 a.m.

Ballroom 20 AB - Upper Level - Convention Center

Agentic AI as the Cancer Researcher: Autonomous Discovery in Oncology

Chair: Marinka Zitnik, Cambridge, MA

10:15 a.m. **Chair Introduction.** Marinka Zitnik, Cambridge, MA

10:16 a.m. **Agentic AI for clinical development in oncology.** Danielle S. Bitterman, Boston, MA

10:41 a.m. **AI agents in clinical tissue medicine and research.** Sebastian Foersch, Mainz, Germany

11:06 a.m. **Empowering Cancer Research with AI Scientists.** Marinka Zitnik, Cambridge, MA

Major Symposia
10:15 a.m.–11:45 a.m.

Ballroom 6 DE - Upper Level - Convention Center

Chromatin, Epigenetics, and Cancer: Dedicated to the Memory of James D. Watson

Chair: Charles WM Roberts, Memphis, TN

10:15 a.m. **Chair Introduction.** Charles WM Roberts, Memphis, TN

10:20 a.m. **Chromatin-associated condensates: A new layer of gene dysregulation in cancer.** Liling Wan, Philadelphia, PA

10:45 a.m. **Targeting histone-modifying complexes in cancer.** Scott A. Armstrong, Boston, MA

11:10 a.m. **Chromatin and cancer: From mechanisms to emerging therapies.** Charles WM Roberts, Memphis, TN

Ballroom 6 CF - Upper Level - Convention Center

Harnessing the Power of the Immune System: Turning Cold Tumors Hot

Chair: Thomas Frank Gajewski, Chicago, IL

10:15 a.m. **Chair Introduction.** Thomas Frank Gajewski, Chicago, IL

10:20 a.m. **Novel regulators of suppressive myeloid cells in the tumor microenvironment.** Thomas Frank Gajewski, Chicago, IL

10:45 a.m. **SY12-02 Tumor-reactive heterotypic T cell clusters from clinical samples to improve immunotherapy.** Daniel S. Peeper, Amsterdam, Netherlands

11:10 a.m. **Context dependence of myeloid-mediated immunosuppression.** Lawrence Fong, Seattle, WA

Room 15 - Mezzanine Level - Convention Center

Minorities in Cancer Research Scientific Symposium: Ancestry-Informed Precision Oncology—Integrating Genomic Diversity into Cancer Prevention and Treatment

Cochairs: Melissa B. Davis, Atlanta, GA; Electron Kebebew, Stanford, CA

10:15 a.m. **Welcome and opening remarks.** Melissa B. Davis, Atlanta, GA

10:20 a.m. **SY38-01 Gapless but Not Global: Ancestry-Enriched Functional Sequence Still Missing from Human Reference Genomes.** Nyasha Chambwe, Manhasset, NY

10:40 a.m. **SY38-02 Epigenetics, ancestry, and cancer disparities: When nature might be nurture.** I. King Jordan, Atlanta, GA

11:00 a.m. **Translating genomic equity: Building infrastructure for global precision oncology.** Clayton C. Yates, Baltimore, MD

11:40 a.m. **Closing remarks.** Electron Kebebew, Stanford, CA

Room 14 - Mezzanine Level - Convention Center

Mitochondrial Transfer Networks in Cancer Progression

Chair: Yosuke Togashi, Okayama, Japan

10:15 a.m. **Chair Introduction.** Yosuke Togashi, Okayama, Japan

10:20 a.m. **SY23-01 Lineage tracing of the intercellular transfer of mitochondria during cancer progression.** Simon Grelet, Mobile, AL

10:45 a.m. **SY23-02 Tumor-derived mitochondrial transfer dictates immune cell fate and therapeutic vulnerability.** Yosuke Togashi, Okayama, Japan

11:10 a.m. **Powering T-Cell therapy through mitochondrial transfer.** Luca Gattinoni, Regensburg, Germany

Room 11 - Upper Level - Convention Center

Pediatric Brain Tumors: Biology to Therapy

Chair: Richard J. Gilbertson, Cambridge, United Kingdom

10:15 a.m. **Chair Introduction.** Richard J. Gilbertson, Cambridge, United Kingdom

10:20 a.m. **Form follows function: Multi-dimensional profiling of tumor cell heterogeneity in supratentorial ependymomas.** Mariella G. Filbin, Boston, MA

10:45 a.m. **Itaconate is an oncometabolite in ZFTA-RELA ependymomas.** Sriram Venneti, Ann Arbor, MI

11:10 a.m. **SY30-03 Reversing brain tumor immunotolerance: A new therapeutic approach for childhood brain tumors.** Richard J. Gilbertson, Cambridge, United Kingdom

Room 28 - Upper Level - Convention Center

Structural Insights to Cancer Biology and Therapy

Chair: Charalampos Babis Kalodimos, Memphis, TN

10:15 a.m. **Chair Introduction.** Charalampos Babis Kalodimos, Memphis, TN

10:20 a.m. **Advances in the systematic discovery of molecular glue degraders.** Eric S. Fischer, Boston, MA

10:45 a.m. **Mechanisms of PI3Kα activation by RTKs, Ras, and cancer-associated mutations.** Natalia Z. Jura, San Francisco, CA

11:10 a.m. **Conformational landscapes of protein kinases and their therapeutic exploitation.** Charalampos Babis Kalodimos, Memphis, TN

Room 29 - Upper Level - Convention Center

Tumor-secreted Factors: The Next Hallmark of Cancer?

Chair: Ashani T. Weeraratna, Baltimore, MD

10:15 a.m. **Chair Introduction.** Ashani T. Weeraratna, Baltimore, MD

10:20 a.m. **Identifying selective dependencies of liver metastatic pancreatic cancer cells.** Rushika M. Perera, San Francisco, CA

10:45 a.m. **Microenvironmental regulators of myeloid leukemia.** Jeevisha Bajaj, Rochester, NY

11:10 a.m. **A Complex TIME: The impact of age on tumor progression.** Ashani T. Weeraratna, Baltimore, MD

TUESDAY, APRIL 21

Clinical Trials Plenary Session
10:15 a.m.–12:15 p.m.

Hall H - Ground Level - Convention Center

Advances in Immunotherapy

Cochairs: Ryan J. Sullivan, Boston, MA; Evanthia T. Roussos Torres, Los Angeles, CA

10:15 a.m. **CT230 STRIDE regimen of tremelimumab and durvalumab as non-operative management strategy of microsatellite instability-high (MSI-H) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): Final results of the cohort 2 of INFINITY study by GONO GI.** Alberto Giovanni Leone, Milano, Italy

10:30 a.m. **Discussant.** Yelena Yuriy Janjigian, New York, NY

10:45 a.m. **CT231 Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC.** Fabrice Barlesi, Villejuif, France

11:00 a.m. **Discussant.** Tina Cascone, Houston, TX

11:15 a.m. **CT232 Preliminary results of a phase 1, first-in-human, dose-escalation study of the anti-CCR8 antibody denikitug in participants with advanced solid tumors.** Bruno Bockorny, Boston, MA

11:30 a.m. **Discussant.** Ignacio Garrido-Laguna, Tampa, FL

11:45 a.m. **CT233 Multi-modal multi-omic analyses reveal mechanisms of immunotherapy resistance in non-small cell lung cancer (NSCLC).** Archana Balan, Baltimore, MD

12:00 p.m. **Discussant.** Michele Maio, Siena, Italy

Awards and Lectures
12:00 p.m.–12:30 p.m.

Room 17 - Mezzanine Level - Convention Center

AACR Gertrude B. Elion Cancer Research Award Lecture

Chair: Marica Speranza, Philadelphia, PA

12:00 p.m. **Chair Introduction.** Marica Speranza, Philadelphia, PA

12:05 p.m. **Harness insights from chromatin priming for early interception of basal-like breast cancer.** Carman Li, Philadelphia, PA

Meet and Greet
12:30 p.m.–1:30 p.m.

AACR Publications Booth 3537 - Hall D

Meet the Editor-in-Chief of *Cancer Epidemiology, Biomarkers & Prevention:* Elizabeth A. Platz, ScD, MPH

NCI-NIH-Selected Session
12:30 p.m.–1:30 p.m.

Room 2 - Upper Level - Convention Center

FLAIMME: A National Federated Learning Consortium Advancing Privacy-Preserving Oncology AI Through Foundation Model Adaptation

Moderator: Juli Klemm, Bethesda, MD

12:31 p.m. **Moderator and FIAIMME Overview.** Juli Klemm, Bethesda, MD

12:40 p.m. **Federated foundation model adaptation: Fine-tuning MedGemma across cancer centers.** Umit Topaloglu, Bethesda, MD

12:50 p.m. **Governance, standardization, and onboarding: scaling FLAIMME membership.** Shannon L. Silkensen, Bethesda, MD

1:00 p.m. **Traditional model approaches on FLAIMME: Lessons from glioblastoma and beyond.** Rakesh Khanna, Bethesda, MD

Advances in Diagnostics and Therapeutics
12:30 p.m.–2:00 p.m.

Room 31 - Upper Level - Convention Center
Claudin-Targeted Therapies: From Tight Junction Biology to Next-Generation Precision Oncology

Chair: Kohei Shitara, Chiba, Japan

12:30 p.m. **Chair Introduction.** Kohei Shitara, Chiba, Japan

12:35 p.m. **Why CLDN? Tight junction biology and tumor-selective vulnerability in gastrointestinal and other solid tumors.** Kohei Shitara, Chiba, Japan

1:00 p.m. **Beyond monoclonal antibodies: Translational rationale for CLDN targeted ADCs and bispecific therapies.** Samuel J. Klempner, Boston, MA

1:25 p.m. **Cellular therapies targeting CLDNs: Lessons from CAR-T development and next-generation strategies.** Lin Shen, Boston, MA, China

Ballroom 20 AB - Upper Level - Convention Center
Resistance to Antibody Drug Conjugates

Chair: Sarat Chandarlapaty, New York, NY

12:30 p.m. **Chair Introduction.** Sarat Chandarlapaty, New York, NY

12:35 p.m. **Mechanisms of ADC resistance informing novel combination therapy strategies.** Leif W. Ellisen, Boston, MA

1:00 p.m. **Tumor cell intrinsic and extrinsic mechanisms of ADC resistance.** Jonathan Chou, San Francisco, CA

1:25 p.m. **Resistance to anti-HER2 ADCs.** Sarat Chandarlapaty, New York, NY

Advances in Hematologic Malignancies
12:30 p.m.–2:00 p.m.

Ballroom 6 DE - Upper Level - Convention Center
Dissecting Hematologic Malignancies at Single-Cell Resolution: Cutting-Edge Advances in Spatial Omics

Chair: Mamiko Sakata-Yanagimoto, Tsukuba, Japan

12:30 p.m. **Chair Introduction.** Mamiko Sakata-Yanagimoto, Tsukuba, Japan

12:35 p.m. **Spatially decoding human lymphoma transformers.** Rong Fan, New Haven, CT

1:20 p.m. **Spatial biology concepts in B-cell lymphomas.** Eric D. Hsi, Rochester, MN

1:00 p.m. **Spatial multi-omics dissects immune and stromal cell heterogeneity in T-cell lymphoma.** Mamiko Sakata-Yanagimoto, Tsukuba, Japan

Advances in Organ Site Research
12:30 p.m.–2:00 p.m.

Room 33 - Upper Level - Convention Center
Advances in Melanoma Research and Treatment

Chair: Antoni Ribas, Los Angeles, CA

12:30 p.m. **Chair Introduction.** Antoni Ribas, Los Angeles, CA

12:35 p.m. **Advances in basic science melanoma research.** Eva M. Hernando-Monge, New York, NY

1:00 p.m. **Advances in clinical science melanoma research.** Georgina V. Long, Sydney, NSW, Australia

1:25 p.m. **Advances in how to target resistant melanoma.** Antoni Ribas, Los Angeles, CA

Room 11 - Upper Level - Convention Center
Advancing Precision Approaches to Head and Neck Cancers

Chair: Barbara A. Burtness, New Haven, CT

12:30 p.m. **Chair Introduction.** Barbara Burtness, New Haven, CT

12:35 p.m. **Novel therapies for HPV-independent head and neck cancer.** Barbara A. Burtness, New Haven, CT

1:00 p.m. **Subtypes of HPV-initiated head and neck cancer - implications for deescalation and precision therapy.** Wendell G. Yarbrough, Chapel Hill, NC

1:25 p.m. **Minimal residual disease and treatment optimization in head and neck cancer.** Ari Joseph Rosenberg, Chicago, IL

Ballroom 6 A - Upper Level - Convention Center

Turning the Tide in the Fight Against Pancreatic Cancer

Chair: Anirban Maitra, New York, NY

12:30 p.m. **Chair Introduction.** Anirban Maitra, New York, NY

12:32 p.m. **Recent advances in treatment of pancreatic cancer.** Shubham Pant, Houston, TX

12:52 p.m. **NG08 Cancer-restricted cryptic antigens: Novel targets for next-generation T cell-based therapies.** William Freed-Pastor, Boston, MA

1:07 p.m. **Insights into CA19-9 in pancreatic cancer and in pancreatitis: Mechanisms and models.** Dannielle D. Engle, La Jolla, CA

1:27 p.m. **Early detection and interception of pancreatic cancer.** Anirban Maitra, New York, NY

Advances in Population Sciences
12:30 p.m.–2:00 p.m.

Room 30 - Upper Level - Convention Center

Multi-kingdom Microbial Determinants of Cancer

Chair: Long H. Nguyen, Boston, MA

12:30 p.m. **Chair Introduction.** Long H. Nguyen, Boston,

12:35 p.m. **Gut microeukaryotes, endogenous viruses, and cancer.** Long H. Nguyen, Boston, MA

1:00 p.m. **Population scale sequencing resolves the determinants and consequences of persistence Epstein Barr Virus infection.** Caleb A. Lareau, New York, NY

1:25 p.m. **The cancer mycobiome: truth, myth, and current data.** Iliyan Iliev, New York, NY

Advances in Prevention Research
12:30 p.m.–2:00 p.m.

Room 5 - Upper Level - Convention Center

Cancer Predisposition Syndromes

Chair: Jennifer Rubin Grandis, San Francisco, CA

12:30 p.m. **Chair Introduction.** Jennifer Rubin Grandis, San Francisco, CA

12:35 p.m. **Cancer in telomere biology disorders.** Sharon A. Savage, Bethesda, MD

1:00 p.m. **Opportunities and challenges in cancer Screening and early detection in individuals with Lynch syndrome.** Fay Kastrinos, New York, NY

1:25 p.m. **Solid tumors in Fanconi anemia.** Jennifer Rubin Grandis, San Francisco, CA

Advances in Technologies
12:30 p.m.–2:00 p.m.

Ballroom 20 CD - Upper Level - Convention Center

AI-Based Tissue Biomarkers in Cancer: Multimodal AI Across Scales

Chair: Benjamin Haibe-Kains, Toronto, ON , Canada

12:30 p.m. **Chair Introduction.** Benjamin Haibe-Kains, Toronto, ON , Canada

12:35 p.m. **Decoding patient-derived models drug response with multimodal AI: Joint modelling of genomes, transcriptomes, chromatin accessibility and pathology across cancer types.** Benjamin Haibe-Kains, Toronto, ON , Canada

12:50 p.m. **Do we really need everything everywhere all at once? Spatial, AI, and everything in between.** Sizun Jiang, Boston, MA

1:15 p.m. **Beyond prediction: Generative and autonomous AI for cross-scale cancer.** Christina Curtis, Stanford, CA

Major Symposia
12:30 p.m.–2:00 p.m.

Room 15 - Mezzanine Level - Convention Center

Beyond Genetics: Macroenvironmental and Microenvironmental Determinants of Cancer Risk, Disease Progression, and Treatment Response

Chair: Khadijah A. Mitchell, Philadelphia, PA

12:30 p.m. **Chair Introduction.** Khadijah A. Mitchell, Philadelphia, PA

12:35 p.m. **From DNA repair to disparities: Rethinking lung cancer susceptibility through environmental risk factors.** Khadijah A. Mitchell, Philadelphia, PA

12:55 p.m. **Environmental risk factors for prostate cancer pathology in men of African ancestry.** Maria Argos, Boston, MA

1:15 p.m. **Spatially organized immune hubs in human tumors.** Karin Pelka, San Francisco, CA

Room 1 - Upper Level - Convention Center

Regulatory Science and Policy Session

Code Meets Cure: Navigating the Regulatory Landscape of AI in Oncology Drug Development

Moderator: Jeevan Puthiamadathil, Silver Spring, MD

12:30 p.m. **Title to be announced.** Jeff Leek, Seattle, WA

12:41 p.m. **Title to be announced.** Jorge S. Reis-Filho, Gaithersburg, MD

12:51 p.m. **Title to be announced.** Jeevan Puthiamadathil, Silver Spring, MD

Panelists: Carlos Sandi, Monrovia, CA; Jakob Nikolas Kather, Dresden, Germany; Jeffrey Leek, Seattle, WA

Ballroom 6 B - Upper Level - Convention Center

Dharma Master Jiantai Symposium in Targeted Therapy: Immunotherapy and DNA Repair

Chair: Alberto Bardelli, Turin, Italy

12:30 p.m. **Chair Introduction.** Alberto Bardelli, Turin, Italy

12:35 p.m. **Revisiting the neoantigen approach to cancer immunotherapy.** Yardena Samuels, Rehovot, Israel

1:00 p.m. **Inhibition of DNA mismatch repair for therapeutic purposes.** Alberto Bardelli, Turin, Italy

1:25 p.m. **Chemical engineering of mismatch repair deficiency to induce tumor immunogenicity.** Luis A. Diaz, New York, NY

Ballroom 6 CF - Upper Level - Convention Center

Immune and Stromal Reprogramming Across the Tumor Micro- and Macroenvironment

Chair: Neta Erez, Tel Aviv, Israel

12:30 p.m. **Chair Introduction.** Neta Erez, Tel Aviv, Israel

12:35 p.m. **SY41-01 Immune checkpoint blockade induces extracellular remodeling through cytotoxic T cells expressing BMP1.** Yuval Shaked, Haifa, Israel

1:00 p.m. **The role of aging in immune mediated reactivation from metastatic dormancy.** Mitchell Fane, Philadelphia, PA

1:25 p.m. **Stromal and immune plasticity shape the metastatic microenvironment.** Neta Erez, Tel Aviv, Israel

Room 14 - Mezzanine Level - Convention Center

Inflammaging and Cancer: Mechanistic Insights and Therapeutic Opportunities

Chair: Olga A. Anczukow, Farmington, CT

12:30 p.m. **Chair Introduction.** Olga A. Anczukow, Farmington, CT

12:33 p.m. **The role of aged B cells, biological sex and senescence in the pathogenesis of B-cell lymphomas.** Ari M. Melnick, New York, NY

12:53 p.m. **Overcoming age-related immune dysfunction and chemoresistance in breast cancer.** Sandra S. McAllister, Boston, MA

1:13 p.m. **NG09 Overcoming aging-driven barriers to effective immunotherapy in pancreatic cancer.** Daniel J. Zabransky, Baltimore, MD

1:33 p.m. **SY02-03 Decoding RNA splicing: A molecular link between aging, inflammation and cancer.** Olga A. Anczukow, Farmington, CT

Room 28 - Upper Level - Convention Center

Off-the-Shelf Cell Therapies for Cancer and Beyond

Chair: Franco Locatelli, Milan, Italy

12:30 p.m. **Chair Introduction.** Franco Locatelli, Milan, Italy

12:35 p.m. **Allogeneic CAR cells: Are they the new black?** Franco Locatelli, Milan, Italy

1:00 p.m. **Off-the-shelf NK cell therapies from biology to the clinic.** Katayoun Rezvani, Houston, TX

1:25 p.m. **SY13-03 Allogeneic CAR T: Science at scale.** David D. Chang, South San Francisco, CA

Room 29 - Upper Level - Convention Center

RNA Biology in Cancer: Dedicated to the Memory of David Baltimore

Chair: Paul Boutz, Rochester, NY

12:30 p.m. **Chair Introduction.** Paul Boutz, Rochester

12:35 p.m. **SY25-01 NEAT1 long-noncoding RNA controls nuclear phase condensates that suppress ferroptosis in cancer.** Paul L. Boutz, Rochester, NY

1:00 p.m. **SY25-02 RNA as a cancer driver: Recurrent ZC3H18 mutations stabilize oncogenic endogenous retroviral transcripts.** Megan L. Insco, Boston, MA

1:25 p.m. **RNA processing regulation of anti-tumor immune responses.** Omar Abdel-Wahab, New York, NY

Poster Sessions
2:00 p.m.-5:00 p.m.

Halls B-G, Ground Level, San Diego Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

Bioinformatics, Computational Biology, Artificial Intelligence, and Data Science

Section 1 Application of Bioinformatics to Cancer Biology 5

Section 2 Deep Learning in Cancer

Section 3 Machine Learning for Image Analysis

Section 4 New Software Tools for Data Analysis

Immunology

Section 6 Bi- and Tri-Specific Antibody Therapies

Section 7 Oncogenic Pathways and Cancer Immunity

Section 8 T Cell Engagers 2 / Antibody-Drug Conjugates 1

Section 9 TCR and Autologous T Cell Therapies

Experimental and Molecular Therapeutics

Section 10 Antibody-Drug Conjugates and Linker Engineering 4

Section 11 Cell Death Pathways and Treatment

Section 12 Mechanisms of Anticancer Drug Action

Section 13 Molecular Targets 2

Section 14 Multi-Axis Antineoplastic Agents

Section 15 Proximity-Induced Drug Discovery 2

Section 16 Radiopharmacuetical Platforms for Theranostic Precision Oncology

Section 17 Tumor Microenvironment, Multispecifics, and Immunomodulation

Section 18 Tyrosine Kinase, Phosphatase, and Other Inhibitors

Section 53 Late-Breaking Research: Experimental and Molecular Therapeutics 3

Molecular/Cellular Biology and Genetics

Section 20 Functional Roles of Noncoding RNAs in Cancer Progression, Metabolism, and Therapy Response

Section 21 Genetic and Transcriptomic Dissection of Cancer Evolution

Section 22 Mechanisms and Dynamics of Gene Expression

Section 23 RAS/MAPK Signaling, KRAS Targeting, and Adaptive Resistance

Section 24 Senescence and Cell Stress

Tumor Biology

Section 25 Fibroblasts as Architects of the Tumor Microenvironment

Section 26 In Vivo Models 2: Genetically Engineered Mouse Models, PDXs, Syngeneic Models

Section 27 Mechanisms of Metastasis

Section 28 Metastasis and Organ-Specific Microenvironmental Evolution

Section 29 Metastatic Niches and Microenvironment

Section 30 Pediatric Cancer Models

Section 31 Spatial Niches and Functional Boundaries within the Tumor Microenvironment 2

Section 32 Tumor-Neuron Interactions and Neuro-Regulation of Cancer

Population Sciences

Section 33 Environmental and Occupational Risk Factors, Infection, and Aging

Section 34 Genetic Epidemiology 2: Pathway Analysis, Sequencing, Functional Genetics / Family and Hereditary Studies

Section 55 Late-Breaking Research: Population Sciences

Prevention, Early Detection, and Interception

Section 35 Advances in Survivorship

Section 36 Genomics, Proteomics, Biomarkers, and Risk Stratification

Science and Health Policy

Section 37 Science and Health Policy 2

Chemistry

Section 38 Drug Delivery

Section 39 Screening and Technology Advances for Probe and Drug Discovery

Clinical Research

Section 40 Biostatistics in Clinical Trials / Surgical Oncology

Section 41 Clinical Correlates of Immunotherapy

Section 42 Combination Targeted Therapy

Section 43 Diagnostic Biomarkers 2

Section 44 Immune Checkpoint Blockade

Section 45 Inflammation, Immunity, and Cancer

Section 46 Radiation and Photodynamic Therapy Response Modifiers

Section 47 Real World Data to Provide Real World Evidence

Section 48 Spatial Proteomics and Transcriptomics 3

Section 49 Vaccines and Other Immunomodulatory Agents

Section 52 Late-Breaking Research: Clinical Research 3

Clinical Trials

Section 50 Phase II Clinical Trials

Section 51 Phase I and Phase II Clinical Trials in Progress

NCI-NIH-Selected Session
2:30 p.m.–3:30 p.m.

Room 2 - Upper Level - Convention Center

NCI/NIH Opportunities in Funding: NCI-Cancer Diagnosis Program Initiatives and Biospecimen Resources for Investigators

Moderator: Aniruddha Ganguly, Rockville, MD

2:31 p.m. **Funding opportunities for technology development and biospecimen resources.** Aniruddha Ganguly, Rockville, MD

2:46 p.m. **U01 biospecimen science funding opportunity and The Cancer Moonshot Biobank.** Lokesh Agrawal, Rockville, MD

3:01 p.m. **Assay validation of high-quality markers for clinical studies in cancer.** Ana I. Robles, Rockville, MD

Clinical Trials Minisymposium
2:30 p.m.–4:30 p.m.

Hall H - Ground Level - Convention Center

Advances in Precision Oncology

Cochairs: Jia (Jenny) Liu, Sydney, NSW, Australia; Vivek Subbiah, Stanford, CA

2:30 p.m. **Chair Introduction.** Vivek Subbiah, Stanford, CA

2:34 p.m. **CT299 Dirozalkib versus crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): Results from the multicenter, randomized, open-label phase 3 trial.** Haifeng Liu, Changchun, China

2:48 p.m. **CT300 Taletrectinib in tyrosine kinase inhibitor (TKI)-naïve patients with ROS1+ non-small cell lung cancer (NSCLC): Updated data from TRUST-I and TRUST-II.** Lyudmila Bazhenova, San Diego, CA

3:02 p.m. **CT301 SHR-A1811 ± adebrelimab as first-line (1L) treatment for advanced HER2-mutant NSCLC: A randomized phase 2 cohort from a phase 1b/2 study.** Shun Lu, Shanghai, China

3:16 p.m. **CT302 The safety, tolerability, and efficacy of HS-10504 in patients with EGFR mutation-positive locally advanced or metastatic NSCLC: Initial results from a first-in-human phase 1 study.** Zhanhong Xie, Guangzhou, China

3:30 p.m. **CT303 Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: Results from a phase 1/2 study.** Kanwal Pratap Raghav, Houston, TX

3:44 p.m. **CT304 Narmafotinib (a.m.P945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial) a Phase 1b 2a study-Interim analysis.** Terrie-Anne Cock, Melbourne, VIC, Australia

3:58 p.m. **CT305 Fractionated (dose dense) and multiple dose PSMA-targeted alpha emitter 225Ac-J591 for advanced prostate cancer: Final primary and secondary outcomes.** Valentina Marulanda Corzo, New York, NY

4:12 p.m. **CT306 Phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors: Part 1 dose-escalation results.** Patricia LoRusso, New Haven, CT

4:26 p.m. **Closing remarks.** Jia (Jenny) Liu, Sydney, NSW, Australia

Late-Breaking Minisymposium
2:30 p.m.–4:30 p.m.

Room 5 - Upper Level - Convention Center

Minisymposium: Late-Breaking Research

Cochairs: Barbara Pistilli, Villejuif, France; Colin D. Weekes, Boston, MA

2:30 p.m. **Chair Introduction.** Barbara Pistilli, Villejuif, France

2:35 p.m. **LB401 The genomic landscape of likely human precancers.** Christopher D. Steele, San Diego, CA

2:50 p.m. **LB402 Homologous recombination deficiency sensitizes breast cancer to therapeutic targeting of the ectonucleotidase ENPP1.** Brian Ruffell, Tampa, FL

3:05 p.m. **LB403 Mechanisms of tumor dormancy through immune niche formation, and its impact on immune therapeutic relapse.** Abdul Ahad, Bethesda, MD

3:20 p.m. **LB404 A ligandable PNT-domain establishes ERG as a directly targetable oncogenic driver in prostate cancer.** George Wang, Ann Arbor, MI

3:35 p.m. **LB405 Novel brain-penetrant BRAF paradox breaker HSK42360 demonstrates promising antitumor activity in patients with BRAF-mutant glioma.** Shidong Gao, Chengdu, China

3:50 p.m. **LB406 Active RAS inhibition intercepts pancreas cancer in mice.** Minh T. Than, Philadelphia, PA

4:05 p.m. **LB407 Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC).** Brian M. Wolpin, Boston, MA

4:20 p.m. **Closing remarks.** Colin D. Weekes, Boston, MA

Minisymposia
2:30 p.m.–4:30 p.m.

Ballroom 20 CD - Upper Level - Convention Center
Bioinformatics, Computational Biology, Artificial Intelligence, and Data Science
Machine Learning Approaches for Cancer Diagnosis and Treatment Prediction

Cochairs: Alexander R.A. Anderson, Tampa, FL; Noam Auslander, Philadelphia, PA

2:30 p.m. **Chair Introduction.** Alexander R.A. Anderson, Tampa, FL

2:35 p.m **6722 CUPAI-2: A collaborative multi-agent large language model framework for diagnosis of cancer of unknown primary.** Kai Wang, Boston, MA

2:50 p.m. **6723 Multisite analysis of a deep learning model for prediction of palbociclib response in patients with ER+ HER2- advanced breast cancer.** Akshat Singhal, La Jolla, CA

3:05 p.m. **6724 OncoTwin: A multimodal digital twin framework for predicting treatment response and guiding trial design in ALK-rearranged non-small-cell lung cancer.** Hui Xu, Houston, TX

3:20 p.m **6725 AIderived H&E biomarkers predict differential survival under immunotherapy vs chemotherapy in phase-3 metastatic NSCLC study NEPTUNE.** Chintan Parmar, Waltham, MA

3:35 p.m. **6726 A translational deep learning platform predicts metabolic pathway activity from routine H&E slides to enable patient stratification.** Pahini Pandya, Cambridge, United Kingdom

3:50 p.m. **6727 Enhancing lung cancer risk prediction with longitudinal fusion of LDCT data.** Hanieh Ajami, Tampa, FL

4:05 p.m. **6728 Predicting gastric cancer response to anti-PD-1 first-line treatment based on multi-modal data: A multi-center study.** Jingyuan Wang, Shanghai, China

4:20 p.m. **Closing remarks.** Noam Auslander, Philadelphia, PA

Room 33 - Upper Level - Convention Center
Chemistry
Targeted Therapies

Cochairs: Ryan Potts, Thousand Oaks, CA

2:30 p.m. **Chair Introduction.** Claudia A. Benavente, Irvine, CA

2:35 p.m. **6731 CQ-0736, a new polysaccharide-based therapeutic modality, targets pan-KRAS tumors with robust antitumor activity via macropinocytosis.** Jinghua Hu, Jupiter, FL

2:50 p.m. **6732 Potent, orally bioavailable small molecules that inhibit c-Myc translation and suppress tumor growth in vivo.** Michelle Kriner, Seattle, WA

3:05 p.m. **6733 Discovery and characterization of CBL-B intramolecular glue inhibitors that increase T cell activation and suppress tumor growth.** Frederick Cohen, Brisbane, CA

3:20 p.m. **6734 Discovery and optimization of NEO-811, a first-in-class molecular glue degrader of ARNT, utilizing structure-based drug design.** Jennifer Griffin, San Diego, CA

3:35 p.m. **6735 DNA-templated, spatially controlled proteolysis targeting chimeras enable coordinated degradation of the Cyclin D1-CDK4/6 complex.** Rong Zheng, Tempe, AZ

3:50 p.m. **6736 Discovery and characterization of BH-501284: A non-covalent, pan-KRAS inhibitor for treatment of diverse KRAS-mutant tumors.** Jean Cui, San Diego, CA

4:05 p.m. **6737 Selective degradation of pathologic multimers via a novel TRIM21-engaging molecular glue and PROTAC platform.** Aijuan Yu, Beijing, China

4:20 p.m. **Closing remarks.** William J. Gibson, Boston, MA

Room 28 - Upper Level - Convention Center
Clinical Research
Immunotherapy: Mechanisms and Responses

Cochairs: May Daher, Houston, TX; Robert Manguso, Boston, MA

2:30 p.m. **Chair Introduction.** Robert Manguso, Boston, MA

2:35 p.m. **6740 Selective immune activation of antigen activated T cells with STK-012, an a/b IL-2 receptor biased partial agonist, with pembrolizumab and** chemotherapy in 1L PD-L1 negative non-squamous NSCLC. Salman Punekar, New York, NY

2:50 p.m. **6741 Tertiary lymphoid structure (TLS)-associated immune circuits define response to durvalumab, trastuzumab, and pertuzumab (DTP) in HER2-enriched early breast cancer.** Mailin Li, Houston, TX

3:05 p.m. **6742 Nonsense-mediated mRNA decay inhibition augments in vitro, in vivo, and ex vivo anti-tumor immunity.** Hongchang Fu, London, United Kingdom

3:20 p.m. **6743 Peripheral immune profiling from the DIET trial - A randomized double blinded dietary intervention study in melanoma patients receiving immunotherapy.** Yufan Qiu, Houston, TX

3:35 p.m. **6744 Persistent neuro-antigen-reactive Th17 cells drive IL-17-dependent neurotoxicity in CNS immune-related adverse events.** Jingyao Zhang, Danbury, CT

3:50 p.m. **6745 NAT10-MYC loop induces MHC-I loss through autophagy to promote immune evasion and immunotherapy resistance in colorectal cancer.** Junyong Weng, Duarte, CA

4:05 p.m. **6746 Biomarker-driven restoration of tumor provisional matrix signaling network reverses resistance to checkpoint inhibition immunotherapy.** Daniel J. Lagal, Chicago, IL

4:20 p.m. **Closing remarks.** May Daher, Houston, TX

Ballroom 6 B - Upper Level - Convention Center
Clinical Research

Spatial Biomarkers at Single-Cell Resolution: Mapping Tumor Ecosystems with Proteomics, Transcriptomics, and AI

Cochairs: Joshua LaBaer, Tempe, AZ; Irene M. Ghobrial, Boston, MA

2:30 p.m. **Chair Introduction.** Joshua LaBaer, Tempe, AZ

2:35 p.m. **6749 Spatial transcriptomics profiling of colorectal cancer tumors in Alaska Native peoples: Discovery of prognostic biomarkers.** Garrick Chang, Seattle, WA

2:50 p.m. **6750 Highly multiplexed immunoassays enable discovery of multimarker EV surface signatures as novel biomarkers.** David Aaron Routenberg, Rockville, MD

3:05 p.m. **6751 Differences in survival outcomes among metastatic colorectal cancer patients across fibroblast growth factor receptor 2 and 3 expression levels.** Steve Soto Trujillo, Los Angeles, CA

3:20 p.m. **6752 Mapping the spatial organization of B cells and immune signalling in TNBC to characterize response to immunotherapy.** Lubna Ahmad, Cambridge, United Kingdom

3:35 p.m. **6753 AI-powered Deep Visual Proteomics (DVP) links pancreatic precursor biology to PDAC survival phenotypes.** Andreas Mund, Copenhagen, Denmark

3:50 p.m. **6754 Spatial-immune multiomics refines prognostication in early-stage, estrogen receptor-positive breast cancer.** Zak Kinsella, Dublin, Ireland

4:05 p.m. **6755 Unbiased phenotyping of CRISPR-edited tumors with Perturb-map and subcellular imaging of the mouse whole transcriptome (22,000-plex).** Maxime Dhainaut, San Francisco, CA

4:20 p.m. **Closing remarks.** Irene M. Ghobrial, Boston, MA

Room 31 - Upper Level - Convention Center
Clinical Research

Targeted Therapy: Data Driven Approaches and Novel Drugs

Cochairs: Karisa C. Schreck, Baltimore, MD; Jenna VanLiere Canzoniero, Baltimore, MD

2:30 p.m. **Chair Introduction.** Karisa C. Schreck, Baltimore, MD

2:35 p.m. **6758 MUlti-epitope Targeting Tetravalent Antibody (MUTTA™) platform for developing NexGen ADCs with an improved therapeutic window.** Jagath R. Junutula, Hayward, CA

2:50 p.m. **6759 High-throughput drug screening and single-cell network analysis identify rational combination therapies in IDH-mutant glioma.** Patrick Kerwin, New York, NY

3:05 p.m. **6760 Age-dependent lung vulnerability identifies serum hyaluronic acid as a predictive biomarker of ADC-induced interstitial lung disease.** Liming Jin, Hangzhou, China

3:20 p.m. **6761 Antitumor activity of datopotamab deruxtecan in a co-clinical trial with patient derived xenografts.** Dhruv Chachad, Houston, TX

3:35 p.m. **6762 A novel therapeutic approach for targeting p53-mutant cancers by leveraging DNA damage response vulnerabilities.** Andrei Bakin, Buffalo, NY

3:50 p.m. **6763 KBD111 is a highly selective, long-acting and brain-penetrant PARP1 inhibitor.** Xiaoke Liu, Chengdu, China

4:05 p.m. **6764 Comparative profiling of TEAD palmitoylation and YAP-TEAD protein-protein interaction inhibitors as combination agents with KRAS inhibitors.** Danielle J. Sanchez, Waltham, MA

4:20 p.m. **Closing remarks.** Jenna VanLiere Canzoniero, Baltimore, MD

Ballroom 20 AB - Upper Level - Convention Center
Experimental and Molecular Therapeutics

KRAS-Targeted Therapies: Overcoming Resistance and Novel Combinations

Cochairs: Jyoti Malhotra, Duarte, CA; David Hong, Houston, TX

2:30 p.m. **Chair Introduction.** Jyoti Malhotra, Duarte, CA

2:35 p.m. **6767 Defining a molecular signature for KEAP1-NRF2 mediated resistance to KRAS inhibition in KRAS-mutant pancreatic and lung cancer.** Wen-Hsuan Chang, Chapel Hill, NC

2:50 p.m. **6768 Selective ULK1/2 inhibitors enhance KRAS pathway blockade and uncover stress-adaptive programs.** Simon Bayle, Tampa, FL

3:05 p.m. **6769 Modeling of acquired resistance to the multi-RAS inhibitor RMC6236 in KRAS mutant pancreatic ductal adenocarcinoma.** Di Zhan, Shanghai, China

3:20 p.m. **6770 Combining RAS inhibitors with the clinical RNR inhibitor BBI-825 to prevent the emergence of extrachromosomal DNA (ecDNA)-driven resistance to RAS-targeted therapies in colorectal cancer.** Silvia Palladino, New York, NY

3:35 p.m. **6771 Targeting the JAK-STAT pathway sensitizes KRAS-mutant cancer to KRAS inhibitors.** Yi Zhao, Shanghai, China

3:50 p.m. **6772 VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation.** Sung-Hyun Hwang, Seongnam-si, Republic of Korea

4:05 p.m. **6773 Targeted therapy-induced chromosomal instability dictates mitotic dependency on Aurora kinase A.** Chendi Li, Boston, MA

4:20 p.m. **Closing remarks.** David Hong, Houston, TX

Ballroom 6 DE - Upper Level - Convention Center
Experimental and Molecular Therapeutics

Targeted Protein Degradation and Non-cannonical Oncogenic Signaling

Cochairs: Anita C. Bellail, Indianapolis, IN; Andrii Monastyrskyi, Tampa, FL

2:30 p.m. **Chair Introduction.** Anita C. Bellail, Indianapolis, IN

2:40 p.m. **6776 Targeting non-enzymatic HDAC-mediated repression reveals a selective stress-adaptive mechanism for cancer therapy.** Olivia Debnath, Boston, MA

2:55 p.m. **6777 Targeting HIF-2a pathway with a novel and potent ARNT molecular glue degrader for the treatment of renal cell carcinoma.** Jake Fathman, San Diego, CA

3:10 p.m. **6778 Selective targeting of CCNE1 using molecular glue degraders for the treatment of CCNE1 amplified cancers.** Ralph Tiedt, Basel, Switzerland

3:25 p.m. **6779 Molecular glue degraders of the RNA binding protein HuR to treat BRAF-mutant colorectal cancer.** Zheng Yang, Shanghai, China

3:40 p.m. **6780 The RAS: PI3Kα breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2+ models through non-canonical RAS signaling blockade.** James P. Stice, South San Francisco, CA

3:55 p.m. **6781 First in class catalytic inhibitor of KAT2A/B demonstrates anti-tumor activity in multiple myeloma.** Kristen Jensen-Pergakes, San Diego, CA

4:10 p.m. **6782 Discovery of a new class of mutant-targeted catalytic RAS(ON) inhibitors with retained antitumor activity in setting of emergent resistance due to elevated RAS flux.** Jacqueline A. Smith, Redwood City, CA

4:25 p.m. **Closing remarks.** Andrii Monastyrskyi, Tampa, FL

Room 14 - Mezzanine Level - Convention Center
Immunology

Inflammation and Immunity in Cancer Progression

Cochairs: Andrew J. Gunderson, Columbus, OH; Kelly Kersten, La Jolla, CA

2:30 p.m. **Chair Introduction.** Andrew J. Gunderson, Columbus, OH

2:35 p.m. **6785 Evasion of hepatic ILC1 immunosurveillance drives breast cancer liver metastasis.** Peng Li, New York, NY

2:50 p.m. **6786 Neutrophil extracellular trap inhibition mitigates tumor necrosis and metastasis in colorectal cancer.** Sepideh Gholami, Cold Spring Harbor, NY

3:05 p.m. **6787 Metabolic reuse of tumor-derived signals coordinates dendritic cell function.** Meriem Belabed, New York, NY

3:20 p.m. **6788 Spatial single-cell analysis reveals stage-dependent mechanisms of anti-IL-1β therapy in lung adenocarcinoma.** Bo Zhu, Houston, TX

3:35 p.m. **6789 Gut commensal dysbiosis modulates the lung microenvironment to promote breast tumor metastasis in a mast cell dependent axis.** Mika Poblete, Charlottesville, VA

3:50 p.m. **6790 Myeloid IFN-γsignaling regulates immunosuppressive and fibrotic tumor microenvironment in PDAC liver metastasis.** Takeshi Tanaka, Los Angeles, CA

4:05 p.m. **6791 Target chronic inflammation in cancer and fibrosis with engineered immune cells.** Zeda Zhang, New York, NY

4:20 p.m. **Closing remarks.** Kelly Kersten, La Jolla, CA

Room 11 - Upper Level - Convention Center
Molecular/Cellular Biology and Genetics

Genomic Approaches to Understanding Tumor Evolution

Cochairs: Arnav Mehta, Stanford, CA; Hui Shen, Grand Rapids, MI

2:30 p.m. **Chair Introduction.** Hui Shen, Grand Rapids, MI

2:35 p.m. **6793 Clinico-genomic characteristics of multiple primary cancers in TRACERx.** Charlotte Grieco, London, United Kingdom

2:50 p.m. **6794 The mouse cancer cell line atlas reveals core principles of tissue-specific cancer evolution.** Sebastian Mueller, Munich, Germany

3:05 p.m. **6795 The Genomics England 100,000 genome programme: Allele-specific KRAS mutational signatures define distinct subtypes in lung adenocarcinoma.** Colin R. Lindsay, The University of Manchester, United Kingdom

3:20 p.m. **6796 AI enabled imaging and single cell multiomics reveal how gene amplification architecture shapes gene expression.** Elizabeth C. Brunk, Chapel Hill, NC

3:35 p.m. **6797 Basal-state origins and genotype-specific trajectories of neuroendocrine plasticity in lung cancer.** Joseph M. Chan, New York, NY

3:50 p.m. **6798 Mechanistic dissection of regulators of cancer plasticity using high-content optical pooled screens at clonal resolution.** Mikolaj Godzik, Cambridge, MA

4:05 p.m. **6799 Dissecting the epigenetic inter- and intra-tumor heterogeneity of glioma at single-cell resolution.** Yue Wu, La Jolla, CA

4:20 p.m. **Closing remarks.** Arnav Mehta, Stanford, CA

Ballroom 6 CF - Upper Level - Convention Center
Molecular/Cellular Biology and Genetics

Metabolic Signaling and Therapeutic Vulnerabilities in Cancer

Cochairs: Aitziber Buque Martinez, Philadelphia, PA; Samuel K. McBrayer, Dallas, TX

2:30 p.m. **Chair Introduction.** Aitziber Buque Martinez, Philadelphia, PA

2:35 p.m. **6802 Metabolite signaling drives oncogenic neuron-glioma crosstalk.** Kalil G. Abdullah, Pittsburgh, PA

2:50 p.m. **6803 Targeting mitochondrial complex I overcomes adaptive response to chemotherapy in advanced pancreatic cancer.** Sergio Attanasio, Houston, TX

3:05 p.m. **6804 Estrogen therapy alleviates cancer-associated cachexia in mouse models of both sexes.** Vincent T. Pham, San Antonio, TX

3:20 p.m. **6805 A ketogenic diet sensitizes pancreatic cancer to metabolic therapies.** Omid Hajihassani, Cleveland, OH

3:35 p.m. **6806 Metabolic changes associated with senescence in CAFs regulate fibrosis in pancreatic cancer.** Devashish Sen, Saint Louis, MO

3:50 p.m. **6807 Mitochondrial genome alterations as early drivers of lung adenocarcinoma evolution.** Alvaro Gutierrez, Temuco, Chile

4:05 p.m. **6808 Targeting metabolism in BRCA-deficient tumors.** Maira Di Tano, New York, NY

4:20 p.m. **Closing remarks.** Samuel K. McBrayer, Dallas, TX

Room 15 - Mezzanine Level - Convention Center
Population Sciences

Population Sciences at the Forefront 2: Molecular and Genetic Epidemiology of Cancer Risk and Outcomes

Cochairs: Song Yao, Buffalo, NY; Linda Kachuri, Stanford, CA

2:30 p.m. **Chair Introduction.** Song Yao, Buffalo, NY

2:35 p.m. **6811 Plasma proteomic signature for persistent smoking effects and its association with risk of smoking-related cancers among former smokers.** Duc Huy Le, Nashville, TN

2:50 p.m. **6812 Adult height and prostate cancer in the Health Professionals Follow-Up Study: Integrating epidemiologic, genetic, and transcriptomic evidence.** Anqi Wang, Los Angeles, CA

3:05 p.m. **6813 Characterization of high-grade serous ovarian cancer copy number alterations in Black and White Women.** Irma M. Vlasac, Hanover, NH

3:20 p.m. **6814 Tumor-stroma spatial context of T cell infiltration and exhaustion as determinants of ovarian cancer survival in Black women.** Brett M. Reid, Tampa, FL

3:35 p.m. **6815 Biologic processes enriched in the primary tumors of invasive breast cancer patients with disseminated tumor cells.** Katherine Anne Lawson-Michod, Seattle, WA

3:50 p.m. **6816 Germline genetic impact on risk of colorectal cancer according to birth cohorts.** Xinyu Wang, Boston, MA

4:05 p.m. **6817 STARD13-LATS2 Axis as a potential genetic modifier of BRCA2 in breast cancer.** Shiv Prakash Verma, New York, NY

4:20 p.m. **Closing remarks.** Linda Kachuri, Stanford, CA

Ballroom 6 A - Upper Level - Convention Center
Tumor Biology

Aging Micro- and Macro-Environments in Tumor Progression and Therapy

Cochairs: Ashani T. Weeraratna, Baltimore, MD; Cosimo Commisso, La Jolla, CA

2:30 p.m. **Chair Introduction.** Ashani T. Weeraratna, Baltimore, MD

2:35 p.m. **6820 Age-related clonal hematopoiesis drives immune remodeling that promotes lung cancer and alters neoadjuvant chemo-immunotherapy outcomes.** Janghee Woo, Atlanta, GA

2:50 p.m. **6821 The temporal dynamics and molecular impact of clonal hematopoiesis in non-small cell lung cancer.** Aino-Maija Leppä, London, United Kingdom

3:05 p.m. **6822 TFF2 deficiency amplifies IL-1β-driven inflammation and promotes aging-associated gastric tumor progression.** Shuang Li, New York, NY

3:20 p.m. **6823 The role of aging in immune mediated reactivation from metastatic dormancy.** Kelly Coutant, Philadelphia, PA

3:35 p.m. **6824 Old age uncovers FGFR-dependent metabolic dependencies in TNBC lung metastasis with therapeutic potential.** Stanislav Drapela, Tampa, FL

3:50 p.m. **6825 Age-stratified therapeutic strategies targeting tumor cell subclones that drive chemoresistance and immunosuppression in triple-negative breast cancer.** Milos Spasic, Boston, MA

4:05 p.m. **6826 Age-dependent neuro-immune changes in glioblastoma shape therapeutic response and reveal senescent microglia as a targetable vulnerability.** Manon Penco-Campillo, Maywood, IL

4:20 p.m. **Closing remarks.** Cosimo Commisso, La Jolla, CA

Awards and Lectures
3:00 p.m.-3:45 p.m.

Room 30 - Upper Level - Convention Center

AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology

Chair: Alexander Y. Rudensky, New York, NY

Funder Remarks: Alicia Zhou, San Francisco, CA

DC subsets: Why so much specialization? Kenneth M. Murphy, St. Louis, MO

Major Symposium
3:00 p.m.–4:30 p.m.

Room 1 - Upper Level - Convention Center
Science Policy Session
Patient Advocate Poster Symposium: Advancing Cancer Research Through Patient and Community Partnerships

Chair: Patricia Spears, Chapel Hill, NC

3:00 p.m. **Chair Introduction.** Patricia Spears, Chapel Hill, NC

3:05 p.m. **Lineberger Excellence in Advocacy Program (LEAP): Implementation and evaluation of a comprehensive patient and community engagement program at the University of North Carolina to improve patient centered research.** Patricia Spears, Chapel Hill, NC

3:20 p.m. **Building the first comprehensive research ecosystem and preclinical model platform for myoepithelial carcinoma.** Michael Casaus, Albuquerque, NM

3:35 p.m. **Project Cure CRC: a patient-powered ecosystem uniting data, discovery and accelerating cures for colorectal cancer.** Kimberly Lynn Newcomer, Washington, DC

3:50 p.m. **Optimization of outreach and engagement of patients/survivors and community supporters to reduce the cancer burden.** Lourdes Baezconde-Garbanati, Los Angeles, CA

4:05 p.m. **MATCHMAKERS Cancer Grand Challenge Team: partnership and purpose to maximize patient research advocate involvement in collaborative preclinical research.** Annie Ellis, White Plains, NY

4:20 p.m. **Discussion**

Awards and Lectures
4:00 p.m.-4:45 p.m.

Room 29 - Upper Level - Convention Center
AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chair: Margaret A. Tempero, San Francisco, CA

Chromatin, epigenetics, and developing the next generation of talent. Charles W.M. Roberts, Memphis, TN

NCI-NIH-Selected Session
4:00 p.m.–5:00 p.m.

Room 2 - Upper Level - Convention Center
NCI Funding of Extramural Cancer Biology Research

Moderator: Daniel L. Gallahan, Rockville, MD

4:01 p.m. **Introduction to the NCI grants system.** Daniel L. Gallahan, Rockville, MD

4:06 p.m. **Introduction to the NCI grants system.** Sharmistha Ghosh-Janjigian, Rockville, MD

4:16 p.m. **Communicating with a program director.** Cheryl Cero, Rockville, MD

4:26 p.m. **Data management and sharing.** Soumya Korrapati, Rockville, MD

4:36 p.m. **DCB funding opportunities and NIH highlighted topics.** Claire McCarthy, Rockville, MD

4:46 p.m. **Discussion**

Town Meeting
4:00 p.m.–5:30 p.m.

Harbor Ballroom DEF - Manchester Grand Hyatt San Diego
Minorities in Cancer Research Town Hall Meeting

Chair: Carmen E. Guerra, Philadelphia, PA

TUESDAY, APRIL 21

Awards and Lectures
4:15 p.m.-5:00 p.m.

Room 30 - Upper Level - Convention Center
AACR Award for Outstanding Achievement in Blood Cancer Research

Chair: Kimberly Stegmaier, Boston, MA

Killing the bad without the good: CART for T-cell malignancies. John F. DiPersio, St. Louis, MO

Meet-the-Expert Sessions
5:00 p.m.–5:45 p.m.

Room 5 - Upper Level - Convention Center
Applying Molecular Classifications to Therapy and Trials in Large B-Cell Lymphoma

Christopher R. Flowers, Houston, TX

Ballroom 6 B - Upper Level - Convention Center
Correcting Altered Tumor-Immune Cell Interactions for Anti-Cancer Treatment

Kurt Alex Schalper, Branford, CT

Room 31 - Upper Level - Convention Center
Leveraging Novel Technologies to Delineate Therapeutic Resistance in Contemporary Clinical Trials

Daniel S.W. Tan, Singapore, Singapore

Ballroom 6 DE - Upper Level - Convention Center
Targeting Telomeres in Cancer

María A. Blasco, Madrid, Spain

Forums
5:00 p.m.–6:30 p.m.

Ballroom 20 AB - Upper Level - Convention Center
Cell Therapy at a Crossroads: Exploring the Evolving Landscape between Autologous, Allogeneic, and In Vivo Engineering

Chair: Christine E. Brown, Duarte, CA

5:00 p.m. **Chair Introduction.** Christine E. Brown, Duarte, CA

5:15 p.m. **Title to be announced.** Zachary Roberts, South San Francisco, CA

5:30 p.m. **Title to be announced.** Alberto De Iaco, Boston, MA

5:45 p.m. **Panel Discussion**

Ballroom 6 A - Upper Level - Convention Center
Leveraging Novel Technologies and Knowledge Bases to Optimize Success in Clinical Trials

Chair: Eliezer M. Van Allen, Boston, MA

5:00 p.m. **Autologous cell therapy in a changing landscape.** Eliezer M. Van Allen, Boston, MA

5:10 p.m. **Data foundations for clinical trial innovation.** Lara Mangravite, New York, NY

5:25 p.m. **Title to be announced.** Deb Schrag, New York, NY

5:40 p.m. **Panel Discussion**

Ballroom 6 CF - Upper Level - Convention Center
Multicancer Early Detection (MCED): Where We Are and How We Realize the Hope

Chair: Nickolas Papadopoulos, Baltimore, MD

5:00 p.m. **Chair Introduction.** Nickolas Papadopoulos, Baltimore, MD

5:02 p.m. **MCED screening: Where are we are and where we want to get to.** Peter Sasieni, London, United Kingdom

5:16 p.m. **Navigating from hype to hope in multi-cancer early detection.** Ruth D. Etzioni, Seattle, WA

5:30 p.m. **MCEDs: Moving from hope to practice.** Nickolas Papadopoulos, Baltimore, MD

5:40 p.m. **Panel Discussion**

Room 33 - Upper Level - Convention Center
Reducing Research Friction: How Scientists and Survivors Can Accelerate Progress

Cochairs: Kristen Dahlgren, Middlebury, VT; Anjee Davis, Alexandria, VA

5:00 p.m. **Chair Introductions.** Kristen Dahlgren, Middlebury, VT; Anjee Davis, Alexandria, VA

5:05 p.m. **How survivor driven priorities can accelerate research innovation.** Kristen Dahlgren, Middlebury, VT

5:15 p.m. **Missing voices, missed opportunities: Fixing cancer research for underserved patients.** Sharon Rivera Sanchez, Glen Allen, VA

5:25 p.m. **How advocacy is reshaping the fight against pancreatic cancer.** Julie Fleshman, Manhatten Beach, CA

5:35 p.m. **Connecting advocacy, access, and scientific progress.** Anjee Davis, Alexandria, VA

5:45 p.m. **Panel Discussion**

Special Session
5:00 p.m.–6:30 p.m.

Ballroom 20 CD - Upper Level - Convention Center
AI in Cancer Research and Care: What We've Learned and What Comes Next?

Cochairs: Benjamin Haibe-Kains, Toronto, ON, Canada; Christina Curtis, Stanford, CA

5:00 p.m. **Chair Introduction.** Benjamin Haibe-Kains, Toronto, ON, Canada

5:05 p.m. **Panelist.** Charlotte Bunne, Lausanne, Switzerland

5:10 p.m. **Panelist.** Danielle S. Bitterman, Boston, MA

5:15 p.m. **Panelist.** Alexander T. Pearson, Chicago, IL

5:20 p.m. **Panelist.** Christina Curtis, Stanford, CA

5:25 p.m. **Panelist.** Benjamin Haibe-Kains, Toronto, ON, Canada

5:30 p.m. **Panel Discussion**

Awards and Lectures
5:15 p.m.-6:00 p.m.

Room 29 - Upper Level - Convention Center
AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention

Chair: Paul D.P. Pharoah, Los Angeles, CA

Funder Remarks: William L. Dahut, Bethesda, MD

Advancing understanding of the etiology and progression of prostate and other cancers through epidemiology anchored collaborative research. Elizabeth A. Platz, Baltimore, MD

Professional Development Session
5:30 p.m.–7:30 p.m.

Grand Hall A - Manchester Grand Hyatt San Diego
A Dialogue with Industry: Career and Collaboration Opportunities

Cochairs: Brian M. Rivers, Atlanta, GA; Susan M. Galbraith, Gaithersburg, MD; Carmen E. Guerra, Philadelphia, PA; Tejaswini Reddy, Houston, TX

5:30 p.m. **Welcome and opening remarks.** Brian M. Rivers, Atlanta, GA

5:35 p.m. **Moderated panel discussion**

Moderators: Brian M. Rivers, Atlanta, GA; Carmen E. Guerra, Philadelphia, PA

Panelist: Susan M. Galbraith, Gaithersburg, MD; Heike Keilhack, Cambridge, MA; Michael Penn, South San Francisco, CA

7:20 p.m. **Closing remarks and evaluation.** Tejaswini Reddy, Houston, TX

Town Meeting
7:00 p.m.–8:30 p.m.

Harbor Ballroom DEF - Manchester Grand Hyatt San Diego
Women in Cancer Research Town Hall Meeting

Chair: Mariana C. Stern, Los Angeles, CA

WEDNESDAY, APRIL 22

Plenary Session
8:00 a.m.–10:00 a.m.

Ballroom 20 - Upper Level - Convention Center

Innovative Treatment Modalities: Shaping the Future of Oncology

Chair: Katayoun Rezvani, Houston, TX

8:00 a.m. **Chair Introduction.** Katayoun Rezvani, Houston, TX

8:05 a.m. **Theranostics: Progress and promise.** Martin G. Pomper, Dallas, TX

8:32 a.m. **The (r)evolution of antibody-drug conjugates: From early concepts to next-generation cancer therapy.** Raffaele Colombo, Vancouver, BC, Canada

8:59 a.m. **PL05-03 From molecular design to therapeutic impact: Protein engineering driving T-cell engager innovation.** Angela Coxon, Thousand Oaks, CA

9:26 a.m. **PL05-04 TIL therapy of solid cancers: T cell features of clinical activity.** John B.A.G. Haanen, Amsterdam, Netherlands

9:53 a.m. **Wrap-up and opportunities for the future.** Katayoun Rezvani, Houston, TX

Poster Sessions
9:00 a.m.-12:00 p.m.

Halls B-G, Ground Level, San Diego Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

Bioinformatics, Computational Biology, Artificial Intelligence, and Data Science

Section 2 Mathematical Modeling and Statistical Methods

Section 3 Network Biology and Precision Medicine

Section 4 New Algorithms and Computational Methods

Section 52 Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2

Immunology

Section 6 Antibody-Drug Conjugates 2

Section 7 High-Dimensional Immune Profiling and Preclinical Modeling for Cancer Immunotherapy

Section 8 Novel Models of Immunotherapy Response

Section 9 Tumor-induced Immune Suppression

Experimental and Molecular Therapeutics

Section 11 Drug Resistance 2: Tyrosine Kinase Inhibitors

Section 12 Epigenetic Modulators 2

Section 13 Novel Antitumor Agents 3

Section 14 Novel Strategies to Reverse Drug Resistance

Section 15 Overcoming Microenvironmental and Delivery Barriers in Cancer Therapy

Section 16 Role of the Microenvironment in Therapeutic Response

Section 17 Targeted Radiopharmaceuticals and Combination Strategies in Cancer Therapy

Section 18 Tumor Diagnostics, Prognostics, and Therapeutic Outcomes

Section 53 Late-Breaking Research: Experimental and Molecular Therapeutics 4

Molecular/Cellular Biology and Genetics

Section 20 Chromatin Architecture and Regulatory Landscapes

Section 21 Genomic Approaches to Define Tumor Biology and Clinical Stratification

Section 22 Hypoxic and Proteotoxic Stress Response

Section 23 Metabolic Vulnerabilities in Pancreatic, Hepatic, and Renal Cancers

Section 24 Transcription Factor Function in Cell Identity, Signaling, and Post-Transcriptional Control

Tumor Biology

Section 26 Biological Mechanisms of Tumor and Normal Tissue Response and Clinical Studies

Section 27 Functional and Spatial Regulation of Immune Evasion and Anti-Tumor Immunity

Section 28 Microenvironmental Determinants of Therapy Response and Resistance 2

Section 29 Therapeutic Modulation of the Tumor Microenvironment: New Targets and Approaches 2

Section 30 Tumor Adhesion

Section 31 Tumor Heterogeneity

Section 32 Tumor Models and Assays: In Vitro, In Vivo

Section 54 Late-Breaking Research: Tumor Biology 3

Population Sciences

Section 34 Psychosocial and Behavioral Epidemiology, Health Services Research, Implementation Science, Pharmacoepidemiology, and Other Topics

Section 35 Risk Prediction Modeling, Screening, Early Detection, and Preneoplastic and Tumor Markers

Prevention, Early Detection, and Interception

Section 36 Cancer and Cancer Related Alterations, Detection Approaches, and Molecular Characterization

Chemistry

Section 38 Multi-Omics, Systems Biology, and Biological Mass Spectrometry

Section 39 Proteomics: Biomarker Discovery and Signaling Networks

Clinical Research

Section 41 Biomarkers Predictive of Therapeutic Benefit 6

Section 42 Immune Response to Therapies

Section 43 Immunomodulatory Agents and Interventions

Section 44 Immunotherapies in Pediatric Cancers

Section 45 Liquid Biopsies: Circulating Nucleic Acids 5

Section 46 Real World Impact of Prognostic and Predictive Parameters

Section 47 Targeted Therapies, Predispositions, and Survivorship in Pediatric Cancers

Section 48 Translational Biomarkers and Emerging Molecular Approaches

Section 49 Tumor Microenvironment Modulators

Section 51 Late-Breaking Research: Clinical Research 4

Advances in Diagnostics and Therapeutics
10:15 a.m.–11:45 a.m.

Ballroom 6 A - Upper Level - Convention Center

Advances in Minimal Residual Disease Detection via Circulating Tumor DNA

Chair: Viktor Adalsteinsson, Cambridge, MA

10:15 a.m. **Chair Introduction.** Viktor Adalsteinsson, Cambridge, MA

10:20 a.m. **Actionable MRD using liquid biopsy to guide precision cancer therapy.** Aadel A. Chaudhuri, Rochester, MN

10:45 a.m. **Liquid biopsy approaches to detect, characterize and address residual disease.** Valsamo Anagnostou, Baltimore, MD

11:10 a.m. **New ctDNA technologies that exceed present limits for MRD detection.** Viktor Adalsteinsson, Cambridge, MA

Ballroom 6 CF - Upper Level - Convention Center

Induced Proximity Pharmacology: Degraders and Beyond

Chair: Michelle R. Arkin, San Francisco, CA

10:15 a.m. **Chair Introduction.** Michelle R. Arkin, San Francisco, CA

10:16 a.m. **Towards new cancer medicines with degraders of chromatin regulatory proteins.** Danette L. Daniels, Cambridge, MA

10:36 a.m. **Designing effective degrader therapeutics: What early clinical experience has taught us.** Gwenn Hansen, San Francisco, CA

10:56 a.m. **NG10 First-in-class dual AR/AR-V7 molecular glue degraders targeting the undruggable N-terminal domain to overcome therapeutic resistance in prostate cancer.** CheukMan Cherie Au, New York, NY

11:16 a.m. **Gluing native protein-protein interactions to augment anticancer pathways.** Michelle R. Arkin, San Francisco, CA

Room 28 - Upper Level - Convention Center

Optimizing Efficacy While Limiting Toxicity in Immunotherapy for Cancer Treatment

Chair: Michael Dougan, Boston, MA

10:15 a.m. **Chair Introduction.** Michael Dougan, Boston, MA

10:16 a.m. **Characterizing the mechanistic differences between CTLA-4 and PD-1 blockade colitis.** Michael Dougan, Boston, MA

10:41 a.m. **Migratory vs. tissue-resident leukocytes in checkpoint-induced irAEs.** Kristen E. Pauken, Houston, TX

11:06 a.m. **Microbiota-immune interactions in colitis induced by CTLA-4 antibody blockade.** Gabriel Nunez, Ann Arbor, MI

Room 31 - Upper Level - Convention Center

Targeted Therapy Frontiers in Microsatellite-Stable Metastatic Colorectal Cancer

Chair: Paulo Hoff, São Paulo, Brazil

10:15 a.m. **Chair Introduction.** Paulo Hoff, São Paulo, Brazil

10:20 a.m. **Advances and future therapeutic strategies for BRAF-mutated and RAS-driven colorectal cancer.** Scott Kopetz, Houston, TX

11:05 a.m. **Emerging targets in mCRC.** Paulo Hoff, São Paulo, Brazil

Advances in Early Detection and Interception
10:15 a.m.–11:45 a.m.

Ballroom 6 DE - Upper Level - Convention Center

Silent Lesions, Dynamic Niches: Harnessing the Stroma to Prevent Cancer Initiation

Chair: Edna Cukierman, Philadelphia, PA

10:15 a.m. **Chair Introduction.** Edna Cukierman, Philadelphia, PA

10:16 a.m. **Molecular and cellular alterations associated with malignant progression in the pancreas.** Laura DeLong Wood, Baltimore, MD

10:41 a.m. **Evolution of the pancreatic cancer microenvironment.** Marina Pasca Di Magliano, Ann Arbor, MI

11:06 a.m. **Means for restoring the stroma›s innate tumor-suppressive function.** Edna Cukierman, Philadelphia, PA

Advances in Organ Site Research
10:15 a.m.–11:45 a.m.

Room 15 - Mezzanine Level - Convention Center

Biology and Therapeutic Targeting of HIF2a in Renal Cell Carcinoma

Chair: Brian I. Rini, Nashville, TN

10:15 a.m. **Chair Introduction.** Brian I. Rini, Nashville, TN

10:20 a.m. **From gene discovery to a first-in-class drug and beyond.** James Brugarolas, Dallas, TX

10:45 a.m. **A paradigm shift in Von Hippel Lindau Syndrome through HIF2a targeting.** Eric Jonasch, Houston, TX

11:10 a.m. **Clinical advances with HIF2a targeting in sporadic renal cell carcinoma.** Brian I. Rini, Nashville, TN

Advances in Technologies
10:15 a.m.–11:45 a.m.

Ballroom 6 B - Upper Level - Convention Center

Agentic AI as the Oncologist: Clinical Decision Support and Human-AI Collaboration

Chair: Renato Umeton, Memphis, TN

10:15 a.m. **Chair Introduction.** Renato Umeton, Memphis, TN

10:20 a.m. **Agentic AI in radiation oncology: From imaging to therapy.** Dorin Comaniciu, Princeton, NJ

10:45 a.m. **The 4D oncologist: AI that watches the drug work.** Tae Hyun Hwang, Nashville, TN

11:10 a.m. **AI across research, clinical care, and education: The academic medical center perspective.** Renato Umeton, Memphis, TN

Advances in the Science of Cancer Disparities
10:15 a.m.–11:45 a.m.

Room 11 - Upper Level - Convention Center
Precision for All: Harnessing Multi-omic Technologies to Eliminate Cancer Inequalities

Chair: Yaw Bediako, Accra, Ghana

10:15 a.m. **Chair Introduction.** Yaw Bediako, Accra, Ghana

10:20 a.m. **The African Cancer Atlas - Leveraging African genetic diversity to advance precision oncology globally.** Yaw Bediako, Accra, Ghana

10:45 a.m. **Mapping the African cancer landscape: A proteomics-centric approach to understanding cancers.** Ireshyn S. Govender, Pretoria, South Africa

11:10 a.m. **An integrative multi-omic approach to unraveling endometrial cancer disparities.** Nyasha Chambwe, Manhasset, NY

Major Symposia
10:15 a.m.–11:45 a.m.

Room 5 - Upper Level - Convention Center
Aneuploidy and Mutations in Normal Tissues and Their Role in Cancer Initiation and Cancer Risk

Chair: Teresa Davoli, New York, NY

10:15 a.m. **Chair Introduction.** Teresa Davoli, New York, NY

10:20 a.m. **Chromosome imbalances as drivers of immune evasion and therapeutic resistance.** Teresa Davoli, New York, NY

10:45 a.m. **Single cell portraits of ageing and mutational origins in the breast.** Samuel Aparicio, Vancouver, BC, Canada

11:10 a.m. **What is cancer? Defining aneuploid cells in normal breast tissues.** Nicholas E. Navin, Houston, TX

Room 33 - Upper Level - Convention Center
Genetic and Environmental Determinants of Cancer

Chair: Nuria Lopez-Bigas, Barcelona, Spain

10:15 a.m. **Chair Introduction.** Nuria Lopez-Bigas, Barcelona, Spain

10:16 a.m. **Distinguishing selection in normal tissue from cancer causation.** Kamila Naxerova, Boston, MA

10:36 a.m. **Genetic and environmental effects on cell-cell competition and clonal selection during mouse skin tumor development.** Allan Balmain, San Francisco, CA

10:56 a.m. **NG11 Understand germline determinants of cancer progression using multi-ancestral real-world data.** Jian Carrot-Zhang, New York, NY

11:16 a.m. **Cancer driver mutations in normal tissue and its relation to cancer risk.** Nuria Lopez-Bigas, Barcelona, Spain

Room 16 - Mezzanine Level - Convention Center
Radioligand Therapy: Immunity and Biological Mechanisms

Chair: David R. Piwnica-Worms, Houston, TX

10:15 a.m. **Chair Introduction.** David R. Piwnica-Worms, Houston, TX

10:20 a.m. **Immunological considerations of RLT.** David R. Piwnica-Worms, Houston, TX

10:40 a.m. **Getting a "GRIP" on antitumor immunity with granzyme-targeted PET.** Michael J. Evans, San Francisco, CA

11:00 a.m. **Development of immunostimulatory RLT to enhance efficacy of immunotherapeutic regimens.** Ravi K. Patel, Pittsburgh, PA

Room 30 - Upper Level - Convention Center

The Role of mRNA Translation Reprogramming in Cancer

Chair: Ivan Topisirovic, Montreal, QC, Canada

10:15 a.m. **Chair Introduction.** Ivan Topisirovic, Montreal, QC, Canada

10:20 a.m. **SY24-01 Translational rheostat that drives breast cancer metastasis.** Ivan Topisirovic, Montreal, QC, Canada

10:45 a.m. **SY24-02 Di-codon organization links tRNA modifications to cancer cell proteome composition.** Ola Larsson, Solna, Sweden

11:10 a.m. **Decoding drug tolerance in cancer: The impact of translation specificity.** Davide Ruggero, San Francisco, CA

Room 29 - Upper Level - Convention Center

Understanding the Impact of Mechanobiology on Tumor Evolution

Chair: Valerie M. Weaver, San Francisco, CA

10:15 a.m. **Chair Introduction.** Valerie M. Weaver, San Francisco, CA

10:20 a.m. **Forcing inflammation to drive tumor initiation and progression.** Valerie M. Weaver, San Francisco, CA

10:45 a.m. **Seeing copy number variation (CNV) induced by confining microenvironments align with pan-cancer trends for CNVs.** Dennis E. Discher, Philadelphia, PA

11:10 a.m. **Evolution under pressure: Spatial and mechanical niches in breast cancer.** Christina Curtis, Stanford, CA

Plenary Session
12:10 p.m.–1:30 p.m.

Ballroom 20 - Upper Level - Convention Center

AACR Annual Meeting 2026 Highlights

Cochairs: Paul S. Mischel, Stanford, CA; Alice T. Shaw, Boston, MA

12:10 p.m. **Remarks.** Lillian L. Siu, Toronto, ON, Canada

12:12 p.m. **Chair Introductions.** Paul S. Mischel, Stanford, CA; Alice T. Shaw, Boston, MA

12:14 p.m. **Basic cancer science and translational research.** Katerina A. Politi, New Haven, CT

12:39 p.m. **Prevention, early detection, population sciences, and disparities research.** Christopher I. Li, Seattle, WA

1:04 p.m. **Clinical research and clinical trials.** Ecaterina E. Dumbrava, Houston, TX